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Abstract 
This thesis describes the investigation into the development of novel antagonists of 
the major thrombin receptor, protease-activated receptor-1, in the aim of generating 
analogues of the project lead compound with improved metabolic stability. Chapter 1 
provides  an  introduction  to  the  research  project  and  the  biological  rationale  for 
targeting  protease-activated  receptor-1  for  inhibition.  Chapter  2  describes 
modifications made to the synthetic route to produce RWJ-58259, the project lead, 
and subsequent biological evaluation carried out in order to confirm the compound’s 
identity  and  verify  batch  quality.  Chapter  3  describes  the  investigation  into  the 
metabolic profile of RWJ-58259 to identify major sites of metabolism. Presented in 
this chapter are details of the syntheses of analogues of RWJ-58259 incorporating 
substituents designed to block possible sites of metabolism in the aim of improving 
in vivo stability. The development of an in vitro assay suited to screen analogues 
efficiently is described and the results from the biological evaluation of compounds 
synthesised are presented with discussion of the data generated.        iii 
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  Introduction  Chapter 1
1.1 Fibrosis 
Accounting  for  almost  45%  of  deaths  in  the  developed  world,  chronic 
fibroproliferative  diseases  represent  one  of  the  biggest  challenges  for  modern 
medicine.
1  The  economic  cost  of  the  burden  placed  on  health  care  services,  by 
treating diseases resulting in fibrosis, is estimated to be in the tens of billions of 
dollars per year for the USA alone.
2 As such, development of therapeutics to treat 
fibrosis would not only improve human health considerably but could also plug a 
significant economic drain. 
Fibrosis is defined as the formation of scar tissue due to excessive deposition and 
accumulation of extracellular matrix (ECM) components. The ECM is a dynamic 
network  of  various  fibrous  proteins  and  glycosaminoglycans,  which  provides 
structural  support  which  is  unique  in  its  arrangement  for  specific  anatomical 
locations.
3 The biochemical make-up of the ECM allows for the sequestration of 
growth  factors  and  cytokines,  regulating  access  to  which,  provides  a  means  for 
intercellular  communication  and  the  transmission  of  mechanical  cues  to  the 
surrounding cells. ECM components are synthesised within and excreted from cells 
for which the ECM in turn provides structural support. Fibrosis is believed to stem 
from a combination of persistent local injury and dysregulation of the natural wound 
healing process, and can occur in all tissues and organ systems.
4 Examples of major 
contributing diseases (and the organs affected) include: pulmonary fibrosis (lungs), 
cirrhosis (liver), chronic kidney disease (kidneys), endomyocardial fibrosis (heart), 
scleroderma/systemic  sclerosis  (skin/various  organs)  and  Crohn’s  disease 
(intestines).  
The  origin  of  the  initial  injury  in  various  fibrotic  diseases  may  vary  greatly  for 
different  organs,  and  in  some  cases  the  origin  is  unknown.  For  example,  major 
sources of initial injury to hepatocytes are chronic viral hepatitis B and C infection, 
or aberrant lipid metabolism caused by alcohol-related disorders or high fat diets.
5 
Likewise, sources of injury to kidney cells can range from diabetes or autoimmune 
disease to xenobiotic toxicity.
4 Regardless of the source of initial insult, if persistent, 2 
chronic tissue injury results and may give rise to fibrosis. Gross remodelling then 
distorts the normal tissue architecture of the organ system leading to progressive loss 
of function. The  consequences  are dire in  diseases  such as  idiopathic pulmonary 
fibrosis  (IPF),  liver  cirrhosis,  cardiovascular  fibrosis,  systemic  sclerosis  and 
nephritis, where organ failure ensues and ultimately leads to death.
1  
Despite  the  contribution  of  fibroproliferative  diseases  towards  mortality  in  the 
developed world, research in this field is relatively new. Mechanisms involved in 
disease pathogenesis are poorly understood and as a result there are currently no 
clinically proven therapeutic options to combat fibrosis. Progress in the field over the 
last quarter of a century, however, has led to the recognition of common features in 
different  fibrotic  diseases.
6  This  has  begun  to  generate  a  clearer  picture  of  the 
possible processes involved in disease progression, making therapeutic intervention a 
realistic goal for the near future.  
1.2 Wound Repair and Regeneration 
The ability to detect injury and respond quickly is a process that is well-established 
in most multicellular organisms. Delivery of essential components to fight infection 
and repair or replace injured tissues reduces the damage sustained and increases the 
chance of survival.  
Within a healthy organism the physiological environment is described as being in an 
anticoagulative-profibrinolytic  state,  meaning  conditions  are  held  so  as  to  deter 
coagulation and favour fibrinolysis. Upon injury to cells, the wound healing process 
(Figure 1) is triggered involving a complex network of responses, which temporarily 
alter the normal state of the body towards a procoagulative-antifibrinolytic state. The 
balance between these counterpart positions is maintained until the healing process is 
complete and the anticoagulative-profibrinolytic condition resumes. The process of 
repair  is  generally  recognised  as  being  comprised  of  three  distinct  phases: 
inflammation, fibroplasia and maturation, each of which will be discussed in detail 
below (see sections 1.2.1-1.2.3).
7 In the normal state, following initial injury, the 
healing process culminates in the restoration or replacement of damaged tissue to its 
normal functioning state and concludes leaving little or no scarring. However, in a 
diseased state, sustained injury leads to unbalanced responses and abnormalities in 3 
the healing process, resulting in excessive deposition of ECM components, scarring 
and distortion of the normal tissue architecture.   
 
1 – Injury occurs to healthy tissue; 2 – following injury growth factors and chemokines 
released from damaged epithelial cells trigger various responses in the local environment 
including vasoconstriction, stress responses in neighbouring cells and transforming growth 
factor (TGF)-β activation. Activation of the coagulation cascade leads to the formation of a 
fibrin clot; 3 – activated platelets adhere to the fibrin clot and degranulation leads to the 
release of numerous growth factors and vasoactive substances resulting in vasodilation and 
increased  blood  vessel  permeability;  4  - leukocytes  recruited  from  circulation  release 
various cytokines and growth factors, which direct the healing process. Disruption of the 
ECM and TGF-β activation leads to development of the fibroblast cell into a myofibroblast; 
5  - myofibroblasts  from  various  sources  migrate  to  the  injury  site  and  deposit  ECM 
components; 6 – myofibroblasts contract and close the wound, allowing re-epithelialisation 
of  the  surface.  Myofibroblasts  undergo  apoptosis  and  matrix  metalloproteases  (MMPs) 
degrade excess ECM to restore the tissue to its normal state.  
Figure 1 Wound Healing Process.
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1.2.1 Inflammation Phase 
The  initial  response  following  injury  to  the  epithelium  is  a  period  of  intense 
vasoconstriction  triggered  by  a  combination  of  factors,  including  the  release  of 
components from damaged epithelial cells. Activation of the coagulation cascade is 
one of the earliest responses to tissue injury and is triggered as circulating factor VII 
(FVII)  is  exposed  to  tissue  factor  (TF),  which  is  expressed  in  tissues  that  are 
normally concealed from plasma. The coagulation cascade (Figure 2) involves the 
sequential  activation  of  zymogens  in  circulation  to  their  functional  forms,  which 
ultimately results in the formation of a blood clot through the conversion of soluble 
fibrinogen to insoluble fibrin by activated thrombin (FIIa). 
 
Injury to the  endothelium exposes TF to FVII, which  form  the TF-FVIIa complex and 
initiate  what  is  known as  the extrinsic pathway.  Activation of  factor X (FX) gives  the 
TF-FVIIa-FXa  complex,  which  in  association  with  activated  factor  V  (FVa),  converts 
prothrombin to thrombin (FIIa). Thrombin cleaves soluble fibrinogen into insoluble fibrin, 
which  is  cross-linked  by  activated  factor  XIII  (FXIIIa),  also  a  thrombin  mediated 
activation.  Amplification  of  the  coagulation  cascade  is  achieved  as  thrombin  induces 
positive  feedback  mechanisms.  The  intrinsic  pathway  is  initiated  as  thrombin  activates 
factor XI (FXI), factor VIII (FVIII) and FV, which leads to more prothrombin activation. 
Thrombin also activates protein C, which in turn inhibits FVIII and FV activation, and 
tissue factor pathway inhibitor (TFPI), which inhibits factor IX (FIX) and FX activation, 
both of which reduces the amount of thrombin formed in a negative feedback mechanism. 
Thrombin also plays an important role in the activation of many cellular mechanisms. 
Figure 2 Coagulation Cascade.
9 
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Sub-endothelial  ECM  components  and  proteases  from  the  coagulation  cascade 
trigger platelet aggregation, contributing to the fibrin clot and together they form the 
provisional  matrix.  Platelets  are  storehouses  of  numerous  growth  factors  and 
vasoactive  substances.  Upon  activation,  degranulation  occurs,  promoting 
vasodilation and increased blood vessel permeability, which assists in the recruitment 
of pro-inflammatory cells.
8, 10  
Epithelial cells respond to injury in various ways, which initiate pathways to assist 
the  wound  healing  process.  If  injury  is  severe,  cell  death  occurs,  releasing  cell 
components, which stimulate stress responses in neighbouring cells.
6, 11 In episodes 
of less severity, the cell survives initial injury but a variety of stress responses are 
triggered as a result. Changes in the cell’s local environment as a result of tissue 
damage can lead to complications in the folding of proteins, known as endoplasmic 
reticulum (ER) stress, as gene expression is increased in an attempt to aid survival. 
12  
The unfolded protein response (UPR) is initiated as a consequence to help clear the 
accumulation of misfolded proteins or, for cases in which the situation cannot be 
resolved,  initiate  apoptosis.  Sources  and  mechanisms  by  which  energy  for 
metabolism  is  generated  within  cells,  in  the  form  of  adenosine  5’-triphosphate 
(ATP), are also affected under stress leading to the formation of damaging reactive 
oxygen species (ROS) as by-products, which stimulate pro-fibrotic pathways.
13  
High levels of integrin ʱvβ6 are expressed in epithelial cells in response to stress. 
This trans-membrane protein binds to the latency-associated peptide (LAP) portion 
of latent transforming-growth factor (TGF)-β (Figure 1, page 3) stored in the ECM. 
Activation of cell surface receptors by mediators released or activated as part of the 
stress response, such as the coagulation protease thrombin, initiates epithelial cell 
contraction.  Transmission  of  this  force  to  the  LAPs  via  integrin  ʱvβ6  results  in 
TGF-β  activation.
14  TGF-β  is  a  major  component  in  the  wound  healing  process 
affecting  various  responses  from  many  different  cell  types.  These  include: 
i) connective tissue growth factor (CTGF) expression, which stimulates fibroblast 
proliferation  and  ECM  synthesis;  ii)  ʱvβ6  integrin  expression,  which  creates  a 
positive feedback mechanism by activation of more latent TGF-β; and iii) alteration 
in  gene  expressions  in  epithelial  cells  so  as  to  trigger  epithelial-mesenchymal 
transition (see section 1.4.3.1, page 14).
6, 15, 16  6 
Recruitment of leukocytes, following the secretion of growth factors and chemokines 
by epithelial and endothelial cells, is assisted through disruption of the basement 
membrane  by  matrix  metalloproteases  (MMPs)  produced  by  epithelial  and/or 
endothelial  cells  and  myofibroblasts.
8  The  earliest  to  respond  and  migrate  are 
neutrophils,  which  eliminate  any  invading  organisms  by  phagocytosis  and  the 
formation of phagolysosomes. However, they often release free radicals as a result, 
destroying many healthy host cells in the local environment.
17 Macrophages arrive 
later and clear the wound of tissue debris and expended neutrophils. Also recruited, 
but later still, are mast cells. Together, these different leukocytes secrete a cocktail of 
cytokines and growth factors, which direct the wound healing response and amplify 
the inflammatory signal drawing more leukocytes to the site of injury. Recruitment 
and activation of T-cells promotes the secretion of pro-fibrotic cytokines such as 
interleukin-13 (IL-13) and TGF-β. 
1.2.2 Fibroplasia Phase  
Fibroblast  cells  present  in  connective  tissues  become  activated  as  a  result  of 
disruption to their protective cross-linked ECM micro-environment  during injury. 
Normally a relatively dormant cell, upon activation the fibroblast develops into a 
migratory  phenotype,  termed  “proto-myofibroblast”,  and  travels  towards  the 
wound.
18  Further  activation  by  TGF-β  completes  the  transformation  to  a 
myofibroblast  (a  collagen-secreting  ʱ-smooth  muscle  actin-positive  (ʱ-SMA
+) 
fibroblast). The myofibroblast is the major cell type involved in the production and 
deposition of granulation tissue, comprised mostly of ECM components collagen and 
fibronectin,  which  replace  the  provisional  matrix.
19  Myofibroblasts  differ  from 
fibroblasts by their expression of ʱ-SMA and the presence of contractile apparatus. 
Bundles  of  cytoplasmic  ʱ-SMA  incorporated  actin  microfilaments  align  and 
converge at sites on the cell membrane. These are known as focal adhesions in most 
cell  types,  or  fibronexus  in  myofibroblasts,  and  are  sites  where  transmembrane 
integrins link the intracellular actin with extracellular fibronectin fibrils.
18, 20-22 The 
force generated by the actin stress fibres is transmitted to the surrounding ECM, 
leading to contraction of the tissue and closing of the wound. Regeneration of the 
damaged tissue is  achieved as  epithelial and endothelial cells divide and migrate 
across the basal layer.  7 
1.2.3 Maturation Phase 
Finally, myofibroblasts undergo apoptosis, reducing the rate of ECM deposition. A 
balance is reached between synthesis and MMP degradation of ECM components. 
Reorganisation  of  the  collagen  fibres  occurs  over  a  period  of  up  to  2  years, 
progressively strengthening the tissue.
7, 8, 23  
The wound healing process as a whole is a complex mix of balanced responses to 
various stimuli, which ordinarily play out without issue and result in the regeneration 
of damaged tissues. However, complications arise with serious consequences when 
responses are uncontrolled, as discussed in the following sections.   
1.3 Pulmonary Fibrosis 
Pulmonary  fibrosis  is  a  devastating  progressive  condition,  which  results  from 
scarring of the lung tissue leaving it thickened and stiff. The walls of the alveoli, 
through which gaseous exchange occurs with blood in the pulmonary capillaries, are 
left  unable  to  function  as  a  suitable  membrane  and  the  body  suffers  oxygen 
deficiency  and  carbon  dioxide  build-up  as  a  result.  Patients  diagnosed  with  the 
condition face a devastating prognosis - in the absence of therapeutic options, organ 
transplantation gives the only realistic hope of survival. However, there is a shortage 
of donors and for many the waiting list is too long. 
Rather than a single disease, pulmonary fibrosis represents the common end stage of 
many diffuse parenchymal lung diseases (DPLDs). DPLDs, also known as interstitial 
lung diseases (ILDs), are a group of disorders which affect the alveolar space and/or 
the pulmonary interstitium – the space between the alveolar epithelial and capillary 
endothelial basement membranes.  There are over 200 distinct entities  of DPLDs, 
each characterised by varying levels of inflammation and fibrosis, and are classified 
by  their  differing  etiology,  clinical  course,  radiologic  presentation  and 
histopathology.
24 Not all DPLDs progress towards pulmonary fibrosis and in some 
cases early and accurate classification of the specific disease can allow the cause of 
injury  to  be  treated,  avoiding  disease  progression.
25  Classification,  however,  is  a 
difficult  process  due  to  the  complexity  of  mechanisms  involved  in  progressing 
DPLDs towards the pulmonary fibrosis stage. Continued research in the area means 8 
that previously agreed classes of disease are revised regularly as experience with and 
understanding of the various diseases grows.  
1.3.1 DPLD Classification 
The classification of DPLDs has challenged clinicians and investigators for over a 
century.  Sir  William  Osler,  in  1892,  used  the  term  “cirrhosis  of  the  lung”  and 
described patients as having “a fibrinoid change, which may have its starting point in 
the tissue about the bronchi and blood vessels, the interlobular septa, the alveolar 
walls of the pleura”.
26 He also stated that “so diverse are the different forms and so 
varied the conditions under which this change occurs that proper classification is 
extremely difficult” – as has been the case in the time since.
26  
Cases  of  the  different  diseases  are  relatively  uncommon  and  therefore  very  few 
clinicians  have  extensive  experience;  and  yet  collectively  DPLDs  account  for 
approximately  15%  of  diseases  seen  in  pulmonary  medicine,  which  has  led  to 
discrepancies  in  diagnoses.
27  Accurate  classification  of  the  disease  at  hand  is 
imperative since treatment options and prognosis can vary significantly for different 
DPLDs. Sarcoidosis, for example, in most cases does not require systemic therapy 
and resolves itself over a period of 1-2 years. However, chronic forms, in which the 
disorder persists for more than 2-5 years, may require long-term therapy involving 
corticosteroids  for more than 5  years.
28 Prognosis for collagen vascular diseases, 
such as systemic sclerosis, can vary greatly depending upon the extent and severity 
of the disease, with reports suggesting 10- and 20-year survival rates of 70% and 
45%, respectively, and initial treatment with cyclophosphamide to be efficacious.
29, 30  
The work of Hamman and Rich in the 1930’s, who are generally considered as the 
first to describe IPF as a new clinical and pathological entity, enhanced awareness of 
different classes of fibrotic lung diseases. Over the following decades associations 
were  made  for  certain  symptoms  with  known  causes  such  as  systemic  disease 
(collagen  vascular  diseases),  drugs,  inherited  conditions  and  occupational  or 
environmental exposures (organic/inorganic dust).
31 However, a substantial number 
of  cases  remained  unclassified  with  regards  to  causative  agents  and  formed  a 
category of diseases now generally referred to as idiopathic interstitial pneumonias 
(IIPs).
32, 33 9 
In  2002,  the  American  Thoracic  Society  and  the  European  Respiratory  Society 
published  a  joint  international  consensus  statement  to  aid  in  the  classification  of 
IIPs.
34 The objective was to provide an integrated multidisciplinary approach to IIP 
classification to avoid confusion and misclassification of patients. The statement was 
updated  in  2013,  reflecting  the  continued  progress  made  with  regards  to  disease 
classification.
35 However, although accurate classification of IIPs may provide an 
improved prognosis for some patients, the fact remains that in most cases therapy is 
based  on  relieving  symptoms  rather  than  treating  the  disease.  IPF  is  the  major 
contributor to cases of IIP and as such has been the driving force behind this research 
project.     
1.4 Idiopathic Pulmonary Fibrosis 
IPF represents the most common form of diseases culminating in pulmonary fibrosis, 
with an estimated 5000 new cases diagnosed each year in the UK alone, and with a 
total of 500,000 people currently affected in the USA and Europe.
36,  37 There are 
currently no clinically proven therapeutic options for patients diagnosed with IPF, as 
such it represents a major unmet medical need. 
1.4.1 Diagnosis and Prognosis of Patients with IPF 
Of all DPLDs IPF commands the most devastating prognosis, with a mean survival 
time from diagnosis of only 3 years and 80% mortality within 5 years. Defined as a 
specific form of chronic, progressively fibrosing IIP limited to the lungs, the disease 
occurs predominantly in middle-aged and elderly adults with a mean age of 66 years 
at diagnosis and prevalence is generally higher in men than in women.
38, 39  
IPF has a long asymptotic period (months to years) when it is believed micro-injuries 
occur in the lungs, progressing towards a threshold beyond which the damage is 
sufficient to cause the onset of symptoms. At the time medical attention is sought 
symptoms  observed  include  chronic  and  progressive  dyspnoea,  non-productive 
cough with exertion, bibasilar inspiratory crackles and, frequently, clubbing of the 
fingers. Most patients  have these symptoms  for an  average of 24 months  before 
diagnosis.
40, 41 The clinical course following diagnosis of IPF is recognised as being 
heterogeneous and distinct patterns of comorbidities are becoming associated with 10 
different clinical phenotypes.
40 Factors correlating with a poorer prognosis include 
old age (>70 years), a history of smoking, a low body-mass index, digital clubbing, 
severe physiological impairment, large radiological extent of disease, and pulmonary 
hypertension.
42  
The  typical  clinical  course  in  most  cases  of  IPF  follows  a  stable  or  slowly 
progressive deterioration in health and the patient’s symptoms are carefully managed 
over a period of months to years. In an estimated 10-20% of cases, however, patients 
experience periods of rapid deterioration with no discernible cause. Referred to as 
acute  exacerbations,  episodes  of  abrupt  declines  in  clinical,  physiological  and 
radiological findings precede, and possibly initiate, the terminal phase of the disease. 
Less than 40% of hospital admissions with acute exacerbations survive, and there is 
>90% mortality among survivors within 6 months.
43, 44  
An accelerated variant of IPF is seen in a subgroup of patients and is known as 
accelerated  IPF.  This  generally  affects  male  cigarette  smokers,  and  this  clinical 
phenotype exhibits a rapidly progressive course with significant reduction in survival 
time. Despite presenting no divergent diagnostic features at the time of diagnosis 
from the standard slowly progressive form, the transcriptional profile of this rapidly 
progressing form indicates up-regulation of a number of functional pathways that 
operate  mainly  in  alveolar  epithelial  and  mesenchymal  cells.  Cell  motility, 
myofibroblast differentiation, oxidative stress, coagulation and development may be 
affected as a result of the differing pattern of gene expression.
45 
The diagnosis of IPF in combination with other disorders of the lung is seen to affect 
prognosis.  A  number  of  patients,  mainly  men  who  are  heavy  cigarette  smokers, 
diagnosed  with  IPF  present  lesions  associated  with  emphysema,  which  has  been 
reported to have a negative effect on prognosis compared with IPF patients without 
emphysema.
46 It is unclear whether combined pulmonary fibrosis and emphysema 
(CPFE)  is  a  distinct  condition  or  a  subgroup  of  IPF  patients  with  a  different 
prognosis.
47  
Pulmonary hypertension (PH) has been reported to manifest in almost a third of IPF 
cases  and  could  possibly  indicate  the  beginning  of  the  terminal  phase.
48-50  PH 11 
correlates  with  a  higher  mortality  not  only  in  IPF  but  also  in  other  DPLDs  and 
patients with CPFE are seen to promptly develop severe PH.
47, 48, 51  
High incidence of lung cancer has also been associated with IPF (10-38% of cases).
52 
Although  the  mechanisms  by  which  fibrosis  leads  to  the  development  of  lung 
carcinoma are obscure, regions of honeycombing lesions distinctive of IPF seem to 
be highly susceptible, suggesting a contributory relationship.
53  
1.4.2 Etiology of IPF 
By definition, IPF is a disease of unknown origin. Potential risk factors have been 
proposed,  such  as  cigarette  smoking,  viral  infections,  environmental  exposures, 
gastro-oesophageal  reflux  (GOR)  and  surfactant  protein  polymorphism,  however 
specific  etiology  remains  poorly  understood.
54,  55  A  combination  of  genetic 
predisposition  and  exposure  to  injurious  environmental  agents  is  currently  the 
generally accepted cause of persistent injury. 
1.4.2.1 Genetic factors 
Although  the  occurrence  of  IIPs  in  two  or  more  members  of  the  same  primary 
biological family is reportedly seen in only 0.5-2% of patients, sufficient clustering 
of cases occurs to suggest the involvement of genetic factors in the development of 
disease.
56  
Mutations in surfactant protein (SP)-C have long been associated with familial cases 
of interstitial pneumonias, with a recent study reporting 25% of unrelated cases of 
familial pulmonary fibrosis showing SP-C mutations that were absent in sporadic 
cases.
57  Expression  of  SP-A  &  SP-C  mutations  leads  to  dysfunction  in  alveolar 
epithelial  Type-II  (AT2)  cells  and,  together  with  mutations  associated  with  cell 
stability such as telomerase mutations (hTERT and hTER), can compromise normal 
healing of the epithelium.
58  
Reports linking IPF to the ELMOD2 gene implicate genetic alterations in disease 
development  for  both  familial  and  sporadic  cases.  mRNA  expression  of  the 
ELMOD2 gene, shown to be involved in the regulation of anti-viral responses, is 
significantly  decreased  in  diseased  lungs  by  comparison  to  healthy  individuals.
59 12 
This  observation  gives  strength  to  the  view  that  a  combination  of  genetic  and 
environmental factors may be responsible. 
Increased  existence  in  polymorphisms  of  genes  encoding  for  various  cytokines, 
enzymes,  pro-fibrotic  molecules,  and  other  mediators  of  tissue  repair  and 
regeneration have been reported in cases of IPF, but none have been validated to 
date.
54  
1.4.2.2 Injurious agents   
Various harmful environmental factors have been proposed as possible causes of 
injury, prominent among these are viral infections and GOR.  
The main focus of research into viruses linked with IPF has centred on Epstein-Barr 
virus (EBV) and hepatitis C. A number of studies report the detection of both EBV 
protein and DNA expression in cases of IPF.
60, 61 Tang et al. reported that almost 
two-thirds of both familial and sporadic cases of IPF showed the presence of EBV in 
alveolar epithelial cells and their data suggested a decrease in the rate of decline in 
pulmonary function following anti-viral therapy.
62 Other herpes viruses were also 
tested for and it was found that one or more viruses were present in 96% of cases 
with  IPF compared with 36% of the control population. Studies looking into the 
possible  causative  relationship  between  hepatitis  C  virus  (HCV)  and  IPF  have 
returned varied results.  Significant HCV prevalence is recognised in cases of the 
disease; however, anti-HCV antibody levels did not differ from other lung diseases 
with known etiology.
54, 63 
A  relationship  between  IPF  and  GOR  has  been  suggested  since  the  1970’s  and 
current research estimates the prevalence of GOR in cases of IPF to be as much as 
90%.
64, 65 Abnormal acid GOR was shown to be significantly higher in IPF patients 
than in patients with intractable asthma, a population shown to have high prevalence 
of GOR. However, 63% of IPF patients treated with the standard dose of proton 
pump  inhibitors  (PPIs),  the  primary  medication  for  GOR,  continued  to  display 
abnormal levels of acid GOR.
65 This may signify a reversal in the suspected roles in 
the  relationship,  with  GOR  possibly  a  symptom  in  most  cases  of  IPF.  Another 
interesting study investigated cases of asymmetrical IPF and found a significantly 
increased prevalence of GOR in patients with asymmetrical (63%) compared with 13 
symmetrical IPF (31%).
66 Acute exacerbations were also seen to occur more often in 
cases  of  asymmetrical  IPF,  possibly  suggesting  the  role  of  specific  regional 
conditions – affected by GOR, for example – in the development and/or progression 
of fibrosis.   
1.4.3 Disease Progression in IPF 
Inflammation  is  accepted  as  having  an  important  role  in  many  DPLDs  and,  in 
chronic  forms,  can  progress  towards  fibrosis.  However,  hypotheses  suggesting 
inflammation leads to fibrosis in IPF have been put in doubt as understanding of the 
disease  has  grown  and  various  studies  have  failed  to  confirm  this  relationship.
41 
Locations of extensive fibrosis known as fibroblastic foci, which are characteristic of 
IPF,  were  previously  thought  to  develop  from  lesions  seen  in  desquamative 
interstitial  pneumonia  (DIP)  –  an  IIP  featuring  elevated  accumulation  of 
macrophages in the alveolar interstitium,  i.e. inflammation, resulting from insults 
caused by cigarette smoking. However, these fibroblastic foci are now understood to 
occur via different mechanisms since elevated levels of macrophages are not seen in 
these locations. Some evidence suggests inflammation is not required for fibrosis to 
occur and that, in the absence of certain biological factors, exaggerated inflammation 
can be induced without leading to fibrosis. Also, the extent of inflammation fails to 
correlate with staging of fibrosis and the absence of a response in IPF patients to 
anti-inflammatory therapy would suggest that development of disease is driven by an 
alternative mechanism.
41 
Current understanding of mechanisms involved in the progression of IPF towards 
end-stage  pulmonary  fibrosis  suggests  an  epithelial-driven  hypothesis.  Persistent 
injury, possibly resulting from a combination of genetic predisposition and exposure 
to  a  harmful  environmental  agent,  affects  the  ability  of  alveolar  epithelial  cells 
(AECs)  to  regenerate  and  replenish  the  alveolar  surface  (Figure  3).  Subsequent 
destruction of the basement membrane allows  pro-fibrotic  cells  and mediators  to 
infiltrate.  A  malfunctioning  response  to  tissue  injury  results  in  uncontrolled 
deposition of ECM components whilst processes such as apoptosis and phagocytosis 
are retarded. Normal lung architecture is distorted by fibroblastic foci leading to loss 
of function and ultimately death.  14 
 
1  -  Persistent  injury  leads  to  increase  levels  of  alveolar  epithelial  cell  (AEC)  death; 
2 - release of growth factors and chemokines from damaged AECs trigger stress responses 
in neighbouring cells and surrounding tissue. Increased basement membrane permeability 
allows leakage of plasma, containing activated coagulation proteases, into the site of injury 
triggering a fibrotic response; 3  – further disruption of the basement  membrane allows 
myofibroblasts to infiltrate and deposit ECM components preventing re-epithelialisation; 
4 –  fibroblastic  foci  develop  as  dysregulation  of  the  wound  healing  process  leads  to 
fibrosis.  
Figure 3 Pulmonary Fibrosis
41 
 
A  number  of  key  aspects  of  IPF  are  implicated  in  contributing  towards  disease 
progression,  namely  increased  myofibroblast  cell  population,  increased  levels  of 
pro-inflammatory  cytokines  and  chemokines,  elevated  numbers  of  cells  initiating 
stress responses, and increased levels of proteases as a result of activation of the 
coagulation cascade. These are outlined in more detail in the following sections. 
1.4.3.1 Increased Myofibroblast Population 
Injury  to  AECs  is  understood  to  be  a  key  process  in  the  pathogenesis  of  IPF; 
hyperplasia of alveolar epithelial type 2 (AT2) cells within fibroblastic foci has been 
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reported together with increased apoptosis and denudation of the epithelial basement 
membrane in cases of IPF. As mentioned earlier, expression of gene mutations in 
AECs lead to cell instability and affects their ability to regenerate normal epithelium. 
As much as 70-80% of AT2 cells have been shown to be in stages of apoptosis in 
patients with IPF, which in mouse models has been linked to the development of 
lung  fibrosis.
67,  68  Damage  to  AT2  cells  induces  fibroblasts  resident  in  the 
interstitium  to  differentiate  into  myofibroblasts,  the  other  key  cell  type  in  the 
progression of IPF. 
Myofibroblasts are the major cell type responsible for the production and secretion of 
ECM  in  the interstitium.  Currently,  it  is  understood  that  there  are  three  possible 
sources of myofibroblast cell replenishment at the site of injury, though the relative 
contribution  of  each  to  the  cell  population  in  IPF  is  unclear.  The  first,  already 
mentioned, is the activation of resident lung fibroblasts by the potent pro-fibrotic 
mediator, TGF-β (section 1.2.2, page 6). Increased numbers of cells experiencing 
stress  and undergoing  apoptosis  due to  chronic injury  in  IPF, results  in  elevated 
levels  of  TGF-β,  promoting  more  fibroblast  differentiation.  The  second  possible 
source  is  the  transformation  of  epithelial  cells,  following  stress/injury,  to 
mesenchymal cells, which can then differentiate into myofibroblasts.
16 It has been 
demonstrated in vitro that TGF-β is able to induce this process, known as epithelial-
mesenchymal  transition  (EMT),  whereby  epithelial  cells  lose  their  characteristic 
markers, undergo cytoskeletal reorganisation to adopt a spindle-shaped morphology 
and acquire typical mesenchymal markers.
69 Markers for both cell types have been 
shown to co-localise on hyperplastic AT2 cells in IPF lung tissue suggesting the 
occurrence  of  EMT  to  provide  an  additional  source  of  myofibroblasts  in  lung 
fibrosis.
16 The hypothesis behind the third source of myofibroblasts is that they may 
develop from circulating fibrocytes or other bone marrow-derived progenitor cells, 
the  numbers  of  which  have  been  shown  to  correlate  with  disease  progression  in 
IPF.
55, 70 
1.4.3.2 Pro-inflammatory Mediators 
Many of the various cytokines and chemokines involved in the complex interactions 
in response to tissue injury, when unregulated, have been implicated in promoting 
the generation of a pro-fibrotic environment contributing to the progression of the 16 
disease.  Tumour  necrosis  factor  (TNF)-ʱ  plays  a  central  role  in  many  processes 
involved in an inflammatory response and mice deficient in this cytokine have been 
shown not to develop fibrosis following treatment with bleomycin – a glycoprotein 
antibiotic known to induce pulmonary fibrosis.
71 However, no beneficial effect was 
seen in IPF patients treated with TNF inhibitor Etanercept for 48 weeks.
72 
TGF-β  is  a  pleiotropic  cytokine  produced  by  various  cell  types  and  is  currently 
recognised  as  the  most  potent  mediator  of  fibrosis  in  the  lung.  TGF-β  mRNA 
expression  has  been  shown  to  be  up-regulated  in  the lungs  of  mice  treated  with 
bleomycin.
73 Fibrosis is promoted through increased recruitment and activation of 
monocytes and fibroblasts by elevated levels of TGF-β, which also increase ECM 
gene transcription and suppression of proteins involved in collagen degradation, such 
as matrix metalloproteinases, plasminogen activators and elastases.
74 
Despite the theory of inflammation as a driving force being discounted in IPF, a 
number  of  pro-inflammatory  chemokines,  including  CCL2,  CCL3,  CCL17  and 
CCL22, have been shown to be up-regulated in the fibrotic lung, with benefits seen 
in  their  absence  or  when  neutralised  in  animal  models  of  fibrosis.
74-78  These 
chemokines  are  mainly  responsible  for  the  recruitment  of  monocytes  and 
lymphocytes, activation of which can in turn release pro-fibrotic cytokines.
79 
1.4.3.3 Cell Stress Response 
Chronic injury leads to sustained levels of cell stress, likely to result in fewer cells 
surviving the UPR and resulting in increased levels of apoptosis.
80 Oxidative stress 
may play a role in IPF progression as increased numbers of cells, such as neutrophils, 
generating ROSs outweigh the capacity to neutralise them. Lung myofibroblasts have 
also  been  shown  to  generate  hydrogen  peroxide,  possibly  leading  to  epithelial 
apoptosis.
81 
1.4.3.4 Activation of the Coagulation Cascade 
Although its primary function is the formation of a blood clot to stem the loss of 
blood and prevent infection, the coagulation cascade is increasingly understood to 
have an influence in wound healing beyond haemostasis. Understanding of the roles 
that  coagulation  proteases,  such  as  thrombin  and  FXa,  have  in  the  initiation  of 17 
cellular mechanisms has shed light on the wider influence the coagulation cascade 
has on the inflammation and tissue repair processes.  
Thrombin’s  cellular  responses  are  mediated  by  a  specific  family  of  cell-surface 
receptors  known  as  protease-activated  receptors  (PARs),  of  which  four  members 
have been identified to date, PAR-1 to PAR-4. PAR-1 demonstrates high affinity for 
thrombin and has been shown to be expressed in numerous cell types present in the 
lung, including pulmonary epithelial cells, fibroblasts and macrophages. Activation 
of  PAR-1  in  these  cell  types  leads  to  secretion  of  potent  pro-inflammatory  and 
pro-fibrotic mediators, and in fibroblasts promotes proliferation and differentiation 
into  myofibroblasts.
82-87  Coagulation  factor  X  has  recently  been  reported  to  be 
up-regulated in patients with IPF and that bronchial and alveolar epithelial cells are 
major sources of this zymogen.
88 The fact that sources of coagulation proteases are 
found  outside  of  the  circulatory  system  strengthens  the  recognition  of  their 
importance in processes other than haemostasis.  
Investigations into the participation of the coagulation cascade and its mediators in 
the progression of fibrosis have been carried out in mice using various strategies to 
block either the cascade itself or the activated proteases responsible for initiating 
cellular actions. Results have shown a reduction in lung collagen accumulation and 
fewer fibrotic lesions developing.
89 Mice deficient in the major thrombin receptor, 
PAR-1, also showed a large reduction in fibrosis, inflammatory cell recruitment and 
protection from experimental lung oedema.
82, 90 
Given these results, obtained by our collaborators in Professor Chambers’ research 
group, there is a clear interest in further investigation into the possible role of PAR-1 
in the progression of fibrotic lung diseases. 
1.5 Protease-Activated Receptors 
Since the 1970’s it has been recognised that the role of thrombin extends beyond that 
of  a  key  component  central  to  the  mechanisms  of  the  coagulation  cascade.
91 
Proteolytic cleavage of various zymogens in the coagulation cascade by the serine 
protease  thrombin  not  only  converts  fibrinogen  to  fibrin  but  also  generates  both 
positive and negative feedback mechanisms, resulting in regulation of the cascade 18 
(Figure  2,  page  4).  Further  to  this  role,  thrombin’s  hormone-like  behaviour  in 
stimulating cellular actions on various cell types led to the belief in the existence of a 
thrombin receptor.  
1.5.1 Discovery of PARs 
It was not until the early 1990’s that Vu and co-workers isolated cDNA encoding a 
functional human thrombin receptor, or PAR-1 as it is presently known.
92 Their work 
in  determining  the  amino  acid  sequence  of  the  receptor  revealed  it  to  be  a  new 
member  of  the  guanosine  nucleotide-binding  protein  coupled  receptor  (GPCR) 
superfamily, with an unusually extended amino-terminal extracellular chain.  
 
Figure 4 Protease-Activated Receptor-1.  
Two  observations  were  made  regarding  the  sequence  of  amino  acids  in  the 
extracellular  N-terminus:  i)  the  residue  sequence  leading  up  to  the  arginine  at 
position  41  (LDPR
41S
42)  mimicked  that  of  the  activation  cleavage  site  in  the 
zymogen protein C (LDPR/I, where “/” denotes cleavage site); ii) nearby to  this 
possible  cleavage  site  on  the  carboxyl  side,  a  succession  of  acidic  residues 
(D
50KYEPFWEDEE
60) resembled those found in hirudin - a potent anti-thrombin 
protein found in the saliva of leaches, which binds to the thrombin’s anion-binding 
exosite, inhibiting protease activity and blood coagulation (Figure 4).
93, 94 A novel 
mode of activation was proposed whereby cleavage of the extracellular N-terminus 
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chain between residues R
41 and S
42 uncovers a sequence of amino acids, termed a 
“tethered ligand”, which in turn binds to the receptor activation site. A synthesised 
peptide, representing the 14 amino acid chain uncovered following cleavage, was 
shown to be able to activate the receptor in the absence of thrombin. It was later 
demonstrated  that  the  minimum  length  required  for  efficient  activation  was  five 
residues (SFLLR-NH2) and synthetic peptides containing this motif became known 
as thrombin receptor activating peptides (TRAPs).
95 Site-directed mutagenesis of the 
receptor, replacing arginine with alanine at the proposed cleavage site, rendered the 
receptor  unresponsive  to  thrombin  even  at  high  concentrations  (10  nM),  yet 
activation  was  achieved  when  treated  with  TRAPs.
92  Thus,  the  novel  mode  of 
activation was accepted. 
Since the discovery of the first thrombin sensitive receptor a further three receptors 
bearing a cleavage site in their extended extracellular N-terminus chain have been 
isolated.  In  order  of  their  discovery  members  of  this  sub-group  of  GPCRs  were 
named PAR-1 to -4.
96-99 Some interesting differences and associations between the 
PARs have been documented over the years since their uncovering. All PARs reveal 
a  unique  sequence  of  amino  acids  following  proteolytic  cleavage: 
PAR-1  -  S
42FLLRN;  PAR-2  –  S
35LIGKV;  PAR-3  –  T
39FRGAP;  and  PAR-4  – 
G
48YPGQV. Thrombin is the major, though not exclusive, activating protease for 
PAR-1,  -3  &  -4,  whereas  PAR-2  is  activated  by  trypsin  in  most  cases,  a  serine 
protease  generated  in  the  pancreas,  which  is  itself  activated  by  enteropeptidase. 
Interestingly, although PAR-3 demonstrates high affinity for thrombin, due to the 
presence of a hirudin-like sequence on the extracellular N-terminus chain, cleavage 
fails to initiate cell signalling pathways. Yet PAR-3 has been shown to play a vital 
role  in  the  activation  of  mouse  platelets,  which,  unlike  human  platelets,  do  not 
express PAR-1.
100 Nakanishi-Matsui and co-workers revealed that in the absence of 
PAR-1, a PAR-3/PAR-4 affiliation operates whereby PAR-3 acts as a cofactor for 
PAR-4  activation,  which  lacks  the  hirudin-like  sequence  in  its  extracellular  N-
terminus chain. They propose that following cleavage of the PAR-3 extracellular 
chain, the thrombin active site is made available for cleavage of the neighbouring 
PAR-4 extracellular chain, which uncovers the tethered ligand leading to activation 
of  the  receptor  and  initiation  of  cell  signalling  pathways.  PAR-3  has  also  been 20 
suggested to play a regulatory role with PAR-1 by forming heterodimers and altering 
the extent to which cell signalling pathways are initiated.
101 
1.5.2 PAR-1 Signalling 
In recent years, the mechanisms involved in PAR-1 activation and subsequent signal 
transduction  have  been  revealed  to  be  of  much  greater  complexity  than  initially 
anticipated. As with other GPCRs, PAR-1 can initiate a variety of cell signalling 
pathways  by  affiliation  with  different  G-proteins,  as  well  as  the 
G-protein-independent β-arrestin-mediated pathways - this is known as functional 
selectivity or biased agonism (Figure 5).
102-104 For PAR-1, the pathway is dependent 
upon the nature of the activating protease and, in some cases, the locality of the 
receptor  on  the  cell  surface.  Although  thrombin  is  the  major  activating  protease 
associated with PAR-1, other proteases are also capable of cleaving the extracellular 
N-terminus chain. Cleavage can occur at various sites, some of which result in the 
removal of the SFLLR sequence, effectively deactivating the receptor in relation to 
thrombin activation.
105 Alternatively, unmasking a different sequence of amino acids, 
i.e. a different ligand, can lead to activation and preferential signalling via alternative 
pathways.
102  
Conventional  activation  of  PAR-1  on  endothelial  cells  by  thrombin  leads  to 
signalling mediated by the small GTPase RhoA, which induces pro-inflammatory 
responses  and  increases  endothelial  barrier  permeability.  However, 
compartmentalisation  of  PAR-1  into  micro-domains,  called  caveolae,  on  the 
epithelial cell surface can lead to activated protein C (APC) triggered activation, 
resulting  in  Rac1  mediated  signalling.
106  Different  cellular  actions  result,  though 
mediated by the same receptor, as APC activation is anti-inflammatory and stabilises 
the endothelial barrier.
107  21 
 
 
Cleavage  by  thrombin  or  MMP-1  favours  signalling  via  Gʱ12/13  whereas  activation  by 
TRAPs preferentially leads Gʱq signalling. Cleavage by deactivating proteases may arrest 
conventional signalling pathways whilst allowing alternative pathways to be triggered by 
different ligands. 
Figure 5 Functional Selectivity/Biased Agonism in PAR-1.
102 
Studies investigating the roles of FXa (Figure 2, page 4) have demonstrated that, as 
part  of  the  TF-FVIIa-FXa  complex,  this  protease  could  affect  cell  signalling  in 
endothelial  cells  via  cleavage  and  activation  of  PAR-1.
108  Similarly,  matrix 
metalloprotease (MMP)-1 has been shown to activate PAR-1 and, as with thrombin, 
induce signalling via the RhoA pathway; the cleavage site was deduced as being two 
residues  towards  the  N-terminus  from  the  thrombin  cleavage  site,  to  afford 
P
40RSFLLR as the activating sequence.
109 Human tissue kallikreins have also been 
shown  to  cleave  the  N-terminus  of  PAR-1  leading  to  activation  and  Ca
2+ 
mobilisation  in  human  embryonic  kidney  (HEK)  cells.
110  McLaughlin  and 
co-workers  demonstrated  that  PAR-1  activation  by  TRAPs  led  to  preferential 
signalling  via  Gʱq,  leading  to  Ca
2+  mobilisation,  rather  than  Gʱ12/13  as  favoured 
following thrombin activation.
111 This bias in signalling pathway is significant since 
both thrombin and TRAPs are used in biological assays investigating PAR-1 activity. 
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Conventionally, GPCRs are activated by the binding of an agonist released from a 
source in response to a stimulus. The docking of the ligand is reversible and the 
receptor  alternates  between  an  activated  and  deactivated  conformation,  with  the 
degree of activation dependent upon the concentration of the agonist. With higher 
concentrations of agonist, e.g. resulting from persistent stimulus, receptor occupancy 
is  high  and  desensitisation  occurs.  To  ensure  responsiveness  to  new  stimuli, 
intracellular events lead to endocytosis of the receptor, which is then recycled to the 
cell  membrane  ready  to  function  again,  or  directed  towards  lysosomes  for 
degradation.  
A consequence of the novel mechanism of activation observed in PARs is that the 
activating  ligand  is  tethered  to  the  receptor  and  once  exposed  affects  what  is 
essentially an irreversible interaction with the activation site. To overcome the issue 
of desensitisation, following activation PAR-1 is rapidly phosphorylated by several 
GPCR  kinases  (GRKs).  Deubiquitylation  of  the  activated  receptor  then  leads  to 
clathrin- and dynamin-dependent endocytosis and targeting to the relevant lysosomes 
for degradation.
112 Re-sensitisation is achieved through mobilisation of intracellular 
stores  of  PARs  to  the  cell  membrane,  while  up-regulation  of  PAR-1  expression 
replenishes these stores.
105 
1.5.3 PARs in other diseases 
PARs have been shown to be expressed by a variety of cell types and are found in 
almost  all  tissues  throughout  the  body.  It  is  therefore  understandable  that 
investigations have uncovered many roles for PARs in normal and various diseased 
states of the body. 
1.5.3.1 Cardiovascular Disease 
Based  on  the  importance  of  thrombin  in  haemostasis,  a  major  role  in  the 
cardiovascular  system  for  a  thrombin  receptor  was  predicted  decades  before  the 
discovery  and  isolation  of  PAR-1.  Subsequent  findings  of  elevated  levels  of 
expression of this receptor in platelets and endothelial cells supported the prediction. 
All PARs are now recognised to be expressed throughout the vasculature and have 23 
roles  in  the  regulation  of  platelet  functions,  endothelial  permeability,  leukocyte 
adhesion, nitric oxide release and the formation of atherosclerotic plaques.
102 
Activation of PAR-1 and PAR-2 on the endothelium triggers nitric oxide-mediated 
vasodilation  in  undamaged  endothelium.
113  However,  when  the  endothelium  is 
disrupted, PAR-1 and PAR-2 activation leads to vasoconstriction.
114 Up-regulation of 
PAR-1  expression  has  been  implicated  in  vascular  vasospasm  following 
subarachnoid haemorrhage, which is a major contributor to post-stroke morbidity and 
mortality.
115 PAR-1 inhibition has been shown to attenuate in vitro human platelet 
aggregation  and  thrombosis  in  animal  models,  suggesting  drugs  targeting  this 
receptor in the treatment of thrombosis may block platelet plug formation without 
causing  bleeding  diathesis.
116  Although  discovery  of  the  ability  of  PAR-4  to 
stimulate human platelet aggregation at higher concentrations of thrombin suggests 
antagonising both PAR-1 and PAR-4 may be required to be an effective treatment for 
thrombosis. 
1.5.3.2 Musculoskeletal Disorders 
Vergnolle and co-workers established a role for PAR-1 in peripheral inflammation 
when  in  a  rat  paw  oedema  model  the  receptor  was  shown  to  mediate  a 
pro-inflammatory response induced by thrombin activation.
117 Evidence since this 
has  indicated  a  significant  role  for  PARs  in  inflammation,  with  both  pro-  and 
anti-inflammatory,  as  well  as  nociception,  responses  to  activation  by  different 
proteases  being  observed.  Moreover,  diminished  inflammation  was  observed  in 
PAR-deficient animals.
105,  118 PAR-2 is implicated in joint inflammation and pain, 
with symptoms nullified in a rodent model of acute joint inflammation using PAR-2 
deficient mice.
119 
1.5.3.3 Gastrointestinal Disease 
All PARs are expressed on various cell types throughout the gastrointestinal (GI) 
tract  and  regulate  ion  transport,  mucosal  permeability,  epithelial  cell  motility, 
immune  cell  recruitment  and  nociception.
102  Activation  of  epithelial  PAR-1  and 
PAR-2  can  stimulate  chloride  secretion,  which  leads  to  diarrhoea,  a  common 
symptom in conditions such as inflammatory bowel disease. Epithelial cell apoptosis 24 
triggered  by  PAR-1  activation  increases  intestinal  permeability,  as  does  PAR-2 
through disruption of epithelial cell organisation at tight junctions. Blocking signal 
transduction  mediated  by  these  receptors  could  reduce  infiltration  by 
pro-inflammatory  mediators  and  combat  GI  inflammation  in  conditions  such  as 
colitis.
120,  121  However,  some  reports  suggest  PAR-1  also  exhibits  an 
anti-inflammatory property and may protect against infection in the gut.
122 PAR-1 
and PAR-2 have roles to play in both contraction and relaxation of the muscle tissue 
in  the  GI  tract,  which  is  responsible  for  motility,  disruption  of  which  leads  to 
increased GI transit time.
123, 124  
1.5.3.4 Respiratory Disease 
As well as the aforementioned role in fibrosis, which is the main concern of this 
research, PARs are also believed to have an influence on allergen-induced asthma. 
Neutralising  the  PAR-2  activating  ability  of  an  allergen  led  to  a  reduction  in 
eosinophil  recruitment  in  a  murine  model  of  asthma.
125  However,  there  is  some 
evidence that suggests PAR-2 activation also has an anti-inflammatory role in the 
airways.
126 This suggests that targeting this receptor with regards to the treatment of 
asthma may not be as straight forward as it might seem.  
1.5.3.5 Central Nervous System (CNS) Disorders 
PARs  and their  activating proteases  are  expressed on neuronal  and non-neuronal 
cells of the CNS and research suggests a variety of roles in both normal and diseased 
states.  PAR-1  demonstrates  bimodal  effects  dependent  upon  the  concentration  of 
activating  agents,  with  basal  activation  providing  protection  against  damaging 
stimuli, whereas high levels of activation can have deleterious effects on neurons.
127, 
128  In  low  thrombin  concentration,  PAR-1  activation  has  been  shown  to  reduce 
ceramide-induced astrocyte death, and activation by APC rather than thrombin may 
promote  neurogenesis  and  neovascularisation  in  post-ischaemic  brain.
129,  130 
However,  studies  suggest  PAR-1  predominantly  has  a  neurodegenerative  and/or 
pro-inflammatory role in response to trauma to the brain. PAR-1 deficiency in mice 
or treatment with a PAR-1 antagonist shows a beneficial effect in models for stroke, 
brain haemorrhage and neurotrauma, and increased PAR-1 expression in astrocytes 
has been discovered in patients with HIV-associated dementia.
131, 132 On the other 25 
hand,  PAR-2  activation  has  been  linked  to  neuronal  excitability,  synaptic 
transmission and plasticity, and demonstrates equally both protective and damaging 
roles.
102 
1.5.3.6 Cancer 
A number of proteases capable of activating PAR-1, including APC, the FVIIa-Xa 
complex, MMP1 and kallikreins, have been detected in tumours. 
133-135 Together with 
the known PAR-mediated mitogenic actions of thrombin and trypsin, a possible role 
for this receptor in tumour growth has been proposed. Tumour tissues from prostate 
and colon cancer, as well as malignant melanoma, have revealed upregulation in the 
expression of PARs and possible activating proteases.
136-138 PAR-1 has been linked 
with  promoting  tumour  cell  invasion  and  metastasis,  with  the  level  of  receptor 
expression correlating directly with metastatic potential.
139, 140  
1.6 PAR-1 Antagonist Development 
Given the broad spectrum of diseases in which PAR-1 has been implicated as having 
a role in pathogenesis, development of therapeutics that work by interacting with this 
receptor is an attractive, if somewhat challenging, target. As a consequence of its 
unusual mode of activation many different approaches to the inhibition of PAR-1 
signalling have been employed. Attention has been mainly focussed on: i) interfering 
between  the  activating  protease  and  the  extracellular  N-terminal  domain  with 
antibodies targeting the cleavage site; ii) cell penetrating molecules targeting and 
disrupting  the  interaction  of  the  receptor  with  signal  transducing  proteins;  and 
iii) small molecule attachment to the binding site blocking its interaction with the 
tethered ligand. The latter of these approaches has yielded the most success to date 
and will be discussed in the following sections. Work in this area has adopted two 
distinct approaches towards the development of active compounds: i) optimisation of 
non-peptidic compounds discovered through target based high throughput screening 
(HTS); and ii) rationally designed compounds derived from SAR data obtained for 
PAR-1 activating peptides. 
Due to the functional selectivity demonstrated by PAR-1, assays investigating the 
activity of new compounds on the receptor are routinely tested against both thrombin 26 
and  TRAPs  containing  the  peptide  sequence  TFLLR,  which  has  been  shown  to 
selectively activate PAR-1 over other PARs.
141 Doing so ensures identification of 
compounds active against PAR-1 signalling via Gʱq, Gʱ12/13 or both. 
1.6.1 Nonpeptidic PAR-1 Antagonists 
1.6.1.1 FR171113 
 
Figure 6 PAR-1 antagonist FR17113 
The first non-peptidic PAR-1 antagonist was developed at Fujisawa Pharmaceutical 
through optimisation of an undisclosed compound identified by HTS. In vitro testing 
of the optimised compound, FR171113 1 (Figure 6), in a human washed platelet 
aggregation assay demonstrated IC50 values of 0.15 μM and 0.29 μM versus TRAP-6 
(1 μM) and thrombin (0.1 NIH unit/mL or 0.9 nM), respectively.
142 FR171113 was 
also shown to inhibit FeCl3-induced carotid artery thrombosis in a dose-dependent 
manner in in vivo studies of arterial thrombosis in guinea pigs.
143 The compound is 
currently commercially available as a biological tool for investigating the role of 
PAR-1 in various diseases.    
1.6.1.2 Tri-substituted Ureas 
Barrow and co-workers at Merck research laboratories reported the identification of a 
potent,  non-peptidic  PAR-1  antagonist  2  (Figure  7)  following  the  screening  of 
combinatorial  libraries  of  compounds.
144  This  tri-substituted  urea  demonstrated 
sub-micromolar activity in a human washed platelet activation assay in competition 
with TRAP-5 (3 μM) as agonist.  
1  IC50 = 0.29 μM 27 
 
Figure 7 Tri-substituted ureas 
Optimisation of the initial hit included replacement of the central urea in compound 2 
with a pivaloyl protected amine. The shortened analogues gave compounds of similar 
potency but improved solubility and reduced molecular weight. However, loss of 
activity  occurred  in  the  absence  of  the  amide.  Other  key  residues,  leading  to 
significant  reductions  in  potency  in  their  absence,  were  identified  as  the 
3,4-dichlorophenyl ring, the secondary OH and the urea NH. A slight increase in 
bulk  of  the  urea  N-alkyl  substituent  led  to  the  development  of  analogues  with 
reduced IC50 values, the N-sec-butyl analogue 3 (Figure 7) proving to be the most 
potent with an IC50 = 0.23 μM
*. However, room for development here proved to be 
limited since the N-cyclopentyl analogue turned out to be inactive. The introduction 
of  rigidity  into  a  bioactive  molecule  is  often  favourable  in  order  to  hold 
pharmacophoric moieties in optimal spatial arrangements. In this case, incorporating 
the tertiary amine of the urea into a six-membered ring also gave a potent compound, 
4 (IC50 = 0.5 μM
*) (Figure 7). 
1.6.1.3 Isoxazoles 
Also  developed  within  the  Merck  laboratories  were  a  series  of  PAR-1  active 
isoxazoles,  which  were  discovered  following  directed  screening  based  on 
tri-substituted urea 5 (Figure 8).  
                                                 
* Platelet aggregation assay versus TRAP-5 (3 μM) 
2 
IC50 = 0.6 μM
* 
 
4 
IC50 = 0.5 μM
* 
3 
IC50 = 0.23 μM
* 
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Figure 8 Development of isoxazole analogues 
Isoxazole 6 (Figure 8), represented a structurally novel compound with moderate 
potency  (IC50  =  9  μM
†),  which  improved  significantly  following  optimisation.
145 
Modifications involved substitution on the N-benzyl substituent, expansion of the 
piperidine ring and substitution on the 3-aryl substituent. Optimisation resulted in 
compound 7 (Figure 8) which had IC50 values of 0.09 μM and 0.51 μM in a human 
washed platelet activation assay versus TRAP-5 (3 μM) and thrombin (1 nM) as 
agonists, respectively.   
1.6.1.4 E5555 (Atopaxar) 
 
 
Figure 9 Small molecule PAR-1 antagonists
‡ 
Atopaxar 8 (Figure 9) is a potent small molecule PAR-1 antagonist developed by 
Eisai, which demonstrates a high degree of affinity for the receptor. In a thrombosis 
model in guinea pigs, Atopaxar exhibited an anti-thrombotic effect and was also able 
                                                 
† Platelet aggregation assay versus TRAP-5 (3 μM) 
‡ Platelet aggregation assay versus thrombin 
5
 
  2 
7 
IC50 = 0.09 μM
† 
6 
IC50 = 9 μM
† 
7 
4 
8 (Atopaxar) 
IC50 = 64 nM
‡ 
 
12 (Himbucine)  
11 (Vorapaxar) 
IC50 = 47 nM
‡  
Merck - Launched  9  R = H;  IC50 = 0.3 μM
† 
10  R = Me; IC50 = 0.15 μM
† 29 
to inhibit neo-intimal hyperplasia in a rat balloon injury model.
146 Following very 
encouraging results in Phase I studies, the compound was entered into two Phase II 
clinical trials where it achieved a significant reduction in heart problems compared 
with the control group.
147 The clinical trials showed that although increased bleeding 
was seen as the dose of Atopaxar was increased, the risk of serious bleeding was not 
significantly higher. However, based on the number of test subjects experiencing 
dose-dependent  hepatic  dysfunction  and  QT  prolongation,  these  trials  had  to  be 
terminated  on  safety  grounds;  Eisai  decided  to  discontinue  the  development  of 
Atopaxar in 2012.  
1.6.1.5 SCH79797 
A  series  of  pyrroloquinazolines,  reported  by  Schering-Plough  to  be  active  small 
non-peptidic  PAR-1  antagonists,  were  discovered  by  HTS  of  the  company’s 
chemical compound library.
148 The initial hit required minor optimisation to yield 
two potent compounds, SCH79797 9 (Figure 9) and SCH203099 10 (Figure 9) with 
IC50  values  of  0.3  μM  and  0.15  μM,  respectively,  in  a  TRAP-induced  platelet 
aggregation assay. 
1.6.1.6 SCH530348 (Vorapaxar) 
Also  developed  by  Schering-Plough  scientists  initially,  and  later  by  Merck,  is 
Vorapaxar  11  (Figure  9),  which  is  currently  the  most  potent  PAR-1  antagonist 
known.  The  original  hit  in  the  developmental  series  for  this  compound  was  the 
natural product himbacine 12 (Figure 9), which was actually of interest as part of a 
research  program  into  Alzheimer’s  disease,  due  to  its  activity  at  muscarinic 
receptors.
149 One of the analogues in the developmental process was identified as 
having  PAR-1  antagonist  activity  and  was  progressed  further  in  this  alternative 
direction. Early in the optimisation process the enantiomer of himbacine was found 
to be greater than 10-fold more potent than the naturally occurring isomer.
150 Further 
developments  involved  variation  in  substitution  at  the  4-position  of  the  tricycle, 
before later incorporation of the ethyl carbamate at the 7-position to tackle clearance 
issues with the methylene precursor.
151 Vorapaxar demonstrated exceptional potency 
in  ex  vivo  human  platelet  aggregation  assays  induced  by  TRAP  (15  μM)  and 
thrombin (10 nM) with IC50 values of 25 nM and 47 nM, respectively.  30 
In 2011, Vorapaxar was  assessed in  two separate Phase  III clinical  trials for the 
treatment of myocardial infarction (MI) in patients with atherosclerosis (trial name: 
TRA2°P-TIMI  50)  and  patients  with  acute  coronary  syndrome  (trial  name: 
TRA-CER). Results from the TRA2°P-TIMI 50 trial found that Vorapaxar did not 
reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients 
with peripheral artery disease.
152 However, the compound was found to significantly 
reduce acute limb ischemia and peripheral revascularisation but an increased risk of 
bleeding accompanied these beneficial effects, which resulted in the termination of 
the trial. Initial results from TRA-CER indicated that Vorapaxar was associated with 
a reduction of MI, however, the trial was halted as a result of the findings in the 
TRA2°P-TIMI 50 study.
153  
Vorapaxar underwent review by the U.S. Food and Drug Administration for approval 
to be used for the secondary prevention of cardiovascular events in a sub-population 
of patients with a history of myocardial infarction or peripheral arterial disease but 
no history of stroke or transient ischemic attack (TIA). In May 2014, Vorapaxar was 
approved as the first-in-class PAR-1 antagonist for the treatment of patients with a 
history of health corresponding to that described above and is the API in Zontivity
TM.  
1.6.2 Peptidomimetic PAR-1 Antagonists 
Selective partial agonists and antagonists of the thrombin receptor, with low potency, 
had been reported even before the isolation and cloning of PAR-1.
154, 155 However, 
following elucidation of the amino acid sequence of the receptor, and in particular 
the discovery of the tethered ligand sequence SFLLR-NH2  13 (Figure  10), sharp 
progress  in  the development  of antagonists  ensued.
92 The later discovery that  all 
PARs had unique tethered ligand sequences gave reassurance that this approach may 
lead to selective PAR-1 active compounds.  31 
 
 
 
Figure 10 PAR-1 activating pentapeptide sequence (TRAP-5) 
A  number  of  SAR  studies  of  the  TRAPs  determined  the  minimal  structural 
requirements  for  PAR-1  agonism  to  be  attained.  These  were  reported  to  be  an 
N-terminal pentapeptide with an aromatic residue at position 2 (P2), a basic residue 
at P5 and a large hydrophobic residue at P4.
95, 156 A small side chain and free amine 
at P1 are also important, but substitution at P3 is widely tolerated. Investigations into 
the backbone conformation and N-methylation of TRAPs were carried out by Ceruso 
and co-workers suggesting that an extended conformation is required for receptor 
recognition, as well as the amide nitrogen between residues 1 and 2.
157 Carbonyl 
groups along the backbone were suggested to be involved in hydrogen bonding with 
the receptor. 
The proposition that PAR-1 was activated by the docking of the tethered ligand on 
the extracellular loops of the receptor was generally accepted; however, information 
regarding the actual binding site and specific interactions with the ligand was scarce. 
GPCRs traverse the cell membrane and isolation of this type of receptor in order to 
obtain  crystal  structures  is  notoriously  difficult  due  to  their  instability  when  not 
supported by the cell membrane. The only example of a resolved structure for a 
7-transmembrane  (7TM)  receptor  at  the  time  of  development  of  early 
peptidomimetic  PAR-1  active  compounds  was  bacteriorhodopsin.  Homology 
modelling  of  GPCRs  based  on  the  structure  of  bacteriorhodopsin  was  generally 
unreliable due to low sequence identity (i.e. similarities in amino acid sequence). 
Beavers and co-workers, however, reported a novel approach to building a model of 
PAR-1, which also incorporated a mutagenesis study of the receptor. The results of 
13  EC50 = 6.0 μM 
Ser   Phe   Leu   Leu   Arg 
P1    P2    P3    P4    P5 32 
this  study  highlighted  important  residues  required  for  the  effective  activation  of 
PAR-1.
158  The  extracellular  loops  (ECs)  were  noted  as  containing  many  acidic 
residues and individual mutagenesis of these with alanine identified D
256 on EC2 and 
E
347 on EC3 as having a major influence on ligand binding and receptor activation. 
Replacement  of  E
347  with  serine  also  led  to  loss  of  function,  implying  the 
requirement of an acidic residue rather than simply a hydrogen bond donor, and thus 
a likely electrostatic interaction with the ligand at this position. Loss of the di-sulfide 
bridge between cysteine residues C
175 and C
254 resulted in moderate loss of activity 
suggesting a role in receptor conformation.  
During the current research the stabilised crystal structure of PAR-1 bound with the 
potent  antagonist  Vorapaxar  was  reported,  which  may  assist  with  future 
developments towards PAR-1 antagonists.
159 
1.6.2.1 BMS-200261 
 
Figure 11 PAR-1 active synthetic peptides
§ 
Systematic substitution, by Bernatowicz and co-workers at Bristol-Myers Squibb, of 
the second and third residues in a pentapeptide analogue of TRAP -5 led to agonists 
with enhanced potency – S(p-fluoro)F(p-guanidino)FLR-NH2 14 (Figure 11) proved 
to be ~10-fold more potent than TRAP-5.
160 This was followed by substitution of the 
serine residue leading to the development of partial agonists initially, and eventually 
producing  full  antagonists.  BMS-200261  15  (Figure  11)  is  still  one  of  the  most 
potent PAR-1 antagonists for the inhibition of TRAP-7-induced platelet aggregation, 
with  an  IC50  ~20  nM.  However,  this  compound  was  unable  to  inhibit  platelet 
aggregation induced by thrombin.    
                                                 
§ Platelet aggregation assay versus TRAP-7 (3 μM) 
14 
EC50 = 0.04 μM 
15  
IC50 = 0.02 μM
§ 
 33 
1.6.2.2 RWJ-56110 
Expanding on the SAR work done previously on TRAPs, Hoekstra and co-workers 
looked  to  introduce  a  central  constraint  on  the  compounds  by  incorporating  a 
heterocycle at the 2/3 linker position.
161 Results showed that introducing an oxazole 
ring to yield compound 16 (Figure 12) was well tolerated but fell short of enhancing 
antagonist potency. McComsey and co-workers also looked at introducing rigidity to 
the  agonist  backbone,  by  replacing  serine  with  heterocycles  to  make 
heterocycle-peptide hybrids such as compound 17 (Figure 12), resulting in potent 
PAR-1 agonists and partial agonists.
162  
 
The  triangle  over  compound  13  illustrates  the  three-point  model  devised  by 
Andrade-Gordon and co-workers in their development of PAR-1 antagonists.  
Figure 12 Peptidomimetic PAR-1 active compounds
**†† 
                                                 
** Platelet aggregation assay versus thrombin (0.05-0.5 nM) 
†† Platelet aggregation assay versus thrombin (0.15 nM) 
16 
IC50 = 25 μM
** 
17  
EC50 = 0.76 μM 
18  
IC50 = 2.32 μM
†† 
13  
 
19 (RWJ-56110) X = CH; IC50 = 0.34 μM
†† 
20 (RWJ-58259) X = N; IC50 = 0.37 μM
†† 34 
A  de  novo  approach  was  employed  by  Andrade-Gordon  and  co-workers,  which 
considered the SAR data for PAR-1 agonist peptide epitopes developed to date, the 
spatial  constraints  in  the  TRAP-5  ligand  and  the  desirable  integration  of  a  rigid 
heterocyclic template in order to display key functional groups in the correct spatial 
positions.
163 A three-point model was proposed giving ideal distance ranges between 
the amine group (P1), the centre of the aromatic ring (P2) and the central carbon 
atom of the arginine residue (P5) (13, Figure 12).  
Various aromatic rings and heterocycles were investigated before incorporation of an 
indole framework led to an early lead compound with RWJ-53052 18 (Figure 12). 
An  SAR  study  of  this  compound  resulted  in  the  development  of  potent  PAR-1 
antagonist RWJ-56110 19 (Figure 12), demonstrating IC50 values of 0.16 μM and 
0.34 μM in a TRAP-6 (2 μM) and thrombin (0.15 nM) induced platelet aggregation 
assay, respectively. 
However, in a guinea pig model of ex vivo platelet aggregation to determine the 
ability  of  RWJ-56110  to  inhibit  the  actions  of  thrombin  on  platelets, 
i.v. administration of the compound was discovered to cause severe hypertension.
164 
1.7 RWJ-58259 
Investigations  into  the  hypertension  witnessed  in  the  ex  vivo  study  involving 
RWJ-56110 and analogues suggested that the size of the substituent at the 2-position 
of  the  indole  may  contribute  towards  the  unwanted  cardiovascular  side-effects. 
Exchanging  the  indole  framework  for  indazole  meant  that  the  2-position  was 
occupied by a lone pair of electrons only, which led to the development of the potent 
and  selective  PAR-1  antagonist  RWJ-58259  20  (Figure  12).  Not  only  did  this 
compound avoid the hypertensive issues seen with previous analogues, but it also 
demonstrated an increased binding affinity for PAR-1 whilst maintaining potency 
against TRAP-6 (2 μM) and thrombin (0.15 nM) in the platelet aggregation assay 
with  IC50  =  0.11  μM  and  0.37  μM,  respectively.
164  Further  RWJ-58259  in  vitro 
studies have also shown its ability to inhibit thrombin-induced Ca
2+ mobilisation in 
human and rat aortic smooth muscle cells (SMCs) (IC50 = 0.14 μM and 0.07 μM, 
respectively), cell proliferation in rat vascular SMCs (IC50 = 2.3 μM) and interleukin 
(IL)-6 release in human vascular SMCs (IC50 = 3.6 μM).
165  35 
Ex  vivo  studies  have  demonstrated  that  RWJ-58259  inhibits  low  concentration 
thrombin-induced  guinea  pig  platelet  aggregation  in  a  dose-dependent  manner 
following  i.v.  administration  at  0.3,  1.0  and  3.0  mg/kg.  At  high  thrombin 
concentration, RWJ-58259 failed to inhibit platelet aggregation due to the ability of 
PAR-4,  also  expressed  on  guinea  pig  platelets,  to  activate  this  cell  type  when 
exposed to higher levels of thrombin. RWJ-58259 also failed to reduce the weight of 
thrombus and time to occlusion in two different in vivo models in guinea pigs, which 
was reasoned to be due to sufficient presence of thrombin in vivo to enable activation 
of  PAR-4  via  the  PAR-3/PAR-4  heterodimer.  However,  in  cynamolgus  monkeys 
where  platelets  do  not  express  PAR-3,  as  in  humans,  time  to  occlusion  was 
significantly increased in an electrolytic injury-induced carotid thrombosis model.
166 
Carotid arteries from three out of five RWJ-58259-treated animals failed to occlude 
within the observation period (60 min) and the thrombi that did form were found to 
have a reduced platelet count. Also, RWJ-58259 was found not to affect the numbers 
of white/red blood cells and platelets in circulation, nor did it affect coagulation, with 
respect  to  activated  clotting  time.  These  findings  are  all  consistent  with  the 
selectivity of RWJ-58259 for PAR-1 mediated cellular responses to thrombin.  
A  rat  model  of  balloon-injury  induced  carotid  stenosis  investigated  the  use  of 
RWJ-58259 to inhibit PAR-1 mediated effects of thrombin on vascular SMCs during 
injury.
165 Normal responses include cell proliferation, ECM synthesis, inflammatory 
cytokine  release  and  changes  in  vascular  tone.  Perivascular  administration  of 
RWJ-58259 resulted in a reduction in intimal thickness and area; these results can be 
deemed to be independent of platelet action since rat platelets do not express PAR-1.  
1.8 Research Objectives 
As a result of the proven in vivo selectivity and potency of RWJ-58259 for PAR-1 
antagonism,  this  compound  was  selected  by  our  collaborators  in  the  Chambers 
research  group  as  a  tool  compound  to  investigate  the  role  of  PAR-1  in  the 
pathogenesis of IPF. However, some concerns were raised over the bioavailability of 
the compound following the report of studies in rats having been i.v. administered a 
dose of RWJ-58259 measuring a half-life (t½) of 0.32 h.
166  36 
A short t½ would not be a major issue for a drug in the treatment of pulmonary 
fibrosis since administration as an inhaled formulation would allow direct access to 
the site where treatment would be required. This would avoid the need for the drug to 
survive  first-pass  metabolism.  In  fact,  given  the  broad  distribution  of  PAR-1 
throughout the body and its possible roles in various diseases, a short t½ may be 
beneficial for a drug acting as a PAR-1 antagonist taken as an inhaled formulation. 
Side effects associated with off target PAR-1 inhibition may be minimised should the 
drug be rapidly metabolised once in circulation. 
Concerns do arise, however, when considering the use of RWJ-58259 as a research 
tool compound in animal models of pulmonary fibrosis. Although administering the 
drug  as  an  aspirated  formulation  to  allow  inhalation  by  the  animal  is  possible, 
inconsistencies in the amount of drug actually taken in by each animal has led to a 
preference  for  intraperitoneal  administration.  As  such,  systemic  distribution  is 
required in order to deliver the compound to the site of interest, which means such a 
short t½ would be an unfavourable characteristic.         
The main objective of this research was to develop analogues of the project lead 
compound RWJ-58259, which maintained its potency as a PAR-1 antagonist whilst 
improving its metabolic stability. This would involve expanding the currently limited 
drug metabolism/pharmacokinetic (DM/PK) profile of RWJ-58259 by investigating 
the  major  pathways  responsible  for  transforming  the  parent  compound  into  its 
metabolites. Identifying properties of the metabolites formed would allow for a better 
understanding of this compound’s activity in a biological setting, which may assist in 
deciphering  mechanisms  involved  in  the  progression  of  fibrosis.  Guided  by 
knowledge of the metabolic pathways involved in the transformation of RWJ-58259, 
analogues  would  be  synthesised  aiming  to  improve  metabolic  stability.  These 
compounds would then be used as tool compounds in future investigations into the 
pathogenesis  of  pulmonary  fibrosis  carried  out  by  our  collaborators  in  Prof 
Chambers’ research group.    
1.9 Review of RWJ-series SAR data  
During the optimisation process of the initial hit RWJ-53052 18 (Figure 12, page 33) 
a large amount of SAR data was generated by the investigators at Johnson & Johnson 37 
for compounds synthesised and tested in a platelet aggregation assay. Following the 
discovery of RWJ-58259, this information was made available through publication of 
patents  and  literature  articles  covering  their  discoveries.  With  the  intention  of 
synthesising  analogues  of  RWJ-58259  in  mind,  a  review  of  this  SAR  data  was 
important in order to guide any decisions made on proposed synthetic targets in the 
aim of maintaining PAR-1 antagonist activity. 
Biological activity data for 256 different compounds in the platelet aggregation assay 
was published allowing for important deductions to be made regarding the effect of 
structural variations in different regions of the compound on PAR-1 activity. Figure 
13 illustrates the balance of variations and the following sections will summarise the 
main findings for structural variation in the different regions of the molecule.   
 
 
 
 
Figure 13 Balance of structural variation seen from published SAR data 
1.9.1 Terminal substituent variation 
Investigation of the left-hand side (as drawn) terminal substituent saw the greatest 
variation of all the positions highlighted, with 56 structurally different substituents 
being tested. Though no significant improvement in IC50 values was demonstrated by 
analogues over the original benzylamine, results suggested that slight enhancement 
in binding affinity was  achieved for compounds with a basic moiety at the  para 
position or at the end of an alkyl chain of similar distance. Interestingly, it was also 
recognised that such compounds with a basic moiety at the terminal position showed 
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a greater tolerance for variation at the neighbouring amino acid position (P1, Figure 
13).  
Substitution  at  the  benzylic  position  was  investigated  with  incorporation  of  a 
(R)-CH3, (S)-CO2H or (S)-CO2CH3 group and were shown to be tolerated quite well 
with only a slight reduction in potency. 
1.9.2 Amino acid variation at P1 
In the absence of a basic moiety on the terminal substituent it was found that a basic 
residue on the side chain of this first amino acid position was essential. Conflicting 
results were given, however, with regards to the alkyl  chain length to the amine 
group. Binding affinity was shown to increase with chain length going from Dbu to 
Orn, and again to Lys; though IC50 values in the platelet aggregation assay improved 
in the opposite direction with the best result seen for Dbu.  Binding affinity was seen 
to increase with no loss of potency when the amine of Dbu and Orn residues was 
converted  to  the  bidentate  acetimidoamide  group.  The  tightest  binding  analogue 
comprised  a  combination  of  methionine  at  the  first  amino  acid  position  with 
ethane-1,2-diamine as the terminal substituent - however, this compound proved to 
be cytotoxic to platelets at higher concentrations.
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1.9.3 Amino acid variation at P2 
Biological data suggests the second amino acid position tolerates a wide range of 
variation  when  in  combination  with  an  Arg  residue  at  P1.  Tolerance  of  large 
lipophilic substituents such as Tyr(Bn) and di-Ph-Ala, increasing the IC50 value by 
less than an order of magnitude, suggests the presence of a significant lipophilic 
pocket close to this position. Variation became more restricted, however, when Arg 
was replaced with Dbu at the first amino acid position; though the best performing 
compounds involved the Dbu (P1) with 3,4-diF-Phe (P2) combination. 
A handful of analogues were synthesised where the urea linker was eliminated by 
reversing the order of the amino acid and coupling the indazole amine directly to the 
acid of the amino acid residue at P2. This resulted in loss of activity in most cases 
and a significant reduction in others and so the urea linker was retained.   39 
1.9.4 Heterocyclic frame variation 
Three different heterocyclic frames were investigated during the optimisation process 
and the transition from indole to indazole has already been discussed (see section 1.7, 
page 34). Also investigated was the benzimidazolone heterocycle, which despite only 
slightly reducing potency against low thrombin concentration (0.15 nM), showed a 
significant drop in binding affinity suggesting the effectiveness of such compounds 
may suffer against higher thrombin concentrations. 
The substitution position on the benzene ring of the heterocycle was also investigated 
but  deviation  from  the  6-position  for  linkage  to  the  dipeptide  fragment  failed  to 
produce any compounds of interest as PAR-1 antagonists.     
1.9.5 Indole N-substituent variation 
Substitution at the 1-position nitrogen of the heterocyclic ring system seems to be 
driven  by  sterics  rather  than  electronics  as  both  electron-donating  and 
electron-withdrawing groups are tolerated at the para position of a benzyl group - 
any substitution at the meta position is less tolerated. Slight improvements in IC50 
values were demonstrated for the 2,6-dichloro and the 2-methylbenzyl derivatives. 
Extending the ring system  to  a 2-naphthyl,  or  the alkyl  chain  to  two  CH2 units, 
resulted in a reduction in activity suggesting the presence of quite a tight fitting 
pocket into which this substituent lies. 
No  information  on  biological  data  or  the  synthesis  of  compounds  involving 
substitution at this benzylic position was reported.    
1.9.6 Indole 3-position variation  
From the data available it would seem that the heterocycle 3-position substitution is 
the least tolerant of all regions of the molecule. Any variation away from the original 
pyrrolidin-1-ylmethyl substituent results in a significant decrease in potency. The 
nearest performing analogue features an azetidine ring rather than a pyrrolidine ring, 
however this compound decreases potency by more than an order of magnitude.   40 
1.9.7 Summary  
Collectively, this SAR data provides valuable information that will assist in decisions 
made, following the determination of major metabolites from RWJ-58259, on the 
synthesis  of  analogues  aimed  at  improving  metabolic  stability  while  maintaining 
PAR-1  antagonist  activity.  Encouragingly,  it  would  seem  that  there  is  a  level  of 
tolerance in most regions of the molecule for small changes without impacting its 
activity on PAR-1. However, the drop in activity of any variation of the pyrrolidine 
is disappointing as options for analogue synthesis seem to be limited should this 
region prove to be the site of major metabolism. 
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  Lead Compound Validation  Chapter 2
2.1 Introduction 
It is imperative in every medicinal chemistry project that the identity and quality of 
the lead compound, against which all analogues are be compared, be verified in order 
to  avoid  the  generation  of  data  based  on  a  misconception  regarding  the  active 
compound.  Typically,  this  simply  requires  analysis  of  the  sample  by  analytical 
techniques such as high resolution mass spectrometry (HRMS) and nuclear magnetic 
resonance  (NMR)  spectroscopy.  The  sample  of  RWJ-58259,  20  (Figure  14), 
previously used within the Chambers research group was donated by  Dr Claudia 
Derian, Johnson & Johnson. Unfortunately, very little remained at the beginning of 
this research project and was deemed insufficient for the planned work.   
 
Figure 14 RWJ-58259 
RWJ-58259 is not commercially available and thus it was necessary to synthesise a 
new batch of the lead compound. The few aliquots that remained of the original 
batch were insufficient for analysis by NMR spectroscopy and were to be used as a 
standard to validate the new batch of synthesised RWJ-58259.  
2.2 Synthesis of RWJ-58259  
During the development of analogues of the initial hit in the RWJ-series of PAR-1 
antagonists, compound RWJ-53052 18 (Figure 12, page 33), the investigators utilised 
a solid-phase synthesis approach. Three strategies were employed for attachment of 
the anchoring substituent to the resin (Figure 15): i) following coupling of Fmoc-
Dbu(Boc)-OH with benzylamine and Boc deprotection, Dbu containing analogues 
were loaded onto a 2-chloro-trityl resin via the primary γ-N; ii) analogues capped 
with ethane-1,2-diamine were attached via the terminal primary amine, allowing for 
20 42 
variation  of  the  first  amino  acid  position;  and  iii)  an  amide-type  resin,  such  as 
Tentagel  S  AM,  was  used  to  attach  via  a  tertiary  amide  to  the  first  amino  acid 
position (Figure 15).
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Figure 15 Solid-phase synthetic strategies employed in RWJ-series 
Later,  a  convergent  solution-phase  method  was  described  for  the  synthesis  of 
analogues and it was this approach that Zhang and co-workers reportedly utilised for 
their  synthesis  of  RWJ-58259.
164  From  6-nitroindole,  the  right-hand  side  (RHS) 
fragment 25 (Scheme 1) was reportedly achieved in 4-steps in an overall yield of 
24%.   
 
Reagents and conditions: a) NaNO2, 6 N HCl, 5 h; b) pyrrolidine, NaB(OAc)3H, 
ClCH2CH2Cl/DMF/AcOH (90:9:1), 2.5 h; c) 2,6-dichlorobenzyl bromide, KOH, THF, 1 h; 
d) FeCl3.6H2O, activated charcoal, Me2NNH2, MeOH, reflux, 2 h. 
Scheme 1 RHS fragment synthesis 
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The first step involves a rearrangement of the indole starting material, as described 
by Buchi and co-workers, to form aldehyde 22.
168 Nitrosation of 6-nitroindole 21 
(Scheme  2)  with  sodium  nitrite  under  aqueous  acidic  conditions  leads  to  the 
formation of oxime 26. Nucleophilic attack by water at the 2-position and a second 
nitrosation  of  the  molecule  at  the  1-position  nitrogen  gives  an  ʱ-hydroxy 
nitrosamine, which in the presence of acid collapses, cleaving the C-N bond, to form 
the aldehyde and the hydroxydiazene moieties of compound 27. Loss of water drives 
the closure of the ring as the oxime at the pseudo 3-position reverts to the nitroso 
formation leading to nucleophilic attack on the pseudo 2-position nitrogen. Loss of 
nitric oxide restores aromaticity as 6-nitro-1H-indazole-3-carbaldehyde 22 (Scheme 
1) is formed.      
 
Scheme 2 Indazole Rearrangement Mechanism 
Reductive  amination  of  aldehyde  22  (Scheme  1)  with  pyrrolidine  and  sodium 
triacetoxyborohydride,  followed  by  N-alkylation  gives  the  1,3-disubtituted 
6-nitroindazole compound 24. Reduction of the nitro group is achieved using the 
mild  conditions  first  described  by  Boothroyd  and  Kerr.
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hydrazine, unconventional N,N-dimethylhydrazine is used as the reducing agent with 
a catalytic amount of ferric chloride hexahydrate to give amine 25.      
Left-hand side (LHS) fragment 33 (Scheme 3) was reported as being prepared from 
Fmoc-Dbu(Boc)-OH 28 in 65% yield over 4 steps. The first amide coupling installs 
the  benzylamine  cap  and  reaction  of  deprotected  amine  30  with 
Fmoc-3,4-difluoroPhe-OH 31, followed by a second Fmoc deprotection, yields the 
dipeptide LHS fragment 33.   
 
 
Reagents and conditions: a) BnNH2, DCC, HOBt, MeCN, 3 h; b) Et2NH, MeCN, 2 h; 
c) DIC, HOBt, 30, MeCN, 16 h 
Scheme 3 LHS fragment synthesis 
Converging  of  the  syntheses  of  RHS  and  LHS  fragments  25  and  33  involves 
formation of a urea linker. Zhang and co-workers reported the use of 4-nitrophenyl 
chloroformate as the coupling reagent for this step and, following the subsequent Boc 
deprotection, was accomplished in 26% yield to give RWJ-58259 20 (Scheme 4) as 
its TFA salt.   
 
Reagents and conditions: a) 4-nitrophenyl chloroformate, 
iPr2NEt, CH2Cl2, 
33, -20 to 23 °C, 6 h; b) CF3CO2H, CH2Cl2, 2 h. 
Scheme 4 Urea coupling 
a  b 
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More recently, Valdivielso and co-workers reported an optimisation of the synthesis 
of RWJ-58259, having experienced difficulties when utilising the original conditions 
for two of the synthetic steps.
170 They found that low yields were obtained for the 
N-alkylation  of  indazole  23  (Scheme  5),  and  decided  to  investigate  the  use  of 
alternative bases to promote the reaction. They reported that the use of either sodium 
hydride or triethylamine resulted in the formation of the undesired bromide of the 
di-alkylated compound as the major product – the second alkylation being on the 
pyrrolidine nitrogen (34, Scheme 5). However, an improved yield was achieved with 
the use of caesium carbonate, although a longer reaction time was required, giving 
the desired mono-alkylated product in 66% isolated yield. 
 
Reagents and conditions: 2,6-dichlorobenzyl bromide, Cs2CO3, THF (dry), argon, 24 h. 
Scheme 5 N-alkylation with modified conditions 
Valdivielso  and  co-workers  also  reported  difficulties  in  reproducing  the  urea 
formation  product  in  a  reasonable  yield  and  looked  to  employ  an  alternative 
approach.
170 This was achieved through in situ formation of the isocyanate of the 
indazole  amine  by  reacting  with  bis(trichloromethyl)carbonate  in  the  presence  of 
propylene oxide as an HCl scavenger. They reported that, following addition of the 
dipeptide amine, the desired urea product was obtained in a 91% yield.   
2.2.1 Synthesis of RHS fragment 
Encouraged  by  the  methodological  advances  reported  by  Valdivielso  and 
co-workers,  synthesis  of  RWJ-58259  was  initiated  following  their  improved 
methodology.  As described earlier, treatment  of 6-nitroindole with  sodium  nitrite 
under  acidic  conditions  led  to  nitrosation  and  subsequent  rearrangement  to 
6-nitroindazole-3-carbaldehyde  22  (Scheme  1,  page  42).  Purification  of  this 
compound by flash column chromatography  proved to be problematic due to the 
23  24  34 46 
instability of the aldehyde on silica. Thus the crude material was carried through to 
the next step without further purification. Gratifyingly, reductive amination of the 
aldehyde with pyrrolidine installed the tertiary amine moiety of 23 in 62% yield over 
2 steps. N-alkylation of 23 with 2,6-dichlorobenzyl bromide was achieved in good 
yield  following  the  improved  methodology  developed  by  Valdivielso  and  co-
workers, which employed caesium carbonate as the base (Scheme 5).
170  
Subsequent nitro reduction under the mild reaction conditions stated above (Scheme 
6) afforded RHS fragment 25 in good yield giving an overall yield of 28% over 
4 steps.      
 
Reagents and conditions: Me2NNH2, FeCl3.6H2O, act. charcoal, MeOH, reflux, 2 h. 
Scheme 6 Nitro reduction 
2.2.2 Synthesis of LHS fragment 
Synthesis of LHS dipeptide fragment 33 (Scheme 3, page 44) was initially attempted 
following the methodology described by Zhang and co-workers, using DCC with 
HOBt as coupling reagents for the first amide bond formation and DIC with HOBt 
for  the  second  coupling.  Purification  of  the  dipeptide  product  following  Fmoc 
deprotection proved difficult as the diisopropyl urea (DIU) by-product was found to 
co-elute with the desired product. Although dipeptide 33 was obtained in a calculated 
yield of 25%, this was contaminated with an equal amount of DIU by-product.  
It was envisaged that the use of EDC might result in better separation of by-products, 
since its water solubility would improve its removal during an acid work up. As 
such, the second amide coupling step was repeated using EDC, in conjunction with 
HOBt, to activate the acid (Scheme 7). Although purification of the desired product 
was  achieved,  it  was  found  that  the  reaction  yield  dropped  significantly  to  a 
disappointing 7%.  
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Reagents and conditions: EDC, HOBt, 30, MeCN, 16 h. 
Scheme 7 Second amide coupling step with EDC 
As a result of previous success within our laboratories with the use of HBTU in 
amide couplings, synthesis of LHS fragment 33 was attempted utilising this reagent 
with  HOBt  and  stirring  with  DIPEA  to  ensure  pre-activation  of  the  acid  before 
addition of the benzylamine. To our satisfaction, purification of the desired product 
proved  less  problematic  and  using  HBTU/HOBt  for  both  amide  coupling  steps 
resulted in the isolation of LHS fragment 33 in 57% yield over 4 steps (Scheme 8). 
 
 
Reagents and conditions: a) HBTU, HOBt, DIPEA, BnNH2, DMF, 5 h; b) Et2NH, DMF, 
5 h; c) HBTU, HOBt, DIPEA, 30, DMF, 16 h 
Scheme 8 LHS fragment synthesis 
2.2.3 Urea coupling step    
Unfortunately, despite Valdivielso et al. reporting formation of the desired product in 
a 91% yield, repeated attempts at the urea coupling reaction using this methodology 
failed  to  give  more  than  a  28%  yield  for  the  target  compound,  RWJ-58259  20 
(Scheme 9). As this yield was too low to justify carrying large quantities of relatively 
a  b 
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expensive reagents through the preceding steps, alternative coupling conditions were 
investigated. 
 
Reagents and conditions: a) triphosgene, propylene oxide, THF (dry), 33, 0 to 20 °C, 1 h; 
b) HCl (4 N) in MeOH, 2 h. 
Scheme 9 Urea coupling and deprotection 
It was anticipated that use of a  nucleophilic/base catalyst such as DMAP, which 
could act as both catalyst and HCl scavenger in the reaction, would promote the in 
situ formation of the isocyanate. To investigate this prediction in a model system, 
H-Phe-OMe (36) was used in place of LHS fragment 33 to react with RHS fragment 
25  on  a  test  scale  (20.0  mg)  to  give  di-substituted  urea  35  (Scheme  10).  NMR 
analysis of the crude reaction was used in order to determine the success of a number 
of reaction conditions  based on the degree of conversion of starting materials  to 
products. 
 
Reagents  and  conditions:  triphosgene,  DMAP  or  propylene  oxide,  THF  (dry), 
H-Phe-OMe, 0 to 20 °C, 1 h. 
Scheme 10 Urea coupling investigation model system 
The  homo-coupled  (2S,2’S)-dimethyl  2,2’-[carbonylbis(azanediyl)]bis(3-
phenylpropanoate) 37, is a potential by-product of this reaction. In order to identify 
and  exclude  any  signals  in  the  crude  NMR  relating  to  37,  the  compound  was 
synthesised, purified and analysed by NMR.  
Compound  37,  was  prepared  by  stirring  amine  36  with  bis(trichloromethyl) 
carbonate and Et3N (Scheme 11) at room temperature for 1 h. The 
1H NMR spectrum 
a, b 
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of the product obtained allowed for the identification of chemical shift changes for 
specific protons of interest upon urea coupling, which are indicated in Scheme 11.      
 
Reagents and conditions: triphosgene, Et3N, THF (dry), 20 °C, 1 h. 
Scheme 11 Di-Phe-OMe urea synthesis 
In order to compare the use of DMAP with that of propylene oxide, as used by 
Valdivielso  and  co-workers,  the  reaction  conditions  reported  for  the  modified 
RWJ-58259  synthesis  were  employed  in  the  model  system  (Scheme  10).  RHS 
fragment 25 was stirred with bis(trichloromethyl) carbonate and propylene oxide at 
0 °C for 5 min before addition of aliphatic amine 36 at room temperature and stirring 
for  1  h. 
1H  NMR  spectroscopy  showed  no  discernible  peaks  relating  to  desired 
product 35 nor for the possible homo-coupled products - di-Phe-OMe 37 and di-RHS 
fragment 38.  
The reaction was repeated with the use of DMAP in place of propylene oxide and, 
following a 30 min period of stirring at ambient temperature, aliphatic amine 36 was 
added at 0 °C. This time new peaks were observed in the 
1H NMR spectrum of the 
crude material. Peaks recognised as those representing starting materials 25 and 36 
were  seen  –  the  ʱ-H  doublet  of  doublets  (dd)  at  ʴ  3.70  and  neighbouring 
diastereomeric Hs doublet of dd (ddd) at ʴ 2.83 and 3.06, as well as the aromatic Hs 
of the indazole positions 4, 5 and 7 at ʴ 7.45 (d), 6.53 (dd) and 6.49 (d), respectively. 
Also present were new  peaks of interest which did not match those seen for the 
starting materials nor the homo-coupled by-product 37, indicating successful urea 
coupling to give desired product 35. Assisted by H-H correlation spectroscopy, peaks 
corresponding to the protons mentioned above were identified in a new environment. 
The ʱ-H at ʴ 4.82 coupled to diastereomeric Hs at ʴ 3.06 and 3.14, and to the NH at ʴ 
5.86; the integration of these peaks matched precisely with those for aromatic Hs at ʴ 
7.49,  6.70  and  7.70,  which  correlated  to  each  other  as  seen  in  indazole  25  for 
positions 4, 5 and 7. Analysis of the sample by mass spectrometry also showed the 
presence of a mass ion corresponding to [compound 35+H]
+.  
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Confident that the desired urea coupling product 35 could be identified from the 
crude  reaction  mixture  by 
1H  NMR  spectroscopy,  variations  in  the  reaction 
conditions  were  investigated  for  an  improvement  in  conversion  to  the  desired 
product.  
 
Reagents and conditions: triphosgene, DMAP, 0 to 20 °C, 1 h, Method A-E. 
Scheme 12 Reaction scheme for urea coupling investigation 
Table 1 Showing products identified from urea coupling reaction (Scheme 12) 
    Starting Materials  Products  Ratio of 25 in products 
Method  Solvent  36  25  35  37  35 : 38 : 25 : other
d 
A  THF  1 eq  2 eq  64%
c  0%  0.32 : 0.13 : 0.13 : 0.42 
B  CH2Cl2  1 eq  2 eq  45%
c  0%  0.23 : 0.52 : 0.02 : 0.24 
C
a  THF  1 eq  2 eq  77%
c  0%  0.39 : 0.04 : 0.04 : 0.54 
D
b  THF  1 eq  2 eq  48%
c  0%  0.24 : 0.10 : 0.17 : 0.50 
E  THF  1 eq  0.95 eq  33%
c  0%  0.33 : 0.07 : 0.07 : 0.54 
a
 – the suspension of 25 in THF was sonicated for 5 min before addition of triphosgene and 
DMAP; b - suspension of 25 in THF was added dropwise to a solution of triphosgene and 
DMAP in THF; c - not isolated; d - ratio of initial amount of 25 converted to 35, 38, other 
unidentified products, or unreacted 
Table 1 shows the calculated yields obtained for the desired urea product 35. Also 
shown is the ratio of the initial amount of 25 converted to 35, 38, other unidentified 
35  25  36 
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products or which remained as unreacted 25 - giving an indication of the progress of 
the first part of the reaction to form the isocyanate intermediate. During the original 
execution of the reaction (Method A) it was seen that RHS fragment 25 is sparingly 
soluble in THF and so the reaction was repeated in CH2Cl2 (Method B), in which the 
starting material indazole 25 is soluble. Unfortunately, although more of the starting 
material reacted, this seemed to promote the reaction of 25 with its isocyanate form 
to generate the homo-coupled product 38. Rather than changing to a third solvent, 
Method C involved sonication of the suspension of 25 in the original solvent, THF, 
prior to addition of the other reagents, thus ensuring aggregation was minimised. 
This resulted in a reduction in the relative amount of 38 forming and an increase in 
the conversion of 36 to the desired urea coupled product 35.  
It was reasoned that further reduction of the amount of 38 formed may be achieved 
by  reversing  the  order  of  addition  of  reagents  in  the  first  step,  i.e.  adding  the 
sonicated suspension of 25 in THF to a solution of triphosgene and DMAP in THF. 
Dropwise addition would introduce amine 25 to an environment of excess coupling 
reagent, promoting the formation of the isocyanate over the homo-coupled product. 
Stirring the triphosgene with DMAP before addition of the amine may also activate 
the  coupling  reagent,  again  leading  to  preference  of  the  amine  to  react  with  the 
coupling reagent over the isocyanate intermediate. The result shown for Method D 
contradicts our reasoning, suggesting that less of the starting material reacted either 
to  form  the  isocyanate  intermediate  or  the  urea  by-product  38.  This  suggests  a 
shortage of the coupling reagent and might be explained by the initial activation 
period stirring with DMAP in THF. Nucleophilic attack on triphosgene releases a 
molecule of phosgene, which is itself a coupling agent – hence the requirement of 
0.35 eq. only of triphosgene. However, phosgene has a boiling point of ca. 8 °C and, 
despite the reaction mixture being kept at 0 °C, some may have evaporated leaving a 
shortage of the coupling reagent. 
Valdivielso  and  co-workers  reported  that  increasing  the  equivalence  of  dipeptide 
fragment 33 above 0.5 eq. did not improve the overall yield and only resulted in the 
unreacted  starting  material  co-eluting  with  the  desired  urea  coupled  product. 
Investigating the effect of increasing the equivalence of the aliphatic amine seemed 
to confirm their findings with the ratio of unreacted 36 increasing in Method E.       52 
It was decided to implement the conditions of Method C into a reaction involving an 
inexpensive dipeptide fragment to avoid the unnecessary potential loss of the more 
valuable RWJ-58259 LHS fragment 33, and yet still generate an analogue of interest. 
During  the  development  of  RWJ-58259  Zhang  and  co-workers  showed  that 
analogues where the terminal aromatic moiety was switched with the primary amine 
functional group of the first amino acid position also demonstrated potent PAR-1 
antagonist activity.
171 In some cases these analogues displayed an increased binding 
affinity to the receptor; although inferior selectivity for PAR-1 was also witnessed 
for some analogues. Encouraged by these reported findings, dipeptide fragment 44 
(Scheme 13) was seen as a useful compound to be used to confirm the validity of the 
modified urea coupling reaction conditions.   
tert-Butyl (2-aminoethyl)carbamate 39 was prepared in excellent  yield by stirring 
di-tert-butyl  dicarbonate  with  a  10-fold  excess  of  ethylenediamine  in  CHCl3 
overnight,  followed  by  evaporation  of  the  unreacted  amine  under  high  vacuum. 
Amide coupling of amine 39 with Fmoc-Phe-OH 40 was achieved using coupling 
reagent HBTU with HOBt, and subsequent Fmoc deprotection gave amine 42. The 
reaction sequence was repeated to install the second Phe residue giving the desired 
Boc protected dipeptide product 44 in 25% yield over 4 steps (Scheme 13). 
 
Reagents and conditions: a) HBTU, HOBt, DIPEA, DMF, 39, 3 h; b) Et2NH, DMF, 2 h; 
c) HBTU, HOBt, DIPEA, 42, DMF, 16 h 
Scheme 13 LHS fragment analogue synthesis 
Implementing the optimised conditions (Method C, Table 1), urea coupling of RHS 
fragment  25  with  dipeptide  fragment  44  and  subsequent  Boc  deprotection  was 
a  b 
c  b 
40  41  42 
43  44  40 53 
achieved in 53% yield to give compound 45 as an analogue of RWJ-58259 (Scheme 
14).      
 
Reagents and conditions: a) triphosgene, DMAP, THF, 44, 0-20 °C, 2 h; 
b) HCl (4 N) in 1,4-dioxane, 20 °C, 2 h 
Scheme 14 Urea coupling and Boc deprotection with modified conditions 
Despite still being far from the 91% yield reportedly achieved by Valdivielso and 
co-workers, a significant improvement had been achieved on previous attempts at the 
urea coupling reaction. As a result it was decided that the conditions could be utilised 
in the synthesis of a new batch of RWJ-58259 20 (Scheme 15). Satisfyingly the 
coupling and deprotection steps were achieved in a 53% yield to furnish compound 
20.  
 
 
Reagents and conditions: a) triphosgene, DMAP, THF, 33, 0-20 °C, 2 h; 
b) HCl (4 N) in 1,4-dioxane, 20 °C, 2 h 
Scheme 15 Urea coupling and deprotection to generate RWJ-58259 
2.3 Biological evaluation 
Having  successfully  synthesised  a  new  batch  of  RWJ-58259  it  was  necessary  to 
evaluate its antagonistic activity against PAR-1 and compare this with the previous 
batch of RWJ-58259 used in the Chambers research group. This was done to ensure 
continuity of the quality of data gathered, as well as to validate the structure of active 
compound  in  the  previous  batch.  For  clarity,  despite  having  the  same  chemical 
structure, the batch synthesised during this research is referred to as compound 20 in 
the biological results, and the previous sample as RWJ-58259. 
a, b 
25  45 
a, b 
25  20 54 
2.3.1 In vitro testing 
As introduced in section 1.5.2 (page 20), activation of PAR-1 triggers various cell 
signalling  pathways,  with  preference  for  the  signal  transduction  route  depending 
upon the nature of the activating ligand. Activation following cleavage by thrombin 
favours signalling via the Gʱ12/13 sub-unit and further through the actions of RhoA. 
This small GTPase is a key component in the regulation of diverse cellular processes, 
including stress fiber formation, actin skeleton organisation, gene expression and cell 
division.
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Thrombin induced activation also triggers signalling via the Gʱq sub-unit, albeit not 
to  the  extent  to  which  the  Gʱ12/13  sub-unit  is  activated,  which  initiates  the 
phospholipase C (PLC) signal transduction pathway. Activated PLC is responsible 
for the cleavage of phosphatidylinositol 4,5-biphosphate (PIP2) into diacyl glycerol 
(DAG)  and  inositol  1,4,5-triphosphate  (IP3).  IP3  is  released  into  the  cytosol  and 
interacts with IP3 receptors on the smooth endoplasmic reticulum resulting in the 
release  of  Ca
2+  ions  into  the  cytosol,  which  bind  to  and  activate  various  signal 
transduction components affecting numerous cellular processes. DAG remains bound 
to  the  cell  membrane  following  cleavage  of  PIP2  by  PLC  and  activates  protein 
kinase C  (PKC),  which  goes  on  to  phosphorylate  and  activate  the  Raf1  enzyme, 
among various other proteins, leading to the regulation of gene transcription via the 
mitogen-activated  protein  kinases/extracellular  signal-regulated  kinases 
(MAPK/ERK) signalling pathway.    
In vitro testing methods employed previously within the Chambers research group 
have involved measurement of: i) phosphorylated ERK and total ERK, by western 
blot; and ii) the production and secretion of chemokine (C-C motif) ligand 2 (CCL2), 
by an enzyme-linked immunosorbent assay (ELISA).  However, early efforts with 
the western blot assay revealed significant variability in results gathered. This made 
it difficult to compare accurately between compound 20 and RWJ-58259 other than 
to  confirm  that both  are  somewhat  active against thrombin at  low concentration. 
Therefore, initial in vitro testing to evaluate the biological activity of compound 20 
was focussed on CCL2 ELISA.    55 
On  account  of  RWJ-58259  and  analogues  being  compounds  of  interest  in  the 
development of PAR-1 antagonists to investigate pulmonary fibrosis, the primary 
choice  of  cell  type  employed  for  in  vitro  testing  was  the  human  lung  fibroblast 
(HLF). This was due to the central role the fibroblast cell is believed to play in the 
progression  of  disease  through  proliferation  and  differentiation  into  the 
myofibroblast cell (see section 1.4.3.1). To confirm that results generated with the 
use of HLFs translate accordingly to murine lung fibroblasts (MLFs), since in vivo 
studies are done in mice, initial in vitro testing was done using both cell types.  
2.3.1.1 CCL2 ELISA 
Expression and secretion of chemokine CCL2 is known to be promoted in various 
cell types in response to exposure to thrombin. CCL2 plays an important role in the 
recruitment  of  various  leukocytes  to  the  site  of  injury  through  chemotaxis  -  the 
movement of cells in response to chemical stimulus. An ELISA was used to analyse 
the  ability  of  compound  20  to  inhibit  CCL2  release  in  both  HLFs  and  MLFs. 
Previous work done in the Chambers group by Deng and co-workers had shown 
thrombin signalling to be mediated exclusively via PAR-1 in MLFs, demonstrated by 
the ability of PAR-1 antagonist Q94 to arrest secretion of CCL2 triggered by high 
thrombin concentrations (10 nM).
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Interestingly, more recent work showed that treatment of HLFs with RWJ-58259 
failed to fully prevent CCL2 release following exposure to even low concentrations 
of  thrombin  (0.3  nM);  no  inhibition  was  achieved  at  a  concentration  of  10 nM 
thrombin.
174  Incubating  the  HLFs  with  a  combination  of  cleavage-blocking 
monoclonal  antibodies  (ATAP2  and  WEDE15),  prevented  CCL2  release  at  low 
thrombin  concentration;  however,  at  high  thrombin  concentration  these  too  were 
unable to achieve full inhibition. These findings suggest that CCL2 secretion results 
from thrombin signalling mediated by an alternative route in conjunction with PAR-1 
in HLFs. This may be due to contribution from PAR-4 since this receptor’s lower 
thrombin  affinity  would  mean  signalling  via  PAR-4  would  be  triggered  at  high 
thrombin concentrations.  
 56 
Results  from  the  ELISA  for  compound  20  corroborate  previous  findings  in  that 
CCL2  release  is  reduced  but  not  fully  inhibited  in  HLFs  treated  with  0.3  nM 
thrombin. However, in MLFs treated with 10 nM thrombin full inhibition of CCL2 
secretion was achieved by compound 20 (Figure 16).  
   
Figure 16 CCL2 release in response to thrombin following treatment with 
compound 20; A - in HLFs, B - in MLFs 
2.3.2 In vivo testing 
In order to confirm that the positive in vitro testing results were transferrable to an in 
vivo setting, compound 20 was entered into a mouse model of LPS-induced lung 
inflammation. PAR-1 activation is known to regulate the release of pro-inflammatory 
mediators, including various cytokines and chemokines, which play an integral role 
in the orchestration of the response to injury.
175 One of the earliest responses is the 
recruitment of leukocytes to the area affected and first to respond are neutrophils, 
arriving within minutes of the injury occurring (see section 1.2.1, page 4). Recent 
work reported by the Chambers research group has demonstrated that blockade of 
PAR-1 activation by administration of RWJ-58259 in mice leads to a reduction in 
acute neutrophil recruitment at 3 h after LPS administration.
176 This reduction is also 
maintained, not simply delayed, since measurements at 6 h and 24 h also showed 
reduced numbers of neutrophils in bronchoalveolar lavage (BAL) fluid. Their work 
suggested an important role for chemokines CCL2 and CCL7 in the early recruitment 
of neutrophils, since their expression was identified as being up-regulated in cells in 
response to LPS, and PAR-1 antagonism with RWJ-58259 was shown to attenuate 
their levels of expression. Levels of macrophages recruited after LPS administration 
were shown not to be affected by neutralisation of CCL2 and CCL7 with anti-CCL2 
Control 
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A  B 
Medium  Compound 20  Medium  Compound 20 57 
and anti-CCL7 antibodies, respectively. This indicates an enhanced role for CCL2 
and CCL7 in the recruitment of neutrophils in particular, whereas recruitment of 
other  leukocytes  depend  on  other  chemokines  and  cytokines,  the  expressions  of 
which are likely affected to a lesser degree by PAR-1 antagonism. 
2.3.2.1 LPS-induce lung inflammation study 
Compound  20  was  administered  intraperitoneally  to  mice  30  min  after  being 
challenged with LPS from Streptococcus pneumoniae. Mice were euthanized 24 h 
after exposure to LPS, lungs were lavaged and the cells counted. 
The neutrophil cell counts were shown to be reduced as a result of treatment with 
compound  20  compared  with  those  of  mice  not  given  the  PAR-1  antagonist 
(A, Figure  17);  this  result  unequivocally  confirmed  the  quality  of  synthesised 
compound 20 to be equivalent to RWJ-58259. The ineffectiveness of anti-CCL2 and 
anti-CCL7  antibodies  in  the  reduction  of  macrophage  cell  counts  following 
LPS-induced lung inflammation was also verified through the failure of compound 
20 to reduce the numbers of macrophages recruited to the site of injury (B, Figure 
17).   
   
Figure 17 Cell counts in BAL fluid 24 h after LPS challenge;  
A - neutrophils, B - macrophages 
With the quality of compound 20 confirmed through thorough biological evaluation, 
work could begin on DM/PK profiling of the compound and the development of 
analogues for biological testing with compound 20 as the standard.    
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  Synthesis of Analogues  Chapter 3
3.1 Introduction 
Having confirmed the biological activity of compound 20 relative to that of results 
obtained for the original batch of RWJ-58259, the remainder of the investigation 
could  commence  with  confidence  in  the  identity  and  quality  of  the  project  lead 
compound. 
The next stage of the investigation involved the synthesis of analogues of the project 
lead compound aimed  at  improving metabolic stability while maintaining PAR-1 
antagonist activity. In order to decide on synthetic targets, information was required 
on the metabolic pathways to which RWJ-58259 is susceptible. DM/PK profiling of 
RWJ-58259 would provide information on the major metabolites formed; using this 
information  in  conjunction  with  the  data  obtained  from  literature  regarding  SAR 
studies  of  the  RWJ-series  of  PAR-1  antagonists,  analogues  of  interest  could  be 
selected as synthetic targets. 
Synthesised compounds would then be tested in in vitro studies with HLFs against 
compound 20 as the standard. However, due to the variability experienced in the 
western blot assay and the time consumption associated with running the ELISA, it 
was decided that development of a new assay would be beneficial for the in vitro 
testing of analogues generated during the investigation. This decision was influenced 
by  the  accessibility  to  a  Fluorescence  Imaging  Plate  Reader  (FLIPR)  at  UCL’s 
Department of Physiology. As a consequence, assay development would be required 
in order to ensure accurate and relevant data is acquired.   
3.2 DM/PK profiling 
Very  little  information  is  reported  in  literature  on  the  pharmacokinetics  of 
RWJ-58259; only a short paragraph details the findings of Damiano and co-workers 
on the DM/PK profile of the compound following administration to rats and from a 
human liver microsomes assay.
166 They report a t½ of 9.2 min for RWJ-58259 in a 
human liver microsome assay with oxidation and hydroxylation of the pyrrolidine 59 
ring being the major metabolites formed - though no information is given on the 
precise  location  of  metabolism  or  the  degree  of  oxidation.  The  t½  following 
intravenous  administration  of  the  compound  in  rats  was  measured  as  0.32  h. 
Expanding  the  DM/PK  profile  of  RWJ-58259  would  benefit  future  in  vivo 
investigations using this compound and assist in the development of metabolically 
stable analogues.   
The intended approach  for DM/PK profiling of compound  20 involved firstly an 
investigation into the chemical stability of the compound. The reported negligible 
bioavailability of RWJ-58259 following oral administration in rats may suggest a 
possible issue with the compound surviving conditions found in the digestive tract.
166 
Therefore, it was decided an investigation into the hydrolytic stability of compound 
20 over a range of pH may provide information as to why oral administration is 
unsuccessful.  
Secondly,  using  the  facilities  made  available  through  our  collaborators  at  GSK, 
compound  20  would  be  submitted  to  a  liver  microsome  assay,  as  described  by 
Damiano and co-workers; however, since our in vivo studies are carried out in mice, 
microsomes from mouse as well as from human livers would be used. Data gathered 
from the liver microsome assay would give valuable information on the clearance 
time of compound 20 in mice, which would assist in future decisions on dosing 
regimen for in vivo studies. Analysis of the supernatant from the liver microsome 
assay by LC/MS/MS and by nanoscale 
1H NMR would allow for the identification of 
major  metabolites  generated  during  incubation  of  compound  20  with  the 
microsomes.  
Finally, using the analytical techniques described to analyse supernatant from the 
microsome  assay  (vide  supra)  and  guided  with  information  gained  regarding 
clearance times of compound 20, blood samples taken at time intervals from mice 
treated  with  the  compound  would  be  analysed  to  identify  major  metabolites 
generated in vivo. Based on the identity of these metabolites and those identified 
from the liver microsome assay, analogues of compound 20 could be synthesised 
with structural modifications aimed at blocking major sites of metabolism with the 
intention  of  generating  a  more  metabolically  stable  analogue  with  potent  PAR-1 
antagonistic properties.  60 
Unfortunately, due to complications at GSK during the time of this research, access 
to the facilities required for the running of the liver microsome assay was reduced. 
This resulted in a delay in obtaining the data required for deciding on approaches 
towards  synthesising  analogues  of  interest.  Fortunately,  however,  access  was 
provided to in silico screening facilities at GSK allowing calculated predictions to be 
made for the major sites of metabolism. This approach was adopted whilst access to 
the liver microsome assay was restricted. 
3.2.1 Hydrolytic stability study 
The hydrolytic stability of compound 20 was investigated to determine whether a 
range of physiologically relevant pH would be tolerated. Although the amide bond is 
considered  relatively  stable  to  hydrolysis  under  physiological  conditions,  the 
presence  of  neighbouring  groups  may,  in  some  cases,  act  to  catalyse  the  bond 
cleavage.
177 The chemical stability of compound 20 in an aqueous environment with 
pH ranging from 4 to 9 was investigated with the aim of identifying products of 
hydrolysis. The compound was incubated in buffered solutions of pH 4, 7.4 and 9, at 
20  °C  and  37 °C,  and  aliquots  of  the  solutions  were  taken  for  analysis  at  time 
intervals of 10 min, 3 h, 24 h, 48 h.  
 
     
A - compound 20 standard; B - pH 7.4, 37 °C at 24 h; C - pH 4, 37 °C at 24 h; D - pH 9, 37 
°C at 24 h. The peak at 20 s represents the injection peak and the broad peak at the end 
results  from  high  organic  solvent  content  in  the  mobile  phase  washing  trace  levels  of 
organic compounds from the column.  
Figure 18 ES+ TIC traces for hydrolytic study of compound 20 
Analysis of the samples by LC/MS showed only the parent compound present up to 
48 h, suggesting compound 20 is stable to hydrolysis at physiologically relevant pH. 
ACQ-SQD#F07SQD113W
13-Dec-2011
Time
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
%
0
100
ER95_2_dmso1 1: Scan ES+ 
TIC
5.21e9
1.62
ACQ-SQD#F07SQD113W
14-Dec-2011
Time
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
%
0
100
ER95_2_ph4_24hrs37 1: Scan ES+ 
TIC
5.00e9
1.66
0.27
ACQ-SQD#F07SQD113W
14-Dec-2011
Time
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
%
0
100
ER95_2_ph7_4_24hrs37 1: Scan ES+ 
TIC
1.33e9
1.68
0.29
4.25
4.20 4.44
ACQ-SQD#F07SQD113W
14-Dec-2011
Time
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
%
0
100
ER95_2_ph9_24hrsRT 1: Scan ES+ 
TIC
1.18e9
0.29
4.27 1.68 4.19
4.48
A 
B  D 
C 61 
3.2.2 In silico screening 
Compound 20 was submitted for in silico screening by our collaborators at GSK. The 
screening methodology used, MetaSite (Molecular Discovery Ltd), requires only the 
compound structure information in SMILES format. A 3D structure is generated, 
from  which  a  set  of  descriptors  is  obtained  for  each  atom  using  GRID  probe 
pharmacophore  recognition.  Individual  atoms  are  categorised  based  on  their 
hydrophobic, hydrogen-bond donor, hydrogen-bond acceptor, or charge capabilities 
and their distances in space are binned and converted into clustered distances. A 
fingerprint for each atom in the substrate molecule is generated and compared with 
the fingerprint of human cytochrome P450s (CYPs) recognised as being responsible 
for major drug metabolism. Sets of descriptors based on GRID flexible molecular 
interaction  fields  are  generated  for  CYP1A2,  CYP2C9,  CYP2C19,  CYP2D6  and 
CYP3A4 to give the enzyme fingerprint. The fingerprint of both the substrate and the 
enzyme  are  compared  and  a  score  is  calculated  for  the  reactivity  (Ri)  and 
accessibility  (Ei)  of  each  atom  (i)  in  the  substrate.  The  site  of  metabolism  is 
described as a probability function: PSM,(i) = EiRi. 
The output gained from MetaSite ranks the probability of each atom to be a site of 
metabolism, calculated from its propensity to undergo the reaction type associated 
with  the  enzyme  as  well  as  the  atom’s  accessibility  towards  the  enzyme’s  heme 
group  (Figure  19).  The  output  also  includes  the  likely  products  resulting  from 
metabolism at the most probable sites (Figure 20, page 62). 
   
Graph shows scores calculated for the probability of an atom being a site of metabolism 
with colour coding identifying the position of the atom in the drawn structure; blue - most 
likely; dark red - likely; light red - less likely. See appendix for full MetaSite output.  
Figure 19 Representation of MetaSite output for compound 20  
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Figure 20 Predicted major metabolites formed from RWJ-58259 
As demonstrated in Figure 19 Representation of MetaSite output for compound 20, 
probability  scores  are  displayed  for  each  atom  and  major  sites  likely  to  be 
metabolised  are  highlighted.  For  compound  20,  MetaSite  predicted  the  benzylic 
position  of  the  terminal  benzylamine  (atom  number  7)  as  the  major  site  of 
metabolism, suggesting that this site is likely to undergo oxidation to form (R)-ʱ-
hydroxybenzylamine  analogue  46  (Figure  20).  This  compound  is  likely  to  be  an 
intermediate for both of the compounds predicted as the next most likely metabolites; 
cleavage of the C-N bond leaves primary amide 47 or further oxidation of 46 to yield 
benzamide derivative 48 (Figure 20).  
The benzylic position of the N-(2,6-dichloro)benzyl substituent (atom number 47) 
was ranked as the atom next most probable to be a site of major metabolism, again 
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with oxidation leading to the (S)-ʱ-hydroxy-(2,6-dichloro)benzyl analogue 49 and 
subsequent cleavage of the C-N bond to give 1H-indazole 50 (Figure 20).  
Also  highlighted  as  important  sites  to  consider  with  regards  to  metabolism  of 
compound 20 were the 3-position of the pyrrolidine ring (atom numbers 44 & 45) 
and the methylene substituent at the 3-position of the indazole (atom number 41). 
Taking this information into account, it is possible the hydroxylation and oxidation 
of the pyrrolidine ring, reported by Damiano and co-workers, occurs at the 3-position 
making it an important site to consider investigating.
166 
3.3 Analogue synthesis 
   
Figure 21 Primary synthetic targets 
Guided by the information gained from the in silico screen of compound 20, initial 
focus for the synthesis of analogues aimed at reducing metabolism centred on both 
benzylic positions highlighted in the MetaSite output (Figure 19). It was proposed 
that installation of a relatively small substituent at these positions would be enough 
to reduce their accessibility to the heme group at the active site of the metabolising 
enzyme, yet would be small enough so as not to interfere with vital interactions of 
the compound within the binding site of PAR-1, thus maintaining antagonist activity. 
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The methyl group was selected as the substituent to be introduced at these benzylic 
positions to investigate its effect on biological activity of the compound. Therefore, 
initial synthetic targets were decided as compounds 51 and 52 (Figure 21). 
On  account  of  the  reported  findings  by  Damiano  and  co-workers  regarding 
metabolism of RWJ-58259, it was decided attention should also be directed towards 
the pyrrolidine ring of the molecule. Major metabolites identified from a human liver 
microsome assay involving RWJ-58259 were reported to result from hydroxylation 
and oxidation of the pyrrolidine ring. Taking this information in context with the data 
obtained  from  the  MetaSite  output,  in  which  the  3-position  of  the  ring  was 
highlighted as a probable site of metabolism by CYPs, an analogue with a substituent 
at this position was proposed as a compound of interest (Figure 22). 
 
Figure 22 Secondary synthetic target 
3.3.1 α-Methylbenzylamine analogue synthesis 
Employing a convergent approach to the synthesis of compound 20 meant it was 
necessary only to alter the synthesis of the LHS fragment, followed by urea coupling 
to the previously synthesised RHS fragment  25, in order to achieve analogue  51 
(Figure 21).  
Due  to  the  MetaSite  prediction  that  oxidation  would  lead  to  the 
(R)-ʱ-hydroxybenzylamine  analogue  46  (Figure  20)  stereoisomer  preferentially, 
synthesis of both ʱ-methyl stereoisomers at this benzylic position was explored to 
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see  whether  a  difference  in  metabolic  stability  and  biological  activity  would  be 
observed. Employing the previously validated synthetic route,  acid 28 was activated 
by stirring with HBTU/HOBt in the presence of DIPEA for a short period (3 min) 
before  the  introduction  of  either  (R)-  or  (S)-1-phenylethanamine  (Scheme  16). 
Following  Fmoc  deprotection,  amine  54a/54b  was  stirred  with  HBTU/HOBt 
activated acid 31 to achieve compounds 56a and 56b in good yield (59% and 57%, 
respectively) after a second Fmoc deprotection step. 
 
 
Reagents and conditions: a) HBTU, HOBt, DIPEA, DMF, (R)- or (S)-1-phenylethanamine, 
3 h; b) Et2NH, DMF, 2 h; c) HBTU, HOBt, DIPEA, 54a or 54b, DMF, 16 h 
Scheme 16 Synthetic route to LHS fragment analogues 
Urea coupling of amine 56a/56b to amine 25 was achieved via the in situ isocyanate 
formation of the aniline amine by the optimised conditions  described earlier (see 
section 2.2.3, page 47). 
 
 
Reagents and conditions: a) triphosgene, DMAP, THF, 56a or 56b, 0-20 °C, 2 h; 
b) HCl (4 N) in 1,4-dioxane, 20 °C, 2 h 
Scheme 17 Urea coupling and Boc deprotection 
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Compounds  51a  and  51b  were  obtained  in  reasonable  yield  following  Boc 
deprotection and purification by preparative HPLC.  
3.3.2 α-Methyl-(2,6-dichloro)benzyl analogue synthesis 
For the synthesis of compound 52 a slight modification of the RHS synthetic route 
was required to allow the installation of the methyl group at the benzylic position. 
The modified RHS fragment could be coupled to LHS fragment 33 to give the target 
compound. 
Preparation of the alkylating reagent was required beforehand and was achieved, as 
shown in Scheme 18, in excellent yield. 2,6-Dichlorobenzaldehyde 57 was treated 
with methyl Grignard reagent under an inert atmosphere at 0 °C for 90 min to give 
the secondary alcohol in quantitative yield as a clear yellow oil following the work 
up. The crude product was then stirred with triethylamine at 0 °C, to which was 
added methanesulfonyl chloride and after 90 min, purification of the reaction mixture 
gave the desired mesylate product 58 in 76% yield as a white crystalline solid.  
 
Reagents and conditions: a) MeMgBr (3 M) in Et2O, THF (dry), Argon, 0 °C, 1.5 h; 
b) MsCl, Et3N, CH2Cl2, 0 °C, 1.5 h 
Scheme 18 N-alkylating reagent synthesis 
N-alkylation  of  indazole  23  with  mesylate  58  (Scheme  19)  proved  to  be  more 
difficult than the equivalent reaction with the 2,6-dichlorobenzyl bromide, likely to 
be due to the added steric hinderance by the methyl group at the site of nucleophilic 
attack. The reaction would not proceed without heating, and even after stirring at 
50 °C in THF for 24 h only 25% yield of the desired product 59 was isolated. It was 
noticed that regioisomer 60 was also generated in a ~5% yield, with N-alkylation 
occurring at the 2-position rather than the desired 1-position. In order to heat the 
reaction  mixture  at  a  higher  temperature  a  solvent  change  was  required;  it  was 
reasoned  that  using  a  more  polar  solvent  might  assist  in  stabilizing  the  anion 
formation  and promote  N-alkylation  at  the 1-position.  Unfortunately, the ratio of 
compounds 59:60 was not improved by heating at 100 °C in DMF, however the 
57
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conversion of starting material to products was improved with compounds 59 and 60 
being isolated in 55% and 14% yield, respectively. As a result, sufficient material 
was obtained to carry N-1-alkylated indazole 59 through to the next step. Reduction 
of the nitro group gave amine 61 in 84% yield.  
 
Reagents and conditions: a) CsCO3, 58, DMF, 100 °C, 20 h; b) FeCl3.6H2O, activated 
charcoal, Me2NNH2, MeOH, reflux, 2 h. 
Scheme 19 Synthetic route to RHS fragment methylated analogue 
Urea coupling with dipeptide fragment 33 followed by Boc deprotection provided 
target compound 52 in 35% yield (2 steps) after purification by preparative HPLC 
(Scheme 20). 
 
Reagents and conditions: a) triphosgene, DMAP, THF, 33, 0-20 °C, 2 h; 
b) HCl (4 N) in 1,4-dioxane, 20 °C, 2 h 
Scheme 20 Urea coupling and Boc deprotection 
3.3.3 3-Fluoropyrrolidine analogue synthesis 
When deciding on the substituent to introduce at the pyrrolidine 3-position, a review 
of  the  published  literature  surrounding  the  development  and  optimisation  of 
a, b 
61  52 
a 
b 
23  59  60 
61 68 
RWJ-58259  related  compounds  showed  very  little  variation  away  from  the 
pyrrolidine ring structure for this region of the molecule.
163, 164, 171 Structure-activity 
relationship  (SAR)  data  published  in  patents  filed,  indicate  that  variation  in  this 
region of the molecule is not well tolerated (see section 1.9.6, page 39). A significant 
drop in antagonist activity is seen when bulkier substituents are introduced, as well 
as compounds incorporating a secondary rather than a tertiary amine. Therefore, it 
was proposed that introducing a fluorine atom at the 3-position (62, Figure 23) may 
reduce the likelihood of hydrogen atom abstraction occurring by CYPs, which leads 
to hydroxylation of the carbon atom.  
 
Figure 23 Secondary synthetic target 
Fluorine  is  generally  considered  a  good  bioisostere  for  hydrogen  in  medicinal 
chemistry,  since  many  structural  and  chemical  features  correspond  closely.
178 
Fluorine is the most electronegative atom in the periodic table and as a result its three 
lone pairs of electrons are held tightly by its highly positive nucleus. This renders the 
fluorine atom practically inert to interactions such as resonance or hydrogen bonding, 
unlike nitrogen or oxygen. Many consequences of its electronegativity make fluorine 
the atom/group closest resembling hydrogen in its structural properties. Fluorine’s 
atomic radius is the nearest matching to that of hydrogen (F = 1.47 Å, cf H = 1.2 Å), 
as  is  its  bond  length  to  carbon  (C-F  =  1.35  Å,  cf  C-H  =  1.09  Å).  This  means 
substitution  of  hydrogen  with  fluorine  results  in  minimal  steric  influence.  The 
carbon-fluorine bond is also the strongest bond in organic chemistry with regards to 
homolytic  cleavage  (bond  dissociation  energy  for  C-F  =  105.4  kcal  mol
-1, 
cf C-H = 98.8 kcal mol
-1), which again is a consequence of the high electronegativity 
of fluorine. The C-F bond is highly polarised with most of the electron density near 
the fluorine atom and can be considered more electrostatic in character than covalent. 
Such properties make fluorine a good substitution for hydrogen at  likely  sites of 
metabolism by CYPs, due to increased difficulty in breaking the C-F bond.   
62
62 69 
Therefore synthesis was initiated towards the production of RHS fragments 65a and 
65b (Scheme 21), in which a fluorine atom was incorporated into the pyrrolidine 
3-position as either the R- or S-stereoisomer. As with compounds 51a and 51b, both 
stereoisomers were synthesised to identify any difference in metabolic stability when 
submitted to liver microsome assays.    
As with other RHS fragments, synthesis began from 6-nitroindole 21 and following 
rearrangement to indazole 22, reductive amination of the aldehyde was carried out 
with either (R)- or (S)-3-fluoropyrrolidine to give 63a and 63b in yields of 62% and 
59%, respectively. N-alkylation with 2,6-dichlorobenzyl bromide was achieved in 
good  yield  for both  64a  and 64b;  it was  noted during purification that  retention 
factors (Rf) for these fluorinated compounds on thin layer chromatography (TLC) 
plates were significantly higher than those seen for compounds 24 and 59 (Scheme 1, 
page 42  and  Scheme  19,  page  67,  respectively).  This  suggested  the  extreme 
electronegativity of the fluorine atom may be having an effect on the basicity of the 
neighbouring tertiary amine, which made the compounds easier to purify by flash 
column chromatography. However, this raised concern as to what effect this may 
have on biological activity, since it is likely that the tertiary amine is involved in 
binding site interactions within PAR-1. 
 
 
Reagents and conditions: a) NaNO2, 6 N HCl, 5 h; b) (R)- or (S)-3-fluoropyrrolidine, 
NaB(OAc)3H, CH2Cl2/DMF/AcOH (90:9:1), 3 h; c) 2,6-dichlorobenzyl bromide, CsCO3, 
THF, 20 h; d) FeCl3.6H2O, activated charcoal, Me2NNH2, MeOH, reflux, 3.5 h. 
Scheme 21 Synthetic route to RHS fragment 3-fluoropyrrolidine analogues 
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Nitro  reduction  was  achieved,  requiring  a  slightly  longer  reflux  time,  to  give 
compounds 65a and 65b as pale yellow solids in 72% and 76% yields, respectively.    
Fluorinated RHS fragments 65a and 65b were coupled to the original RWJ-58259 
LHS  fragment  33  by  the  optimised  conditions  to  give  the  Boc  protected 
intermediates in 58% and 64% yield, respectively (Scheme 22). Stirring with HCl 
(4 N) in 1,4-dioxane for 2 h then purification by preparative HPLC gave compounds 
62a and 62b in good yield as white solids after repeated lyophilisation from 0.1 M 
HCl (aq).  
 
 
Reagents and conditions: a) triphosgene, DMAP, THF, 33, 0-20 °C, 2 h; 
b) HCl (4 N) in 1,4-dioxane, 20 °C, 2 h 
Scheme 22 Urea coupling and Boc deprotection 
3.4 Metabolite generation 
In conjunction with investigations into the development of analogues with improved 
metabolic stability, it was considered of interest to examine the biological activity of 
possible metabolites generated from RWJ-58259. Since the compound demonstrates 
efficacy in in vivo studies, and yet has been shown to have such a short t½, it was 
reasoned that metabolism of RWJ-58259 may be generating metabolites that are also 
active against PAR-1, which may be prolonging the expected antagonistic activity of 
the parent compound. To this end it was reasoned that 3-pyrrolidinol analogue 66 
(Figure 24) could be synthesised in much the same way as fluorinated analogues 62a 
and  62b,  avoiding  the  requirement  of  developing  an  alternative  synthetic  route. 
Compound 66 was seen as the representative metabolite proposed by information 
gathered from the MetaSite output together with the findings reported by Damiano 
and co-workers.
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Figure 24 Metabolite target for synthesis  
Also investigated, with assistance from our collaborators at GSK, was the use of 
biocatalysis as an approach to generate a range of possible metabolites directly from 
compound 20. Interest in the use of biocatalysis in industry has increased in recent 
years as greater emphasis is put on environmental sustainability for manufacturing 
processes. No longer seen as the slow option, suitable only for academic curiosity, 
biocatalysis has  seen rapid  development  recently. With the increasing  number of 
protein  structures  being  solved,  growing  understanding  of  protein  functions  in 
biosynthesis and development in computational methods, the process of engineering 
enzymes  for  specific  conversions  at  precise  locations  on  a  substrate  has  become 
highly efficient. As a result, the use of biocatalysis in industry has escalated where 
employing  engineered  enzymes  to  perform  chemical  conversions,  which  would 
otherwise involve a number of synthetic steps, results in improved efficiency and 
ultimately cuts costs. 
It was decided to investigate the use of a Codex
® screening panel (Codexis) to screen 
a  range  of  engineered  microbial  CYP  enzymes  for  activity  on  compound  20. 
Enzymes found to be actively metabolising compound 20 would then be incorporated 
in  scaled  up  reactions  with  the  aim  of  generating  sufficient  amounts  of  the 
metabolites in order to isolate and screen them in our in vitro studies for biological 
activity.  
3.4.1 3-Pyrrolidinol analogue synthesis 
The  3-pyrrolidinol,  to  be  introduced  by  reductive  amination  of  indazole  22,  was 
acquired as the N-Boc protected compound. As such, Boc deprotection was required 
and achieved in quantitative yield by stirring in diethyl ether whilst bubbling HCl (g) 
through the solution. 
66 
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Reductive amination of aldehyde 22 with the Boc deprotected 3-pyrrolidinol was 
achieved in 39%  yield over the two steps from indole  21. Indazole 67 was then 
N-alkylated  with  2,6-dichlorobenzyl  bromide  to  give  indazole  68  in  57%  yield 
(Scheme 23). Nitro reduction was achieved after an extended period at reflux to give 
RHS fragment 69 in 63% yield.   
  
Reagents and conditions: a) NaNO2, 6 N HCl, 5 h; b) 3-pyrrolidinol, NaB(OAc)3H, 
CH2Cl2/DMF/AcOH (90:9:1), 3 h; c) 2,6-dichlorobenzyl bromide, CsCO3, THF, 20 h; 
d) FeCl3.6H2O, activated charcoal, Me2NNH2, MeOH, reflux, 5 h. 
Scheme 23 Synthetic route to RHS fragment 3-pyrrolidinol analogue 
It  was  noticed  during  the  synthesis  that,  similar  to  the  equivalent  fluorinated 
6-nitroindazoles  (64a  and  64b),  the  Rf  for  compound  68  on  TLC  plates  was 
significantly  raised  compared  to  the  original  RWJ-58259  equivalent  synthetic 
intermediate, compound 24. However, introduction of an OH group could not be 
seen as reducing the polarity of the compound. In fact a cLogP for 68 was calculated 
at 3.44 compared with 4.83 for compound 24 (Figure 25), suggesting a significant 
reduction  in  lipophilicity  with  the  introduction  of  an  OH  group,  as  would  be 
expected.  
 
Figure 25 Calculated Log P values for intermediates 
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An alternative explanation may be that the hydrogen of the alcohol group is involved 
in weak hydrogen bonding with a π-bond in the aromatic indazole ring system. This 
may  result  in  reduced  interaction  of  the  OH  group  with  the  silica  during 
chromatography, leading to the increased Rf values witnessed.  
Urea coupling of RHS fragment 69 with dipeptide fragment 33, followed by Boc 
deprotection, gave target compound 66 after purification by preparative HPLC and 
lyophilisation from dilute HCl (aq) (Scheme 24); disappointingly only a 19% yield of 
product was achieved.  
 
Reagents and conditions: a) triphosgene, DMAP, THF, 33, 0-20 °C, 2 h; 
b) HCl (4 N) in 1,4-dioxane, 20 °C, 2 h 
Scheme 24 Urea coupling and Boc deprotection 
3.4.2 Biocatalysis 
The Codex
®
 panel is a 96-well plate with each well containing a different engineered 
microbial  enzyme.  These  enzymes  are  selected  for  their  range  of  reaction  type 
activity  and  high  tolerance  for  substrate  variability.  The  panel  is  used  to  screen 
compounds against a wide range of enzyme classes in order to identify enzymes for 
which  the  compound  is  a  substrate.  The  screen  identifies  the  class  or  classes  of 
enzyme(s) to be investigated further with the objective of discovering or developing 
an engineered enzyme that could be employed to carry out chemical conversions on 
the compound of interest. 
Since  the  aim  of  this  investigation  was  to  generate  possible  metabolites  of 
RWJ-58259  in  order  to  screen  them  for  PAR-1  activity,  a  range  of  engineered 
microbial CYPs were used. Compound 20 was dissolved in a 5% dextrose solution 
and added to the wells, which contained the enzymes dissolved in the reaction buffer 
solution, to give a final concentration of 0.1 mg/mL of compound 20. A porous lid 
was applied to avoid cross contamination between wells and yet allow air to reach 
a, b 
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the reaction mixture, and the plate was shaken thoroughly (250 rpm) at 30 °C for 16 
h. The contents of each well were then diluted with acetonitrile causing the protein to 
precipitate out, the plate was centrifuged and the remaining solution analysed by 
LC/MS to identify any compounds of interest generated. 
The  results  from  LC/MS  analysis  showed  that  despite  positive  controls  proving 
conditions to be optimal for enzyme activity, no reactions were seen to occur in wells 
containing  compound  20. Although this  result  seemed disappointing initially, the 
positive  consequence  of  this  outcome  is  the  indication  that  compound  20  is  not 
extensively metabolised. It is important to state that the Codex
® panel enzymes are 
engineered based on genetic information from microbial CYPs, which are generally 
seen as being more active and stable than plant or animal enzymes, making them 
more suitable for industrial purposes. As a result their activity towards compound 20 
is likely to differ from human or mouse CYPs. However, the fact that compound 20 
proved to be inert to engineered enzymes selected for their activity and substrate 
tolerance would suggest that any metabolism occurring as a result of interaction with 
human or mouse CYPs may be restricted to very few pathways. This would prove to 
be an encouraging result since blocking metabolic pathways might require only very 
few modifications of the project lead compound to achieve the extended t½ desired.    
3.5 Biological evaluation of analogues 
In order to be able to evaluate the compounds generated in the course of this research 
it  was  necessary  to  have  a  robust  method  of  screening  compounds  for  activity. 
Ideally this method would allow for the possibility of its use in a high throughput 
format for potential long ranging applications. Previous in vitro assays used within 
the  Chambers  research  group  to  investigate  PAR-1  inhibition  have  involved  the 
phosphorylated ERK/total ERK western blot and the CCL2 ELISA; however, both 
assays are relatively time consuming and labour intensive and so an alternative assay 
was investigated.  
3.5.1 Calcium ion mobilisation assay 
Access to a Molecular Devices FLIPR Tetra High Throughput Cellular Screening 
System  at  the  Department  of  Physiology,  UCL,  encouraged  us  to  look  into  the 75 
possibility  of  running  a  calcium  ion  mobilisation  assay.  PAR-1  activation  by 
thrombin is known to lead to a quick response in the release of Ca
2+ into the cytosol, 
which  contributes  to  the  activation  of  various  components  responsible  for  signal 
transduction  (see  section  2.3.1,  page  54).  Use  of  a  dye,  which  upon  Ca
2+ 
complexation  increases  its  fluorescence,  allows  for  the  real-time  monitoring  of 
PAR-1 activation and data derived from measurements of fluorescence detected are 
obtained immediately following the running of the assay. This method would reduce 
the  experiment  time  by  up  to  two  days  and  use  of  a  96-well  plate  with  a 
well-designed plate layout would maximise the number of compounds possible to 
test in each assay run. 
3.5.1.1 Assay development 
Use of the FLIPR was made to analyse the degree of PAR-1 activation in HLFs 
following exposure to thrombin. The Fluo-4 AM dye (Molecular Probes®) was used 
to  complex  with  Ca
2+  and  HLFs,  grown  to  confluence  in  96-well  plates,  were 
incubated with either: i) the dye in media only, as control or, ii) dye in media with 
the compound of interest. Since Ca
2+ mobilisation is a relatively quick response to 
PAR-1 activation, addition of the agonist was automated and added to each well 
simultaneously by the FLIPR. The cells were irradiated with light of wavelength (λ) 
470-495 nm, which resulted in excitation of the Ca
2+-Fluo-4 AM complex and its 
emission of light at λ = 515-575 nm was detected. The degree of PAR-1 activation 
was determined by measuring the amount of fluorescence detected over a period of 
time. 
Initially  the  assay  was  run  in  the  absence  of  any  compounds,  with  varying 
concentration of thrombin. This was in order to ensure the Ca
2+ release response was 
measurable  and  to  determine  the  effect  of  agonist  concentration  on  degree  of 
response.  
The initial result was very promising as illustrated in Figure 26 where, in the absence 
of an antagonist, the time and extent of the Ca
2+ mobilisation response is clearly 
related to the concentration of thrombin administered.     
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Figure 26 Ca
2+ mobilisation responses over time in HLFs to varying concentrations 
of thrombin  
The  concentrations  of  thrombin  used  were  chosen  to  represent  low  (0.3  nM), 
standard (3 nM) and high (10 nM) levels of thrombin. Physiological concentrations 
of thrombin vary depending upon the state of the surrounding tissue, since thrombin 
exists as its zymogen, prothrombin, until activation of the coagulation cascade leads 
to its cleavage by FXa (see Figure 2, page 4). In extravascular compartments a range 
of  0.05-0.13  nM  is  considered  typical  for  the  low  thrombin  concentrations  seen 
following  initiation  of  the  coagulation  cascade.  This  concentration  rises  to 
1.2-2.4 nM by the time of clot formation  (22-26 min), due to amplification of the 
initial activation through thrombin’s positive feedback mechanisms.
179 Much higher 
concentrations  of  thrombin  are  possible  for  intravascular  injuries,  however,  a 
concentration  of  10  nM  was  considered  high  yet  physiologically  relevant  with 
respect to the our interest in injuries occurring to the pulmonary interstitium.    
The next stage was to validate the assay using compound 20 and RWJ-58259, both of 
which had demonstrated PAR-1 antagonist activity in the CCL2 ELISA and the in 
vivo LPS-induced lung inflammation study. The 96-well plate layout was designed as 
shown in Figure 27, allowing for six different compounds to be tested against four 
different  concentrations  of  thrombin,  with  four  experimental  replicates  for  each 
condition.  Compound  20  was  tested  alongside  RWJ-58259  in  order  to  compare 
directly between the different batches of the project lead compound. Also tested was 
the di-Phe analogue of RWJ-58259, compound 45, synthesised as a model compound 
of interest in order to validate the synthetic route. Of the final three rows available 
one was filled with dye medium only, as a positive control, and another contained a 
0
200
400
600
800
1000
0 20 40 60 80 100 120 140 160 180
R
e
l
a
t
i
v
e
 
F
l
u
o
r
e
s
c
e
n
c
e
 
U
n
i
t
s
 
Time/s 
10 nM
3 nM
0.3 nM
0 nM77 
compound from a different research project, compound X. The remaining row was 
filled with the dye in media containing 0.1% DMSO; since compound stock solutions 
were made in DMSO it was necessary to demonstrate that the maximum amount of 
DMSO present following dilution did not affect the outcome.  
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Concentration of thrombin added =  
Figure 27 Plate layout for initial screening method 
Results  were  plotted  as  the  average  change  in  relative  fluorescence  units  (RFU) 
detected in the four repeats, i.e. maximum-minimum. As illustrated in Figure 28, the 
effect of 0.1% DMSO in the test medium is negligible and statistically both groups of 
data, from medium only and medium with DMSO, could not be said to have been 
from  different  sources  (see  appendix).    Encouragingly,  compounds  20,  45  and 
RWJ-58259,  tested  at  a  concentration  of  3  μM,  demonstrated  antagonist  activity 
against thrombin concentrations up to and including 10 nM. This result for novel 
compound  45  supports  the  reported  findings  of  Zhang  and  co-workers  that 
compounds in this series with a terminal ethyl- or propyl-diamine substituent coupled 
to an amino acid with an aromatic substituent demonstrate potent PAR-1 antagonist 
activity. 
0 nM  0.3 nM  3 nM  10 nM 78 
 
Results plotted are the mean of four repeated experiments, with error bars representing the 
range of data from individual experiments. 
Figure 28 Change in fluorescence detected following exposure to thrombin 
This initial screening method proved useful in identifying active compounds from 
compounds  with  weak  or  no  PAR-1  antagonist  activity;  however,  occasional 
variability in results motivated further development of the method. Error bars shown 
in Figure 28 represent the range of results given from the four repeated experiments 
on a single 96-well plate. At 10 nM thrombin, results for compound 20 give a much 
larger range than those for RWJ-58259. To be confident that variations in antagonist 
activity were measured accurately a method was required that would give a more 
detailed account of a compound’s performance. Therefore, it was decided that the 
assay  would  be  set  up  to  collect  data  representing  the  effect  varying  antagonist 
concentration  has  on  the  cells’  response  to  agonist  exposure,  a  dose-response 
relationship.  
Initial plate layout for the dose-response method involved only two compounds to 
ensure that four experimental replicates of each condition were performed (Figure 
29). From the initial screening method results it was seen that a slight response was 
achieved  at  the  highest  thrombin  concentration  despite  being  incubated  with  the 
antagonists. Therefore, it was decided to test an antagonist concentration range of 
0.1-10  μM  against  both  3  nM  and  10  nM  thrombin  concentrations,  to  gather 
information on the performance window of the antagonists. 
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Figure 29 Initial plate layout for dose-response method 
Results  obtained from  the assay clearly showed that  the antagonist concentration 
span was too narrow and a broader range would be required in order to obtain a full 
dose-response curve. Also, from the two thrombin concentrations employed in the 
assay, the data plotted for 10 nM showed the beginnings of the curve representing a 
dose-response (B, Figure 30), whereas data points for 3 nM were all plotted at 100% 
inhibition  (A,  Figure  30).  Therefore,  it  was  decided  the  higher  thrombin 
concentration would be better to achieve data for a full dose-response curve.   
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Results plotted are the mean of four repeated experiments, with error bars representing the 
range of data from individual experiments. A - [thrombin] = 3 nM; B - [thrombin] = 10 nM. 
Figure 30 Initial dose-response results for RWJ-58259 versus thrombin  
3 nM  10 nM 
A  B 80 
Based on the findings from the initial dose-response method the plate layout was 
adapted to cover an antagonist concentration range of 0.1 nM to 10 μM, to be tested 
against a thrombin concentration of 10 nM only (Figure 31).  
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Figure 31 Modified plate layout for dose-response method 
Data gathered from the Ca
2+ mobilisation assay with the adapted plate layout were 
very  pleasing.  Percentage  of  full  inhibition  was  calculated  for  each  antagonist 
concentration  and  plotted  to  give  full  dose-response  curves  for  RWJ-58259  and 
compound 20 (A and C, Figure 32). A second plate was also used to test compound 
45 at the same time, which also achieved a full dose-response curve (D, Figure 32).  
Analysis  of  the  data  using  GraphPad  Prism  software  calculated  IC50  values  of 
320 nM and 279 nM for compound 20 and RWJ-58259, respectively. This result 
confirmed the quality of compound 20 compared with the earlier batch and gave 
confidence for its planned use as the standard against which analogues would be 
tested in further Ca
2+ mobilisation assays. An IC50 of 362 nM was determined for 
compound 45 confirming this analogue too as a potent PAR-1 antagonist.     
10 nM 81 
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Graphs  A,  C  and  D  plot  mean  values  for  data  points  at  different  concentrations  for 
RWJ-58259, compound 20 and compound 45, respectively, with error bars representing the 
range. Graph B plots each data point at different concentrations of RWJ-58259 with each 
horizontal row on the plate grouped into a run allowing for a representative dose-response 
curve to be generated for each experimental replicate (run). 
Figure 32 Dose-response curves for compounds versus thrombin (10 nM) in HLFs 
The error bars shown in graphs A, C and D (Figure 32) illustrate the range of data for 
percentage inhibition at any given antagonist concentration. Although, in general, the 
data is quite tight fitting, a broad range was seen for RWJ-58259 at a concentration 
of 1 x 10
-10 M. However, plotting the four repeated experiments separately (B, Figure 
32)  shows that one data point is responsible for this  wide range and although it 
cannot be ruled out statistically as an outlier, these plots would indicate it as an 
exception to the normal trend. 
Since discrepancies have been reported in the responsiveness to thrombin of cells 
from  different  species,  it  was  important  to  confirm  that  the  performance  of 
compound 20 in HLFs was repeated in MLFs. Therefore, dose-response data was 
gathered from the Ca
2+ mobilisation assay using MLFs and showed compound 20 to 
have an increased level of potency (Figure 33). The dose-response curve shows a 
shift to the left by more than one log unit compared to those seen in Figure 32 for 
HLFs, and IC50 was measured at a value of 11 nM. This outcome suggests that MLFs 
are  less  responsive  to  thrombin,  since  50%  inhibition  of  the  Ca
2+  mobilisation 
response was achieve at almost a 30-fold lower concentration of compound 20. 
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Figure 33 Dose-response curve for compound 20 versus thrombin (10 nM) in MLFs 
During the course of this investigation further modifications were made to the plate 
layout in order to ensure the quality of the data was reliable and to optimise the assay 
with  the  objective  of  maximising  the  possible  number  of  compounds  tested 
simultaneously.  Commonly  encountered  in  cell-based  assays  is  a  phenomenon 
known as the temporal effect, whereby the performance of cells in wells located at 
the edges of a plate tends to vary unexplainably from those located away from the 
edges.  The  causes  of  such  effects  are  likely  to  be  numerous  and  complex,  and 
screening  departments  often  avoid  the  use  of  the  peripheral  wells  to  ensure 
variability of results is minimised. As a result of witnessing the edge effect on cells 
in the Ca
2+ mobilisation assay on a few occasions, which resulted in the loss of data 
from the positive controls, an alternative plate layout was designed (Figure 34). Loss 
of the data from the positive controls, i.e. wells containing medium only, invalidates 
all other data gathered from the assay since there is no control measure of the cells’ 
normal response to thrombin (10 nM) exposure.  
This modified design to the plate layout ensured that plenty of wells representing the 
positive  controls  were  placed  away  from  the  edges  of  the  plate.  An  antagonist 
concentration range of 0.1nM to 10 μM was maintained whilst also introducing a 
column of wells that were not exposed to thrombin - as a negative control - in order 
to identify any partial agonist behaviour exhibited by compounds tested. 
The number of repeat experiments for the standard (compound 20) in each assay run 
was reduced to a single row due to the consistency observed in data obtained for this 
compound.  This  allowed  for  two  other  compounds  to  be  tested,  in  three  repeat 
experiments, on each 96-well plate and so maximising the throughput for the Ca
2+ 
mobilisation assay.         83 
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Figure 34 Optimised plate layout for dose-response method 
3.5.2 Biological evaluation of methylated analogues 
Synthesised compounds 51a, 51b and 52 were evaluated for their PAR-1 antagonist 
activity in the Ca
2+ mobilisation assay described earlier (see section 3.5.1, page 74). 
Dose-response data was obtained for each compound versus thrombin (10 nM) using 
compound 20 as the standard for setting full inhibition (Figure 35). This means the 
percentage  inhibition  determined  for  these  compounds  was  calculated  as  a 
percentage of the value for full inhibition by compound 20. 
As can be seen from the dose-response curves in Figure 35 compounds 51a, 51b and 
52 were all shown to perform as full antagonists of PAR-1. These compounds are 
able  to  block  Ca
2+  mobilisation  in  HLFs  triggered  by  a  high  concentration  of 
thrombin (10 nM) to the same extent as compound 20. Compounds 51a and 51b 
were determined to have IC50 values of 524 nM and 548 nM, respectively. This 
indicates that the binding site pocket, into which RWJ-58259-like compounds sit, can 
accommodate substitution at the benzylic position of the LHS terminal benzylamine. 
This is an encouraging result since this benzylic position was predicted in the in 
silico  screen  as  being  the  most  probable  site  of  metabolism  (see  section  3.2.2, 
page 61). Interestingly, data for compound 52 was calculated as giving an IC50 value 
0 nM  10 nM 84 
of 89 nM, suggesting substitution at this benzylic position results in a more potent 
PAR-1 antagonist.      
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Figure 35 Dose-response curves for compounds versus thrombin (10 nM) in HLFs 
3.5.3 Biological evaluation of fluorinated analogues 
Following  repeated  attempts  to  run  the  Ca
2+  mobilisation  assay  with  fluorinated 
compounds 62a and 62b and failing to obtain reliable data, the compounds were 
tested at a higher concentration range. The 3-fluoropyrrolidine analogues were tested 
at a range of 3 nM to 300 μM against a thrombin concentration of 10 nM. 
Gratifyingly, data was obtained that fitted a dose-response relationship between the 
antagonist and the receptor (Figure 36). Interestingly, however, it was noticed that 
both  compound  62a  and  62b  did  not  achieve  full  inhibition  of  the  cells’  Ca
2+ 
mobilisation response to thrombin (10 nM).  Comparing these results with that of full 
antagonist compound 20, tested on the same plate, compounds 62a and 62b were 
seen to achieve a maximum of 79% and 63% inhibition, respectively. Repeating the 
assay with an even higher concentration of antagonist, in the hope of achieving full 
inhibition, was deemed to be of no use since data obtained at a concentration of 
300 μM was found not to be viable due to the baseline fluorescence detection being 
abnormally  heightened  before  thrombin  addition  (see  appendix).  There  is  a 85 
possibility that the antagonist might be interacting with the fluorescent dye at higher 
concentrations resulting in obscured results. 
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Figure 36 Dose-response curves for compounds versus thrombin (10 nM) in HLFs 
IC50  values  were  calculated  using  the  GraphPad  Prism  software,  indicating  the 
concentration  at  which  50%  of  the  full  pharmacological  inhibitory  effect  of  the 
compounds  was  achieved.  Values  of  384  nM  and  332  nM  were  calculated  for 
compounds  62a  and  62b,  respectively.  This  suggests  that  the  pharmacologically 
active  window  for  these  compounds  is  similar  to  the  project  lead  compound, 
RWJ-58259, despite being unable to fully inhibit PAR-1 activation in competition 
with high concentrations of thrombin.   
3.5.4 Biological evaluation of 3-pyrrolidinol analogue 
Following the interesting results obtained for fluorinated compounds 62a and 62b, 
compound 66 was tested under the suspicion that substitution of the pyrrolidine ring 
had detrimental effects on the PAR-1 activity of RWJ-58259-like compounds.    
Tested against thrombin (10 nM) over a concentration range of 0.1 nM to 10 μM, 
data obtained for compound 66 was plotted and shown to follow a dose-response 
relationship  (Figure  37). However, as  with  the  3-fluoropyrrolidine  analogues,  the 
3-pyrrolidinol derivative 66 failed to achieve full inhibition of the Ca
2+ mobilisation 
response  in  HLFs.  Maximum  inhibitory  effect  was  measured  at  54%  of  the  full 
inhibition  achieved  with  compound  20.  However,  IC50  was  calculated  as  being 
266 nM, indicating the compound’s pharmacological effects occur within a similar 
range to the other antagonists tested. 86 
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Figure 37 Dose-response curves for compound 66 versus thrombin (10 nM) in HLFs 
3.6 Discussion 
Utilising  a  Ca
2+  mobilisation  assay  optimised  to  determine  the  PAR-1  inhibitory 
activity of synthesised analogues of PAR-1 antagonist RWJ-58259 versus thrombin, 
encouraging results were obtained. With the objective of developing analogues with 
improved metabolic stability and equivalent PAR-1 antagonist activity, compounds 
51a, 51b and 52 were synthesised in which a methyl substituent was incorporated on 
the atoms predicted, by in silico screening, as the most probable sites of metabolism. 
Screening these compounds in the Ca
2+ mobilisation assay demonstrated their PAR-1 
antagonist  activity  to  be  comparable  to,  or  even  slightly  improved  upon,  results 
obtained for the project lead, compound 20 (RWJ-58259). Compounds 51a and 51b, 
with  a  methyl  group  integrated  at  the  benzylic  position  of  the  LHS  fragment 
benzylamine,  were  determined  to  have  IC50  values  of  524  nM  and  548  nM, 
respectively, compared with an IC50 of 320 nM for compound 20. Since this position 
was predicted as the most probable site of metabolism by CYPs, confirmation that 
introduction of a substituent can be tolerated, with regards to receptor binding and 
inhibition, is a very encouraging result. 
Promisingly, data gathered for compound 52 gave an IC50 value of 89 nM, improving 
on the potency of the project lead compound. This is an interesting result, possibly 
indicating a site for potential investigation into further development of analogues. 
SAR data published on the development of RWJ-58259 shows little variation from 
the N-1 benzyl substituent has been investigated, with substitutions on the benzene 
ring  having  been  the  main  focus.  This  slight  enhancement  in  potency  suggests 
incorporating a substituent at this benzylic position leads to a more effective binding 87 
of the receptor, requiring a lower concentration to restrict the conformational change 
promoted by the tethered ligand to activate the receptor. This could be as a result of 
the increased sterics reducing rotational entropy around the C-N bond of the benzyl 
substituent at the 1-position of the indazole, in effect locking it in a more favourable 
position  to  bind  more  effectively  to  the  receptor.  Alternatively,  there  may  be  a 
lipophilic pocket in this region of the receptor and any increase in lipophilicity of the 
molecule at this position would enhance the ligand receptor interaction. In this case, 
perhaps introducing a larger lipophilic group may improve potency further. 
Methylated  analogues  51a,  51b  and  52,  along  with  compound  20,  have  been 
submitted for screening in the liver microsomes assay discussed earlier (see section 
3.2,  page  58).  Identification  of  differences  in  metabolism  of  these  compounds 
compared  with  compound  20  will  determine  whether  modifications  made  to  the 
molecules have improved their metabolic stability. Improvement on the t½ measured 
for  compound  20,  combined  with  the  proven  antagonist  activity,  would  present 
analogues  51a,  51b  and  52  as  enhanced  tool  compounds  for  use  in  in  vivo 
investigations into PAR-1 antagonism. Alternatively, identification of additional sites 
of  metabolism  would  direct  synthesis  of  a  second  generation  of  RWJ-58259 
analogues. 
Biological  evaluation  of  analogues  62a  and  62b,  incorporating  a  fluorine  at  the 
3-position  of  the  pyrrolidine  ring,  produced  some  interesting  results.  Despite 
showing activity over a similar range of concentrations as the full antagonists, these 
compounds failed to achieve full inhibition of thrombin induced PAR-1 activation, 
achieving only 63-79% of the degree of inhibition demonstrated by compound 20. 
Similarly, proposed major metabolite compound 66 with a hydroxyl group at the 
3-position also demonstrated a reduced ability to block receptor activation following 
exposure of the HLFs to thrombin. This latter result, as well as being of interest due 
to  reduced  degree  of  inhibition,  is  significant  due  to  the  observed  retention  of 
antagonist activity. Demonstrating PAR-1 antagonist activity for a likely metabolite 
of RWJ-58259 suggests that data from in vivo studies involving the parent compound 
may result from the biological activity of a combination of the parent compound and 
metabolites.  This  may  provide  a  reason  for  the  significant  biological  response 
achieved by dosing RWJ-58259 in mice despite its suspected short t½. Activity may 88 
be prolonged by the metabolites formed and so extending the desired therapeutic 
effect  and,  in  the  case  of  the  mouse  model  of  LPS-induced  lung  inflammation, 
reducing neutrophil recruitment up to 24h after dosing RWJ-58259.  
With regards to the reduced antagonist effect, a common feature of these compounds 
is the presence of an electronegative substituent at the 3-position of the pyrrolidine 
ring. The proximity of such an electronegative substituent to the pyrrolidine nitrogen 
is likely to significantly reduce the basicity of the amine, which may affect the nature 
of any interactions involving this moiety as the compound sits in the binding pocket 
of the receptor. Precisely what effect is had on the nature of the binding and the 
resulting outcome that is witnessed from the receptor requires further investigation.  
The pKa of a protonated pyrrolidine nitrogen can drop by more than two units as a 
result of introducing a fluorine atom at the 3-position and, though perhaps not quite 
to the same extent, a similar change could be expected with the incorporation of an 
oxygen atom.
180 This would reduce the amount of ionic interaction occurring with 
any negatively charged residues within the receptor binding site. The conformation 
of  ring  structures  are  also  reported  to  be  effected  by  the  preference  of  fluorine 
substituents to be positioned co-axial with positively charged species to maximise 
dipole-dipole interactions.
178 A change in the conformation of the pyrrolidine ring 
system  may  be  effecting  interactions  involving  this  region  of  the  molecule. 
Alternatively, reduced basicity of the pyrrolidine amine may affect its capability of 
forming hydrogen bonding interactions within the receptor’s binding pocket.  Any 
hydrogen bonding interactions occurring with RWJ-58259 may be disrupted by the 
presence of a hydroxyl group at the 3-position, with the oxygen competing with the 
nitrogen as a hydrogen bond acceptor. This may lead to an interaction that creates a 
conformational change in the protein that is less capable of blocking activation. The 
hydroxyl  group  could  alternatively  act  as  a  hydrogen  bond  donor,  picking  up  a 
different interaction altogether.  
The overall outcome resulting from the altered binding interaction is a reduction in 
the  maximal  inhibitory  activity  achieved  on  PAR-1  in  response  to  thrombin 
exposure. However, from the biological data obtained for compounds 62a, 62b and 
66 using the calcium ion mobilisation assay, it is difficult to determine precisely how 
this outcome is achieved. 89 
From the predicted effect on binding interactions of introducing an electronegative 
substituent at the pyrrolidine 3-position, it would be reasonable to suggest that the 
compound’s  receptor  binding  affinity  is  reduced.  This  would  mean  an  increased 
off-/on-rate (Kd, dissociation constant) for the compound binding  to the receptor, 
resulting in a less competitive antagonist. However, the profiles of the dose-response 
curves obtained for these compounds do not match that which would be expected for 
an antagonist with reduced binding affinity. Reduced activity due to an increased Kd 
can be overcome by increasing the antagonist concentration, making the antagonist 
more competitive with the agonist for receptor binding by increasing the number of 
molecules competing. At a high enough concentration, full occupancy of the binding 
site is  achieved by the  antagonist, and thus  full inhibition of receptor activation. 
Plotting the data would give a full dose-response curve, reaching 100% inhibition, 
only  shifted  to  the  right  to  give  a  lower  IC50  value.  From  the  plotted  data  for 
compounds  62a,  62b  and  66  it  can  be  seen  that  the  curves  plateau  at  50-79%, 
meaning  that  increasing  the  concentration  would  have  no  effect  on  degree  of 
inhibition achieved. Also, IC50 values calculated show that no significant shift to the 
right is observed for the dose-response curves. 
A  possible  reason  for  the  activity  seen  would  be  that  the  compounds  behave  as 
partial agonists. This would mean that at low concentration of the partial agonist the 
activity  seen  results  from  the  full  agonist,  thrombin.  However,  as  partial  agonist 
concentration  increases  this  compound  would  out-compete  the  full  agonist  for 
occupancy  of  the  receptor  activation  site,  and  the  resulting  degree  of  receptor 
activation represents the reduced agonist activity achieved by the partial agonist. The 
data  obtained  from  the  calcium  ion  mobilisation  assay  could  be  seen  to  fit  this 
reasoning,  with  50-79%  antagonism  achieved  being  seen  as  21-50%  agonism 
achieved  by  the  partial  agonist  out-competing  the  tethered  ligand,  uncovered  by 
thrombin, for the receptor binding site. 
In the calcium ion mobilisation assay the cells are incubated with the compound of 
interest for 1 hour before addition of thrombin in the FLIPR. This was done so that 
any stress  responses triggered in  receptors on the HLFs by  the introduction of a 
foreign substance would have time to settle before addition of the thrombin and the 
beginning of fluorescence detection. If these compounds demonstrated some agonist 90 
activity, upon exposure to the cells PAR-1 would have been activated, albeit to a 
limited extent, and calcium ion mobilisation triggered well before any measurements 
were recorded. What is unknown is how these compounds affect the PAR-1 surface 
population following addition to the cells. It is known that following activation by 
thrombin, or by TRAPs, PAR-1 is rapidly internalised by endocytosis and trafficked 
to lysosomes for degradation.
105 Alternatively, receptors are modified and recycled to 
the cell membrane to replenish the surface population; however, recycled PAR-1 has 
been shown to be modified such that activation by subsequent addition of thrombin 
does not occur.
181 If compounds 62a, 62b and 66 were performing as agonists, or 
partial  agonists,  and  upon  exposure  to  the  cells  activated  PAR-1  leading  to 
internalisation  and  modification,  it  might  be  expected  that  this  would  have 
consequences on the population of PAR-1 available for activation by thrombin, thus 
resulting in a reduced level of calcium ion mobilisation.  
Another possible explanation would be that these compounds are negative allosteric 
modulators  (NAMs).
182  Rather  than  binding  at  the  site  occupied  by  the  tethered 
ligand  upon  activation,  these  compounds  might  bind  at  an  allosteric  site,  which, 
when occupied,  results  in  a conformational  change  at  the orthosteric site  i.e. the 
activating binding site. The conformational change affected by allosteric modulators 
can have a positive, negative or neutral effect on the interaction of ligands to the 
orthosteric  site.  The  inhibitory  effect  these  compounds  have  on  the  activation  of 
PAR-1 as a result of cleavage by thrombin would make them NAMs. It could be 
conceived that all RWJ-58259-like compounds interact with this allosteric site and 
that  receptor  binding  affinity  at  this  site  is  unaffected  by  modifications  to  the 
pyrrolidine  ring,  hence  the  comparable  IC50  values  for  the  compounds  tested. 
However,  introduction  of  an  electronegative  substituent  at  the  3-position  of  the 
pyrrolidine ring may affect the compound’s ability to achieve the conformational 
change required to alter the orthosteric site in a way that fully inhibits binding of the 
tethered ligand and activation of the receptor. This would result in a maximal effect 
of  only  partially  blocking  activation  of  the  receptor  following  exposure  to  the 
agonist, as seen in the results obtained for compounds 62a, 62b and 66. 
Further  in  vitro  biological  testing  of  the  synthesised  compounds  would  assist  in 
deciphering  the  reasons  behind  the  partial  inhibition  witnessed  in  the  calcium 91 
mobilisation assay for compounds 62a, 62b and 66. Establishing a baseline for all 
compounds,  by  adding  them  at  a  range  of  concentrations  whilst  measuring 
fluorescence in the FLIPR, would help identify any agonist response triggered. This 
would distinguish between a partial agonist and a NAM, since the latter would have 
no agonist activity yet would still only achieve partial inhibition in the conventional 
assay.  
It is of interest to note that during the completion of this research the co-crystal 
structure  of  T4  lysozyme-stabilized  PAR-1  bound  to  vorapaxar  was  solved  and 
published by Zhang and co-workers.
159 The structure identifies interactions of the 
potent PAR-1 antagonist with various amino acid residues located on EC2, EC3 and 
transmembrane segments (TMs) 3-7. Preliminary investigations at GSK into docking 
of RWJ-58259 into the identified vorapaxar binding site indicated that interactions 
observed  with  vorapaxar  were  not  picked  up  by  RWJ-58259.  This  suggests  the 
conformation of the protein may change when bound to RWJ-58259. Alternatively, 
this could support the notion of the compound binding allosterically and exacting its 
inhibitory  effects  by  modifying  the  shape  of  the  agonist  binding  site  rather  than 
directly blocking access to the binding site. In order to investigate the binding of 
RWJ-58259 to PAR-1 thoroughly a co-crystal structure of the receptor bound to the 
antagonist would be needed.  
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3.7 Conclusions and Further Work 
The main objective of this research was to develop analogues of the project lead 
compound,  RWJ-58259,  maintaining  its  potent  PAR-1  antagonist  activity  whilst 
improving on metabolic stability. The work involved investigation of the metabolic 
profile  of  RWJ-58259  to  predict  likely  metabolites  and  identify  possible  in  vivo 
pathways for their generation. In silico screening of the project lead using MetaSite 
software  identified  probable  sites  of  metabolism  and  predicted  likely  metabolites 
formed  as  a  result.  A  chemical  stability  study,  looking  at  the  susceptibility  of 
RWJ-58259 to hydrolysis over a range of pH, as well as a biocatalysis approach, 
aiming  to  generate  possible  metabolites,  was  undertaken.  The  results  suggested 
RWJ-58259 may not be extensively metabolised but rather  a specific site on the 
molecule  may  be  susceptible,  suggesting  that  simple  modifications  may  improve 
metabolic stability significantly.  
The synthesis of novel analogues of RWJ-58259 was accomplished, incorporating 
either a methyl or fluorine substituent on atoms highlighted from the in silico screen 
as the most probable sites of metabolism. Development of a calcium ion mobilisation 
assay was achieved in order to evaluate biological activity of synthesised compounds 
on PAR-1 on HLFs with high efficiency. Encouragingly, compounds 51a, 51b and 
52, with a methyl substituent introduced at benzylic positions of the parent molecule, 
demonstrated full antagonist activity and were shown to maintain the high level of 
potency demonstrated by RWJ-58259. Analogues 62a and 62b, which incorporate a 
fluorine substituents at the pyrrolidine ring 3-position, were shown to have reduced 
antagonist activity, although the potency of these compounds was comparable to the 
full antagonists. This interesting result suggested an alternative activity profile for 
these compounds, possibly performing as partial agonists or NAMs. 
Results are awaited for the synthesised compounds, as well as the project lead, from 
liver  microsome  studies  carried  out  by  collaborators  at  GSK.  Should  the  data 
returned  show  a  reduction  in  the  clearance  rate  for  the  synthesised  analogues 
compared  with  RWJ-58259,  then  an  improved  metabolic  profile  will  have  been 
achieved a new tool compound will have been generated for use in future in vivo 
studies. 93 
Interestingly, this work has shown that a proposed major metabolite of RWJ-58259, 
in which the pyrrolidine ring 3-position is hydroxylated, also demonstrates PAR-1 
antagonist  activity  at  similar  concentrations  to  the  parent  compound.  Although 
activity  resembles  that  of  a  partial  agonist/NAM,  this  result  is  significant  with 
regards to in vivo data obtained following dosing of RWJ-58259.  
Future work in this area of research should establish the nature of the biological 
activity seen for the analogues proposed to be partial agonists/NAMs. Elucidating the 
reason for the reduced inhibition seen for these compounds may shed light on the 
true binding nature of RWJ-58259-like molecules and allow for the development of 
further compounds of interest. For example, should these compounds be shown to 
bind  allosterically  then,  since  PAR-1  has  such  a  wide  distribution  in  tissues 
throughout the body, it might be seen as more beneficial to develop a covalently 
bound NAM which does not fully inhibit PAR-1 activation. This may avoid possible 
side effects caused by full antagonists of PAR-1 with high binding affinity. 
Further analogue synthesis may be guided by results from liver microsome assays 
identifying alternative sites of metabolism not considered in this research. Synthesis 
of a second generation of analogues of RWJ-58259 designed to block these newly 
identified sites may result in compounds with more enhanced metabolic stability. 
Also, synthesis of analogues investigating the space available at the benzylic position 
of the indazole N-1 substituent may uncover new binding interactions and improve 
on the potency demonstrated by RWJ-58259.  
The  FDA  approval  of  vorapaxar  as  the  first  active  ingredient  to  accomplish  its 
therapeutic  effect  by  inhibiting  the  activation  of  PAR-1  can  be  seen  as  a  major 
endorsement  of  the  significance  of  research  in  this  area.  Despite  the  receptor’s 
widespread distribution throughout the body and varied role in many physiological 
processes,  further  investigation  of  the  role  of  PAR-1  in  various  diseases  may 
highlight  a  potential  benefit  for  its  targeting  with  therapeutics.  Diseases  such  as 
pulmonary fibrosis, whereby topical application of a therapeutic to the afflicted area 
is  possible,  may  benefit  most  from  further  investigations  since  such  application 
would limit any side-effects resulting from inhibition of PAR-1 involved in normal 
physiological processes. The development of better tool compounds, such as those 
achieved during this research, may play an important role in assisting investigations 94 
into the role of PAR-1 in various diseases and may lead to novel approaches in the 
treatment of some diseases.    
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Experimental 
Organic Chemistry 
General Experimental 
Reactions carried out under dry conditions were done in oven-dried glassware under 
an argon atmosphere. Where addition of solids was required reactions were carried 
out  in  three-necked  round-bottom  flasks  and  the  addition  done  under  a  positive 
pressure of argon. Reactions were stirred magnetically and monitored by thin-layer 
chromatography  (TLC)  using  aluminium  sheets  coated  with  silica  gel  60  F254 
purchased from Merck, which were then viewed under UV irradiation (λ = 254 nm) 
and  developed  further  with  a  potassium  permanganate,  ninhydrin  or 
4-nitrophenylhydrazine dip. Silica gel 60 (40-63 μm) from Merck was used to purify 
compounds  by  flash  column  chromatography.  All  solvents  were  of  commercial 
grade, purchased from Fisher Scientific, VWR or Sigma-Aldrich and used without 
further purification. Petrol refers to petroleum ether (b.p. 40-60 °C). Reagents were 
purchased from Sigma-Aldrich, Alfa Aesar, Iris Biotech or Acros Organics and used 
as received from the supplier.  
Instrumentation 
Purification by preparative scale HPLC was carried out on a Varian Prostar (column: 
Phenomenex Jupiter 300 A C18, 250 x 4.6 mm, 10 μm; mobile phase gradient: 0-2 
min (5%), 2-8 min (5-95%), 8-14 min (95%), 14-15 min (95-5%), 15-20 min (5%) 
MeCN in H2O with 0.1% TFA). Melting points were measured using a Gallenkamp 
apparatus and are uncorrected. A Perkin Elmer Spectrum 100 FT-IR spectrometer or 
Bruker  Alpha  FT-IR  spectrometer  was  used  to  obtain  infrared  spectra.
  1H  NMR 
spectra of pure samples dissolved in either CDCl3 or DMSO-d6 were recorded at 400 
MHz, 500 MHz and 600 MHz and 
13C NMR at 125 MHz and 150 MHz on a Bruker 
AMX400, Avance 500 and Avance III 600 spectrometer at 25 ﾰC. Chemical shifts (ʴ) 
for 
1H and 
13C nuclei are reported relative to the residual solvent signal on a parts per 
million (ppm) scale. Coupling constants (J values) are reported in Hertz (Hz) and are 
reported as JH-H couplings unless otherwise stated. High resolution mass spectra were 96 
acquired for pure samples on either a Thermo Finnigan MAT900Xp (EI and CI) or 
Water LCT Premier XE (ES) mass spectrometer. LC/MS analysis was carried out 
using a Waters Acquity UPLC (column: C18 BEH 50 x 2.1 mm, 1.7 μm; mobile 
phase gradient (5 min): 5-95% MeCN in H2O with 0.1% formic acid). 
Experimental for chemical stability study 
A solution of compound 20 (1.00 mg, 1.16 μmol) in DMSO (500 μL) was diluted 
50 μL in 950 μL of buffered solutions of pH 4, 7.4 & 9. Eppendorf vials containing 
the different solutions were shaken at either room temperature (~20 °C) or 37 °C 
using a thermomixer and aliquots taken at 10 min, 3 h, 24 h, 48 h, 6 d and 7 d for 
analysis by LC/MS to identify degradation of the parent compound.  
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Experimental data 
6-Nitro-3-(pyrrolidin-1-ylmethyl)-1H-indazole (23)
164  
 
6-Nitroindole (500 mg, 3.08 mmol) was added to a stirred solution of sodium nitrite 
(2.13 g, 30.8 mmol) in H2O (25 mL) and DMF (2 mL) at 18 °C.  6 M HCl (4.6 mL, 
27.8 mmol) was added dropwise over 10 min and stirring continued for 3 h before 
diluting with EtOAc (30 mL) and extracting.  Aqueous layer extracted further with 
EtOAc (2 x 15 mL).  Organic extracts were combined and washed with H2O (15 mL) 
and brine (15 mL), then dried (MgSO4) and concentrated in vacuo. Residual dark 
brown solid was dissolved in CH2Cl2/DMF/AcOH (54/5.4/0.6 mL), to which was 
added pyrrolidine (548 mg, 0.643 mL, 7.70 mmol) and the reaction mixture was 
stirred at 18 °C for 20 min.  Sodium triacetoxyborohydride (1.63 g, 7.70 mmol) was 
added portionwise over 10 min and stirring continued for 3 h before diluting with 
EtOAc (100 mL) and quenching with saturated aqueous NaHCO3 (60 mL).  Aqueous 
layer separated and extracted further with EtOAc (2 x 20 mL).  Organic extracts were 
combined and washed with sat. NaHCO3 (aq) (2 x 25 mL), H2O (2 x 25 mL) and 
brine (2 x 25 mL) then dried (MgSO4) and concentrated in vacuo to leave dark brown 
viscous oil.  Purification by flash column chromatography (0-2% MeOH/CH2Cl2) 
gave target compound (474 mg, 62% (88% crude
164)) as a dark brown oil; Rf 0.18 
(10% MeOH/CH2Cl2); IR νmax (thin film from CHCl3) 3398 (N-H), 1649 (C=N), 
1524  (NO2),  1348  (NO2),  1048-994  (C-N),  824  (ArC-H),  762  (ArC-H)  cm
-1; 
1H 
NMR (500 MHz, DMSO-d6) ʴ 13.49 (1H, bs, NH), 8.39 (1H, d, J = 1.3, CCHCNH), 
8.06 (1H, d, J = 8.8, CHCHCNO2), 7.91 (1H, dd, J = 8.8, 2.0, CHCHCNO2), 3.99 
(2H, s, CH2CNN), 2.51-2.47 (4H, m, 2 x CH2N(CH2)CH2C), 1.71-1.67 (4H, m, 2 x 
CH2CH2N(CH2)CH2); 
13C NMR (125 MHz, DMSO-d6) ʴ 146.3 (ArC), 144.4 (ArC), 
140.0  (ArC),  125.5  (ArC),  122.3  (CHCHCNO2),  114.8  (CHCHCNO2),  107.4 
(CCHCNO2),  54.0  (2  x  CH2N(CH2)CH2C),  51.8  (CH2CNN),  23.7  (2  x 
CH2CH2N(CH2)CH2C);  m/z  (FAB+)  247  (100%,  [M+H]
+);  HRMS  C12H15N4O2 
calcd. 247.1195, found 247.1198.    98 
1-(2,6-Dichlorobenzyl)-6-nitro-3-(pyrrolidin-1-ylmethyl)-1H-indazole (24)
170  
 
To a stirred solution of 23 (468 mg, 1.87 mmol) in dry THF (20 mL) under argon 
was  added  2,6-dichlorobenzyl  bromide  (449 mg,  1.87  mmol)  followed  by 
portionwise addition over 10 min of caesium carbonate (609 mg, 1.87 mmol). The 
reaction mixture was stirred at 16 °C for 24 h then diluted with H2O (10 mL) and 
extracted with EtOAc (2 x 20 mL). Organic extracts were washed with H2O (2 x 10 
mL) then brine (10 mL), dried (MgSO4) and concentrated in vacuo to give a dark 
brown  solid  residue.  Purification  by  flash  column  chromatography  (0-1% 
MeOH/CH2Cl2) gave target compound (453 mg, 60% (66%
170)) as a brown solid; mp 
136-138 °C (138-140 °C
170); Rf 0.25 (5% MeOH/CH2Cl2); IR νmax (neat) 3081-2789 
(C-H), 1521 (NO2), 1438 (C-H), 1342 (NO2), 1090 (C-N), 806-765 (ArC-H), 733 (C-
Cl) cm
-1; 
1H NMR (500 MHz, CDCl3) ʴ 8.33 (1H, d, J = 1.6, CCHCNH), 8.00-7.96 
(1H, d, J = 8.8, CHCHCNO2 & 1H, dd, J = 8.8, 1.6, CHCHCNO2), 7.41 (2H, d, J = 
7.9,  2  x  CHCCl),  7.29  (1H,  m,  CHCHCCl),  5.88  (2H,  s,  CH2NN),  4.01  (2H,  s, 
CH2CNN),  2.59  (4H,  m,  2  x  CH2N(CH2)CH2C),  1.79  (4H,  m,  2  x 
CH2CH2N(CH2)CH2C); 
13C NMR (125 MHz, CDCl3) ʴ 146.9 (ArC), 144.5 (ArC), 
139.8 (ArC), 137.3 (2 x CCl), 131.2 (ArC), 130.9 (CHCHCCl), 129.2 (2 x CHCCl), 
126.9 (ArC), 122.4 (CHCHCNO2), 115.3 (CHCHCNO2), 106.5 (CCHCNO2), 54.6 (2 
x  CH2N(CH2)CH2C),  52.3  (CH2CNN),  49.1  (CH2NN),  24.1  (2  x 
CH2CH2N(CH2)CH2C); m/z (CI+) 405 (100%, [
35,35M+H]
+), 407 (63%, [
35,37M+H]
+), 
409 (12%, [
37,37M+H]
+); HRMS C19H19
35Cl2N4O2 ([M+H]
+) calcd. 405.0885, found 
405.0889. 
   99 
1-(2,6-Dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-amine (25)
164 
 
To a solution of 24 (539 mg, 1.33 mmol) in MeOH (40 mL) was added FeCl3.6H2O 
(83.0  mg,  0.310  mmol)  and  activated  charcoal  (647  mg),  followed  by 
N,N-dimethylhydrazine (2.02 mL, 26.60 mmol). The reaction mixture was heated to 
reflux for 2 h then allowed to cool to ambient temperature before filtering through 
celite, washing through with a cold mixture of CH2Cl2/MeOH (90 mL, 4:1). The 
filtrate was concentrated in vacuo to leave a brown solid residue, which was purified 
by flash column chromatography (0-4% MeOH/CH2Cl2) to give the desired product 
(370 mg,  74%  (60%
170))  as  a  light  brown  solid;  mp  177-179  °C;  Rf  0.1  (10% 
MeOH/CH2Cl2); IR νmax (neat) 3323-3214 (N-H), 2961-2480 (C-H), 1626 (C=N), 
1581-1498 (ArC=C), 1438 (C-H), 1090 (C-N), 816-760 (ArC-H), 730 (C-Cl) cm
-1; 
1H NMR (400 MHz, CDCl3) ʴ 7.45 (1H, d, J = 8.6, CHCHCNH2), 7.27 (2H, m, 2 x 
CHCCl), 7.15 (1H, m, CHCHCl), 6.53 (1H, dd, J = 8.6, 1.8, CHCHCNH2), 6.49 (1H, 
d, J = 1.5, CCHCNH2), 5.51 (2H, s, CH2NN), 4.15 (2H, s, CH2CNN), 4.03 (2H, bs, 
NH2), 2.97 (4H, m, 2 x CH2N(CH2)CH2C), 1.73 (4H, bs, 2 x CH2CH2N(CH2)CH2C); 
13C NMR (100 MHz, CDCl3) ʴ 146.6 (ArC), 142.4 (ArC), 136.82 (ArC), 136.78 (2 x 
CCl), 131.5 (ArC), 130.1 (CHCHCCl), 128.6 (2 x CHCCl), 120.9 (CHCHCNH2), 
117.4 (ArC), 113.4 (CHCHCNH2), 91.9 (CCHCNH2), 52.3 (2 x CH2N(CH2)CH2C), 
48.7 (CH2CNN), 47.9 (CH2NN), 23.7 (2 x CH2CH2N(CH2)CH2C); m/z (CI+) 375 
(27%,  [
35,35M+H]
+),  377  (17%,  [
35,37M+H]
+),  379  (3%,  [
37,37M+H]
+),  84  (100%, 
[1-methylpyrrolidine]
+), 305 (8%, [M+H-C4H8N]
+); HRMS C19H21
35Cl2N4 ([M+H]
+) 
calcd. 375.1143, found 375.1137. 
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tert-Butyl {(S)-3-[(S)-2-amino-3-(3,4-difluorophenyl)propanamido]-4-
(benzylamino)-4-oxobutyl}carbamate (33)  
 
i)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-
[(tert-butoxycarbonyl)amino]butanoic acid (540 mg, 1.24 mmol), HBTU (430 mg, 
1.14 mmol) and HOBt (152 mg, 1.14 mmol) in DMF (25 mL) was added DIPEA 
(0.20 mL, 1.14 mmol). After 3 min of stirring, benzylamine (0.11 mL, 1.04 mmol) 
was  added  and  stirring  continued  at  18  °C  for  5  h.  The  reaction  mixture  was 
concentrated in vacuo and the white residue taken up in CHCl3/EtOAc (60 mL, 1:1) 
and washed with  H2O  (15 mL), 10% citric  acid solution  (15 mL),  sat. NaHCO3 
solution (15 mL) and brine (15 mL). The organic layer was concentrated in vacuo 
and the residue purified by flash column chromatography (25% EtOAc/Pet) to give 
the Fmoc-protected amide intermediate (Rf 0.13 (45% EtOAc/Pet)) as a colourless 
oil.  This  was  dissolved  in  DMF  (10  mL)  and  stirred  with  Et2NH  (1.28  mL, 
12.4 mmol) at 18 °C for 3 h. The reaction mixture was concentrated in vacuo and the 
residue taken up in CHCl3/EtOAc (40 mL, 1:1) and washed with H2O (2 x 15 mL), 
brine (15 mL) and sat. LiCl solution (4 x 15 mL). The organic layer was concentrated 
in  vacuo  and  the  residue  purified  by  flash  column  chromatography  (0-2% 
MeOH/CH2Cl2) to give the deprotected amide intermediate (259 mg, 81%) (Rf 0.2 
(10% MeOH/CH2Cl2). 
ii)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-
(3,4-difluorophenyl)propanoic  acid  (410  mg,  0.97  mmol),  HBTU  (338  mg, 
0.89 mmol) and HOBt (120 mg, 0.89 mmol) in DMF (20 mL) was added DIPEA 
(0.16 mL, 0.89 mmol). After 3 min of stirring, a solution of the deprotected amide 
intermediate (250 mg, 0.81 mmol), from step i),  in DMF (5 mL) was added and 101 
stirring continued at 18 °C for 16 h. The reaction mixture was concentrated in vacuo 
and the residue taken up in EtOAc (30 mL) and washed with H2O (10 mL), 10% 
citric acid solution (10 mL), sat. NaHCO3 solution (10 mL) and brine (10 mL). The 
organic layer was concentrated in vacuo and the residue purified by flash column 
chromatography (25-80% EtOAc/Pet) to give the Fmoc-protected title compound (Rf 
0.19  (50%  EtOAc/Pet)),  which  was  dissolved  in  DMF  (10  mL)  and  stirred  with 
Et2NH  (1.00  mL,  9.69  mmol)  at  18  °C  for  3  h.  The  reaction  mixture  was 
concentrated in vacuo and the residue taken up in EtOAc (30 mL) and washed with 
H2O (2 x 10 mL), brine (10 mL) and sat. LiCl solution (4 x 15 mL). The organic 
layer  was  concentrated  in  vacuo  and  the  residue  purified  by  flash  column 
chromatography (0-2% MeOH/CH2Cl2) to give the title compound (227 mg, 57% 
(84%  crude
164));  as  a  white  solid;  mp  218-224  °C  (decomp.);  Rf  0.56  (10% 
MeOH/CH2Cl2); IR νmax (neat) 3286 (N-H), 3062-2926 (C-H), 1678 (C=O), 1634 
(C=O),  1515  (ArC=C),  1453-1365  (C-H),  1279  (C-O),  1165  (C-N),  1116  (C-F), 
770-694  (ArC-H)  cm
-1; 
1H  NMR  (600  MHz,  DMSO-d6)  ʴ  8.48  (1H,  t,  J  =  6.0, 
NHCH2Ph), 8.12 (1H, d, J = 7.5, CHNHCOCH), 7.33-7.22 (7H, m, ArH), 7.04 (1H, 
m, ArH), 6.74 (1H. t, J = 5.7, NHCH2CH2), 4.32 (1H, m (obscured), CHNHCOCH), 
4.29 (2H, d, J = 6.0, CH2NHCO), 3.44 (1H, dd, J = 8.3, 4.9, CHNH2), 2.96-2.86 (2H, 
m, CH2CH2CHNH & 1H, apparent dd, J = 13.6, 4.9, C(H)HCHNH2), 2.64 (1H, dd, 
J = 13.6, 8.3, C(H)HCHNH2), 1.88 (2H, bs, NH2), 1.78 (1H, m, CH2C(H)HCHNH), 
1.63  (1H,  m,  CH2C(H)HCHNH),  1.38  (9H,  s,  3 x CH3); 
13C  NMR  (150  MHz, 
DMSO-d6) ʴ 174.1 (NHCOC), 171.2 (NHCOC), 155.5 (NHCOO), 149.9-148.9 (dd, 
J = 137.1, 12.5, CF), 148.3-147.3 (dd, J = 135.9, 12.5, CF), 139.2 (ArC), 136.6 
(ArC), 128.3 (ArCH), 127.1 (ArCH), 126.9 (ArCH), 126.1 (ArCH), 118.3 (ArCH), 
118.7 (ArCH), 116.9 (ArCH), 116.8 (ArCH), 77.7 (C(CH3)3), 55.8 (CHNH2), 50.3 
(CHNHCOCH), 42.0 (PhCH2NH), 39.8 (CH2CHNH2), 36.8 (CH2CH2CHNH), 32.9 
(CH2CHNHCOCH), 28.3 (3 x CH3); m/z (CI+) 491 (20%, [M+H]
+), 391 (100%, 
[M+2H-Boc]
+); HRMS C25H33F2N4O4 ([M+H]
+) calcd. 491.2470, found. 491.2467.   102 
 (2S,2’S)-Dimethyl 2,2’-[carbonylbis(azanediyl)]bis(3-phenylpropanoate) (37) 
 
To  a  stirred  solution  of  (S)-methyl  2-amino-3-phenylpropanoate  (19.2  mg, 
0.107 mmol)  in  THF  (dry)  (3  mL)  at  0  °C  was  added  triphosgene  (2.70  mg, 
8.80 μmol)  followed  by  Et3N  (15.0  μL,  0.107  mmol).  The  reaction  mixture  was 
stirred at 0 °C for 5 min before allowing to reach ambient temperature (18 °C) and 
stirring for a further 1 h. The reaction mixture was diluted with EtOAc (30 mL) and 
washed with H2O (2 x 15 mL) then brine (15 mL). Organics were dried (MgSO4), 
concentrated  in  vacuo  and  the  residue  purified  by  flash  column  chromatography 
(33% EtOAc/Petrol) to give the title compound (9.30 mg, 90%); as a white solid; 
mp 158-159 °C (155-157 °C
183); Rf 0.38 (33% EtOAc/Petrol); IR νmax (neat) 3345 
(N-H), 3059-2947 (C-H), 1739 (C=O), 1711 (C=O), 1631 (C=O), 1564 (ArC=C), 
1496-1437 (C-H), 1174 (C-F), 749-696 (ArC-H) cm
-1; 
1H NMR (600 MHz, CDCl3) ʴ 
7.27-7.07 (10H, m, ArH), 5.09 (2H, d, J = 8.1, 2 x NH), 4.77 (2H, dt, J = 7.9, 5.8, 2 x 
CHNH), 3.66 (6H, s, 2 x CH3), 3.03 (4H, m, 2 x CH2); 
13C NMR (150 MHz, CDCl3) 
ʴ 173.1 (2 x CO2CH3), 156.2 (2 x CO), 136.1 (2 x ArC), 129.5 (4 x ArCH), 128.6 
(4 x ArCH), 127.1 (2 x ArCH), 54.1 (2 x CHNH), 52.4 (2 x CH3), 38.6 (2 x CH2); 
m/z  (CI+)  385  (100%,  [M+H]
+);  HRMS  C21H25N2O5  ([M+H]
+)  calcd.  385.1764, 
found. 385.1754. 
(S)-methyl  2-{3-[1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-
yl]ureido}-3-phenylpropanoate (35) 
 
General procedure (Method A): to a stirred solution of 25 (20.0 mg, 53.3 μmol) in 
dry THF (3 mL) cooled to 0 °C was added, under dry conditions, triphosgene (5.40 103 
mg, 17.6 μmol) and DMAP (13.4 mg, 107 μmol). After 5 min the reaction mixture 
was allowed to reach ambient temperature and stirred for 30 min under argon. The 
reaction  mixture  was  cooled  to  0  °C  for  5  min  before  addition  of  a  solution  of 
(S)-methyl 2-amino-3-phenylpropanoate (4.80 mg, 26.8 μmol) in dry THF (0.5 mL). 
The reaction mixture was left to reach ambient temperature and stirred for 1 h under 
argon. The reaction mixture was diluted with EtOAc (8 mL) and washed with H2O 
(2 x 3 mL) then brine (3 mL), dried (MgSO4) and concentrated in vacuo. The crude 
material was analysed by 1D and 2D 
1H NMR spectroscopy to identify peaks for title 
compound as follows: 
1H NMR (600 MHz, CDCl3) ʴ 7.75 (1H, bs, NHCONHCH), 
7.68 (1H, s, CCHCNH), 7.49 (1H, d, J = 8.5, CHCHCNH), 7.34-7.11 (8H, m, ArH), 
6.70 (1H, d, J = 8.7, CHCHCNH), 5.95 (1H, d, J = 7.5, CHNHCONH), 5.54 (2H, s, 
CH2NN), 4.82 (1H, dt, J = 7.3, 6.2, CHNHCONH), 3.87 (2H, s, CH2CNN), 3.68 
(3H,  s,  CH3),  3.08  (2H,  ddd,  J  =  47.1,  13.7,  5.7,  CH2CHNH),  2.56  (4H,  bs, 
CH2N(CH2)CH2C), 1.69 (4H, bs, CH2CH2N(CH2)CH2C); m/z (ESI+) 580 (100%, 
[
35,35M+H]
+),  582  (60%,  [
35,37M+H]
+),  584  (12%,  [
37,37M+H]
+),  548  (80%, 
[M-OMe]
+); HRMS C30H32
35Cl2N5O3 ([M+H]
+) calcd. 580.1882, found. 580.1873.  
Method B: as general procedure using CH2Cl2 in place of THF. 
Method C: as general procedure with sonication (5 min) of solution before addition 
of triphosgene and DMAP. 
Method D: as general procedure except the sonicated (5 min) solution of 25 (20.0 
mg, 53.3 μmol) in dry THF (2.5 mL) was added dropwise to a cooled (0 °C) solution 
of triphosgene (5.40 mg, 17.6 μmol) and DMAP (13.4 mg, 107 μmol) in dry THF 
(0.5 mL). 
Method  E:  as  general  procedure  adding  (S)-methyl  2-amino-3-phenylpropanoate 
(10.0 mg, 56.0 μmol) - 1.05 equivalence in place of 0.5 equivalence. 
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1,3-Bis[1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-yl]urea 
(37) - not isolated 
 
Identifiable peaks: 
1H NMR (600 MHz, CDCl3) ʴ 7.92 (2H, s, 2 x CCHCNH), 7.42 
(2H, obscured d, CHCHCNH), 6.84 (2H, d, J = 8.5, 2 x CHCHCNH). 
tert-Butyl (2-aminoethyl)carbamate (39)
184 
 
To a solution of ethylene diamine (3.35 mL, 50.0 mmol) in CHCl3 (10 mL) stirred at 
18 °C was added a solution of di-tert-butyl dicarbonate (1.09 g, 5.00 mmol) in CHCl3 
(30  mL)  dropwise  over  2  h.  After  stirring  for  20  h  the  reaction  mixture  was 
concentrated in vacuo to leave a white solid, which was dissolved in sat. K2CO3 
solution (50 mL) and extracted with CH2Cl2 (3 x 70 mL). Organics were combined, 
dried (MgSO4), concentrated in vacuo and left to dry under vacuum for 6 h to give 
the title compound (710 mg, 87% (quant.
184)); as a slightly yellow oil; Rf 0.19 (10% 
MeOH/CH2Cl2); IR νmax (neat) 3358 (N-H), 2976 (C-H), 2933 (C-H), 1686 (C=O), 
1517 (C=O), 1391 (C-H), 1365 (C-H), 1272 (C-O), 1249 (C-O), 1164 (C-N) cm
-1; 
1H NMR (600 MHz, CDCl3) ʴ 4.95 (1H, bs, NH), 3.15 (2H, apparent dt, J = 5.8, 5.5, 
CH2NH), 2.77 (2H, t, J = 5.8, CH2NH2), 1.42 (9H, s, 3 x CH3), 1.17 (2H, bs, NH2); 
13C NMR ʴ 156.3 (CO), 79.3 (C(CH3)3), 43.5 (CH2NH), 42.0 (CH2NH2), 28.5 (3 x 
CH3);  m/z  (CI+)  161  (100%,  [M+H]
+);  HRMS  C7H17N2O2  ([M+H]
+)  calcd. 
161.1290, found. 161.1289. 
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tert-Butyl (2-{(S)-2-[(S)-2-amino-3-phenylpropanamido]-3-
phenylpropanamido}ethyl)carbamate (44) 
 
i)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-
phenylpropanoic acid (504 mg, 1.30 mmol) in MeCN (50 mL) was added HOBt 
(172 mg, 1.28 mmol) followed by DCC (526 mg, 2.55 mmol). After 5 min of stirring 
a  solution  of  tert-butyl  (2-aminoethyl)carbamate  (200  mg,  1.25  mmol)  in  MeCN 
(2 mL) was added and stirring was continued at 18 °C for 3 h. The reaction mixture 
was cooled on ice, the precipitate filtered off and washed with cold MeCN (50 mL). 
The white solid collected was suspended in MeCN (50 mL) and stirred with Et2NH 
(1.35 mL, 13.0 mmol) for 2.5 h. The reaction mixture was concentrated in vacuo, the 
residue taken up in EtOAc (25 mL) and washed with H2O (3 x 10 mL). The organic 
layer was dried (MgSO4), concentrated in vacuo and the residue purified by flash 
column  chromatography  (0-5%  MeOH/CH2Cl2)  to  give  the  deprotected  amide 
intermediate (190 mg, 49%) as a white solid (Rf 0.17 (10% MeOH/CH2Cl2)). 
ii)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-
phenylpropanoic acid (127 mg, 0.33 mmol) in MeCN (30 mL) was added HOBt 
(43.0 mg, 0.32 mmol) followed by EDC (0.30  mL, 1.69 mmol). After  5 min of 
stirring a solution of the amide intermediate (101 mg, 0.33 mmol), from step i), in 
MeCN (2 mL) was added and stirring continued at 18 °C for 20 h. The reaction 
mixture was cooled on ice and the precipitate filtered and washed with cold MeCN 
(50 mL). The white solid was suspended in MeCN (30 mL) and stirred with Et2NH 
(1.35 mL, 13.0 mmol) for 16 h. The reaction mixture was concentrated in vacuo and 
the  residue  triturated  in  Petrol  until  flaky  pale  solid  achieved,  which  was  then 
dissolved in CHCl3 (10 mL), dried (MgSO4) and concentrated in vacuo. The residue 
was purified by flash  column chromatography (0-5% MeOH/CH2Cl2) to give the 
desired product  (75.0 mg, 50%);  as  a  yellow oil; Rf 0.08 (10% MeOH/CH2Cl2); 
IR νmax (neat) 3295 (N-H), 2977 (C-H), 2933 (C-H), 1679 (C=O), 1649 (C=O), 1526 106 
(C=O),  1366  (C-H),  1255  (C-O),  1170  (C-N),  743  (ArC-H)  cm
-1; 
1H  NMR 
(600 MHz, CDCl3) ʴ 7.82 (1H, d, J = 7.5, NHCOCHNH2), 7.31-7.15 (10H, m, ArH), 
6.79 (1H, s, NHCOO
tBu), 4.88 (1H, s, NHCOCHNH), 4.65 (1H, m, CHNH), 3.61 
(1H,  m,  CHNH2),  3.31-3.19  (2H,  m,  CH2NHCOO
tBu),  3.17-3.01  (2H,  m, 
CH2NHCOCH, 2H, m, CH2CHNH & 1H, m, C(H)HCHNH2), 2.46 (1H, dd, J = 13.2, 
10.0, C(H)HCHNH2), 1.67 (2H, bs, NH2), 1.39 (9H, s, 3 x CH3); 
13C NMR (150 
MHz,  CDCl3)  ʴ  174.6  (COCHNH2),  171.4  (COCHNH),  156.8  (COO
tBu),  137.7 
(ArC), 136.9 (ArC), 129.5 (ArCH), 129.4 (ArCH), 128.9 (ArCH), 128.7 (ArCH), 
127.1 (ArCH), 127.0 (ArCH), 79.7 (C(CH3)3), 56.4 (CHNH2), 54.2 (CHNH), 40.8 
(CH2CHNH2), 40.7 (CH2NHCOO
tBu), 40.3 (CH2NHCO), 38.3 (CH2CHNH), 28.5 
(3 x  CH3):  m/z  (ESI+)  477  (100%,  [M+Na]
+),  355  (50%,  [M+H-Boc]
+);  HRMS 
C25H34N4O4Na ([M+Na]
+) calcd. 477.2478, found. 477.2484. 
(S)-N-(2-aminoethyl)-2-({S}-2-{3-[1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-
ylmethyl)-1H-indazol-6-yl]ureido}-3-phenylpropanamido)-3-
phenylpropanamide dihydrochloride salt (45) 
 
To a sonicated (5 min), then stirred solution of 25 (100 mg, 330 μmol) in dry THF 
(20 mL), under dry conditions and cooled to 0 °C, was added together triphosgene 
(28.0 mg, 116 μmol) and DMAP (66.0 mg, 660 μmol). After 5 min the reaction 
mixture was allowed to reach ambient temperature and stirred for 1 h under argon. 
The  reaction  mixture  was  cooled  again  to  0  °C  for  5  min  and  a  solution  of  44 
(75.0 mg, 165 μmol) in dry THF (10 mL) was added. The reaction mixture was left 
to reach ambient temperature and stirred for 2 h under argon then diluted with EtOAc 
(100 mL) and washed with H2O (2 x 20 mL) then brine (20 mL), dried (MgSO4) and 
concentrated in vacuo. The pale orange residue was suspended in CH2Cl2 (10 mL), 
sonicated,  filtered  and  rinsed  with  CH2Cl2  (10  mL)  to  give  the  Boc-protected 
intermediate as an off-white solid (75.0 mg, 53%). Solid (63.0 mg, 73.6 μmol) was 107 
taken up in a solution of HCl (4N) in dioxane (2 mL), MeOH (2 drops) added to 
assist solvation and stirred for 2 h before concentrating in vacuo. The product was 
suspended in H2O and lyophilised to give the title compound (41.0 mg, 67%); as a 
white solid; mp 164-168 °C (decomp.); Rf 0.06 (10% MeOH/CH2Cl2); IR νmax (neat) 
3291 (N-H), 3057 (N-H), 2956 (C-H), 1637 (C=O), 1584 (C=O), 1535 (C=O), 1493 
(C-H),  1435  (C-H),  1228  (C-N),  1160  (C-N),  740  (C-Cl),  697  (ArC-H)  cm
-1; 
1H NMR  (600  MHz,  DMSO-d6)  ʴ  10.66  (1H,  bs,  N
+HCH2CNN),  9.25  (1H,  s, 
NHCONHCH),  8.47  (1H,  d,  J  =  8.1,  CHNHCOCH),  8.34  (1H,  t,  J  =  5.7, 
NHCH2CH2N
+H3), 8.10 (3H, bs, N
+H3), 8.01 (1H, d, J = 0.8, CCHCNH), 7.84 (1H, 
d,  J  =  8.7,  CCHCHCNH),  7.54  (2H,  d,  J  =  8.1,  2  x  CHCCl),  7.43  (1H,  m, 
CHCHCCl), 7.27-7.12 (9H, m, ArH), 7.01 (1H, dd, J = 8.7, 1.3, CCHCHCNH), 6.55 
(1H, d, J = 7.9, CHNHCONH), 5.66 (2H, s, CH2NN), 4.59 (2H, s, CH2CNN), 4.52 
(1H, dt, J = 4.9, 8.3, CHNHCONH), 4.48 (1H, dt, J = 5.3, 8.7, CHNHCOCH), 3.36 
(2H  distorted  by  H2O  peak,  m,  2  x  C(H)HN
+H(CH2)CH2C),    3.34-3.26  (2H,  m, 
CH2CH2NHCO),  3.11-3.01  (2H,  m,  2  x  C(H)HN
+H(CH2)CH2C  &  1H,  m, 
CC(H)HCHNHCOCH & 1H, m, CC(H)HCHNHCONH), 2.87 (1H, dd, J = 13.7, 9.2, 
CC(H)HCHNHCOCH),  2.83-2.74  (1H,  m,  CC(H)HCHNHCONH  &  2H,  m, 
CH2CH2NHCO), 1.91-1.85 (2H, m,  2 x C(H)HCH2N
+H(CH2)CH2C), 1.83-1.76 (2H, 
m,  2  x  C(H)HCH2N
+H(CH2)CH2C); 
13C  NMR  (150  MHz,  DMSO-d6)  ʴ  171.4 
(NHCOCH), 154.7 (NHCOCH), 141.5 (NHCONH), 139.8 (ArC), 137.8 (ArC), 137.6 
(ArC),  136.1  (2  x  CCl),  135.6  (ArC),  131.5  (ArC),  131.0  (CHCHCCl),  129.5 
(ArCH), 129.3 (ArCH), 128.8 (2 x CHCCl), 128.1 (ArCH), 126.3 (ArCH), 120.7 
(CHCHCNH),  117.7  (ArC),  114.5  (CHCHCNH),  96.0  (CCHCNH),  54.3 
(CHNHCOCH),  53.9  (CHNHCONH),  52.6  (2  x  CH2N
+H(CH2)CH2C),  47.7 
(CH2CNN),  47.3  (CH2NN),  38.3  (CH2CHNHCONH  &  CH2CH2NHCO),  37.6 
(CH2CHNHCOCH), 36.4 (CH2CH2NHCO), 22.7 (2 x CH2CH2N
+H(CH2)CH2C); m/z 
(ESI+) 755 (100%, [
35,35M+H]
+), 757 (77%, [
35,37M+H]
+), 759 (9%, [
37,37M+H]
+); 
HRMS C40H45
35Cl2N8O3 ([M+H]
+) calcd. 755.2992, found. 755.2996. 
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(S)-4-Amino-N-benzyl-2-({S}-2-{3-[1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-
ylmethyl)-1H-indazol-6-yl]ureido}-3-{3,4-
difluorophenyl}propanamido)butanamide dihydrochloride salt (20) 
 
To a sonicated (5 min), then stirred solution of 25 (40.0 mg, 0.106 mmol) in dry THF 
(9 mL), under dry conditions and cooled to 0 °C, was added together triphosgene 
(11.0 mg, 37.1 μmol) and DMAP (26.0 mg, 212 μmol). After 5 min the reaction 
mixture  was  allowed  to  reach  ambient  temperature  and  stirred  for  30  min  under 
argon. The reaction mixture was cooled again to 0 °C for 5 min and a solution of 33 
(26.0 mg, 53.0 μmol) in dry THF (4 mL) was added. The reaction mixture was left to 
reach ambient temperature and stirred for 2 h under argon then concentrated in vacuo 
and  the  residue  purified  by  flash  column  chromatography  (3-5% 
MeOH.NH3/CH2Cl2) to give the Boc-protected intermediate (25.0 mg), Rf 0.35 (10% 
MeOH/CH2Cl2). The off-white solid was suspended in a solution of HCl (4N) in 
dioxane (2 mL) and stirred for 2.5 h before concentrating in vacuo, taking up in a 
0.1 M HCl (aq) solution (2 mL) and lyophilised to give the title compound (20.0 mg, 
53%); as a white solid; mp 176-184 °C; Rf 0.06 (10% MeOH/CH2Cl2); IR νmax (neat) 
3280 (N-H), 3059 (N-H), 2926 (C-H), 1634 (C=O), 1585 (C=O), 1537 (C=O), 1435 
(C-H), 1209 (C-N), 769 (C-Cl), 696 (ArC-H)  cm
-1;
 1H NMR (600 MHz, DMSO-d6) 
ʴ  10.43  (1H,  bs,  N
+HCH2CNN),  9.26  (1H,  s,  NHCONHCH),  8.64-8.63  (1H,  m, 
NHCH2Ph & 1H, m, CHNHCOCH), 7.97 (1H, s, CCHCNH), 7.95 (3H, bs, N
+H3), 
7.80 (1H, d, J = 8.7, CCHCHCNH), 7.54 (2H, d, J = 8.1, 2 x CHCCl), 7.43 (1H, m, 
CHCHCCl), 7.35-7.21 (7H, m, ArH), 7.09-7.07 (1H, m, ArH), 7.02 (1H, dd, J = 8.7, 
1.1, CHCHCNH), 6.67 (1H, d, J = 7.7, CHNHCONH), 5.61 (2H, s, CH2NN), 4.60-
4.55 (1H, m, CHNHCONH & 2H, m, CH2CNN), 4.42 (1H, apparent dt, J = 6.0, 7.9, 
CHNHCOCH), 4.33 (2H, m, CH2NHCO), 3.38 (2H distorted by H2O peak, m, 2 x 
C(H)HN
+H(CH2)CH2C), 3.11-3.06 (2H, m, 2 x C(H)HN
+H(CH2)CH2C & 1H, m, 
C(H)HCHNHCONH),  2.89-2.78  (1H,  m,  C(H)HCHNHCONH  &  2H,  m, 109 
CH2CH2CHNH),  2.11-1.76  (2H,  m,  CH2CHNHCOCH  &  4H,  m,  2  x 
CH2CH2N
+H(CH2)CH2C); 
13C NMR  (150 MHz, DMSO-d6)  ʴ  171.5 (NHCOCH), 
170.5 (NHCOCH), 154.8 (NHCONH), 148.2 (d, JCF = 12.5, CF), 147.5 (d, JCF = 
12.5, CF), 141.4 (ArC), 139.6 (ArC), 139.1 (ArC), 136.1 (2 x CCl), 131.5 (ArC), 
131.0  (CHCHCCl),  128.8  (2  x  CHCCl),  128.5  (ArC),  128.3  (2  x  ArCH),  127.5 
(ArC), 127.1 (2 x ArCH), 126.9 (ArCH), 126.3 (ArCH), 120.7 (CHCHCNH), 118.3 
(d, J = 16.7, ArCH), 117.7 (ArC), 117.0 (d, J = 16.1, ArCH), 114.5 (CHCHCNH), 
96.2  (CCHCNH),  53.8  (CHNHCONH),  52.8  (2  x  CH2N
+H(CH2)CH2C),  50.6 
(CHNHCOCH),  48.0  (CH2CNN),  47.2  (CH2NN),  42.1  (CH2NHCO),  37.5 
(CH2CHNHCONH),  36.2  (CH2CH2CHNH),  30.1  (CH2CHNHCOCH),  22.7  (2  x 
CH2CH2N
+H(CH2)CH2C);  m/z  (ESI+)  791  (100%,  [
35,35M+H]
+),  793  (80%, 
[
35,37M+H]
+),  795  (9%,  [
37,37M+H]
+);  HRMS  C40H43
35Cl2F2N8O3  calcd.  791.2803, 
found 791.2819. 
tert-Butyl ([S]-3-[(S)-2-amino-3-(3,4-difluorophenyl)propanamido]-4-oxo-4-
{[(R)-1-phenylethyl]amino}butyl)carbamate (56a) 
 
i)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-
[(tert-butoxycarbonyl)amino]butanoic acid (100 mg, 0.23 mmol), HBTU (80.0 mg, 
0.21 mmol) and HOBt (28.0 mg, 0.21 mmol) in DMF (5 mL) was added DIPEA 
(37.0 μL, 0.21 mmol). After 3 min of stirring, (R)-1-phenylethanamine (24.0 μL, 
0.19 mmol) was added and stirring continued at 18 °C for 5 h. The reaction mixture 
was concentrated in vacuo and the white residue taken up in CHCl3/EtOAc (60 mL, 
1:1) and washed with H2O (15 mL), 10% citric acid solution (15 mL), sat. NaHCO3 
solution (15 mL) and brine (15 mL). The organic layer was concentrated in vacuo 
and  the  residue  dissolved  in  DMF  (5  mL)  and  stirred  with  Et2NH  (0.24  mL, 110 
2.30 mmol) at 18 °C for 3 h. The reaction mixture was concentrated in vacuo and the 
residue taken up in CHCl3/EtOAc (40 mL, 1:1) and washed with H2O (2 x 15 mL), 
brine (15 mL) and sat. LiCl solution (4 x 15 mL). The organic layer was concentrated 
in  vacuo  and  the  residue  purified  by  flash  column  chromatography  (0-2% 
MeOH/CH2Cl2) to give the deprotected amide intermediate (48.0 mg, 79%) (Rf 0.63 
(10% MeOH/CH2Cl2). 
ii)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-
(3,4-difluorophenyl)propanoic  acid  (74.0  mg,  0.17  mmol),  HBTU  (61.0  mg, 
0.16 mmol) and HOBt (22.0 mg, 0.16 mmol) in DMF (5 mL) was added DIPEA 
(28.0 μL, 0.16 mmol). After 3 min of stirring, a solution of the deprotected amide 
intermediate (47.0 mg, 0.15 mmol), from step i),  in DMF (5 mL) was added and 
stirring continued at 18 °C for 16 h. The reaction mixture was concentrated in vacuo 
and the residue taken up in EtOAc (30 mL) and washed with H2O (10 mL), 10% 
citric acid solution (10 mL), sat. NaHCO3 solution (10 mL) and brine (10 mL). The 
organic layer was concentrated in vacuo and the residue dissolved in DMF (5 mL) 
and stirred with Et2NH (0.18 mL, 1.74 mmol) at 18 °C for 3 h. The reaction mixture 
was concentrated in vacuo and the residue taken up in EtOAc (30 mL) and washed 
with H2O (2 x 10 mL), brine (10 mL) and sat. LiCl solution (4 x 15 mL). The organic 
layer  was  concentrated  in  vacuo  and  the  residue  purified  by  flash  column 
chromatography (0-2% MeOH/CH2Cl2) to give the title compound (55.0 mg, 75%); 
as a white solid; mp 118-120 °C; Rf 0.38 (10% MeOH/CH2Cl2); IR νmax (neat) 3293 
(N-H),  3061  (N-H),  2971-2871  (C-H),  1673  (C=O),  1634  (C=O),  1514  (C=O), 
1446-1365 (C-H), 1280 (C-O), 1250 (C-N), 1209 (C-N), 1115 (C-F), 696 (ArC-H) 
cm
-1;
 1H NMR (600 MHz, DMSO-d6) ʴ 8.46 (1H, d, J = 7.9, NHCH(CH3)Ph), 8.07 
(1H, d, J = 7.9, NHCHCH2CH2), 7.33-7.19 (7H, m, ArH), 7.00 (1H, m, ArH), 6.75 
(1H, t, J = 5.7, NHCH2CH2), 4.90 (1H, quintet, J = 7.2, CHCH3), 4.32 (1H, apparent 
dt, J = 6.8, 7.5, NHCHCH2CH2), 3.39 (1H, dd, J = 8.3, 4.9, CHNH2), 2.94-2.87 (2H, 
m, NHCHCH2CH2 & 1H, apparent dd, J = 13.6, 4.5, C(H)HCHNH2), 2.60 (1H, dd, 
J = 13.6, 8.3, C(H)HCHNH2), 1.81 (2H, bs, NH2), 1.74 (1H, m, NHCHC(H)HCH2), 
1.61  (1H,  m,  NHCHC(H)HCH2),  1.38  (9H,  s,  (CH3)3C),  1.34  (3H,  d,  J  =  7.2, 
CH3CH); 
13C  NMR  (150  MHz,  DMSO-d6)  ʴ  173.9  (NHCOC),  170.1  (NHCOC), 
155.5  (NHCOO),  149.8-148.8  (dd,  JC-F  =  137.7,  12.5,  CF),  148.2-147.2  (dd, 
JC-F = 136.5, 12.5, CF), 144.1 (ArC), 136.6 (ArC), 128.3 (2 x ArCH), 126.8 (ArCH), 111 
126.1 (ArCH), 126.0 (2 x ArCH), 118.2 (d, JC-F = 16.7, CHCF), 116.8 (d, JC-F = 16.7, 
CHCF), 77.7 (C(CH3)3), 55.7 (CHNH2), 50.2 (NHCHCH2CH2), 47.9 (CHCH3), 40.1 
(CH2CHNH2), 36.7 (CH2CH2NHCO), 33.2 (CH2CH2NHCO), 28.3 (C(CH3)3), 22.4 
(CH3CH);  m/z  (CI+)  505  (88%,  [M+H]
+),  405  (100%,  [M+H-Boc]
+);  HRMS 
C26H35F2N4O4 ([M+H]
+) calcd. 505.2626, found. 505.2623. 
tert-Butyl ([S]-3-[(S)-2-amino-3-(3,4-difluorophenyl)propanamido]-4-oxo-4-
{[(S)-1-phenylethyl]amino}butyl)carbamate (56b) 
 
i)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-
[(tert-butoxycarbonyl)amino]butanoic acid (200 mg, 0.46 mmol), HBTU (160 mg, 
0.42 mmol) and HOBt (56.0 mg, 0.42 mmol) in DMF (5 mL) was added DIPEA 
(74.0 μL, 0.42 mmol). After 3 min of stirring (S)-1-phenylethanamine (48.0 μL, 0.38 
mmol) was added and stirring continued at 18 °C for 5 h. The reaction mixture was 
concentrated  in  vacuo  and  purified  by  flash  column  chromatography  (25% 
EtOAc/Pet)  to  give  the  Fmoc-protected  amide  intermediate  (Rf  0.75  (50% 
EtOAc/Pet)), which was dissolved in DMF (5 mL) and stirred with Et2NH (0.48 mL, 
4.60 mmol) at 18 °C for 5 h. The reaction mixture was concentrated in vacuo and the 
residue taken up in CHCl3/EtOAc (40 mL, 1:1) and washed with H2O (2 x 15 mL), 
brine (15 mL) and sat. LiCl solution (4 x 15 mL). The organic layer was concentrated 
in  vacuo  and  the  residue  purified  by  flash  column  chromatography 
(0-10% MeOH/CH2Cl2) to give the deprotected amide intermediate (90.0 mg, 74%) 
(Rf 0.25 (10% MeOH/CH2Cl2). 
ii)  To  a  stirred  solution  of  (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-
(3,4-difluorophenyl)propanoic  acid  (133  mg,  0.31  mmol),  HBTU  (111  mg, 
0.29 mmol) and HOBt (38.0 mg, 0.29 mmol) in DMF (5 mL) was added DIPEA 112 
(51.0 μL, 0.29 mmol). After 3 min of stirring, a solution of the deprotected amide 
intermediate (88.0 mg, 0.27 mmol), from step i),  in DMF (2mL) was added and 
stirring continued at 18 °C for 16 h. The reaction mixture was concentrated in vacuo 
and the residue taken up in EtOAc (30 mL) and washed with H2O (10 mL), 10% 
citric acid solution (10 mL), sat. NaHCO3 solution (10 mL) and brine (10 mL). The 
organic layer was concentrated in vacuo and the residue dissolved in DMF (5 mL) 
and stirred with Et2NH (0.33 mL, 3.14 mmol) at 18 °C for 5 h. The reaction mixture 
was concentrated in vacuo and the residue purified by flash column chromatography 
(0-3% MeOH/CH2Cl2) to give the title compound (106 mg, 77%); as a white solid; 
mp  106-112 °C; Rf 0.38 (10% MeOH/CH2Cl2;  IR  νmax  (neat) 3291 (N-H), 3061 
(N-H), 2973-2873 (C-H), 1676 (C=O), 1633 (C=O), 1515 (C=O), 1446-1365 (C-H), 
1280 (C-O), 1249 (C-N), 1210 (C-N), 1116 (C-F), 696 (ArC-H) cm
-1; 
1H NMR (600 
MHz, DMSO-d6) ʴ 8.50 (1H, d, J = 7.9, NHCH(CH3)Ph), 8.06 (1H, d, J = 8.3, 
NHCHCH2CH2), 7.32-7.20 (7H, m, ArH), 7.04 (1H, m, ArH), 6.71 (1H, t, J = 5.7, 
NHCH2CH2), 4.88 (1H, quintet, J = 7.3, CHCH3), 4.34 (1H, apparent dt, J = 6.0, 8.1, 
NHCHCH2CH2), 3.43 (1H, dd, J = 8.3, 4.9, CHNH2), 2.91 (1H, dd, J = 13.6, 4.9, 
C(H)HCHNH2), 2.88-2.79 (2H, m,  NHCHCH2CH2), 2.63 (1H, dd, J  = 13.6, 8.3, 
C(H)HCHNH2), 1.79 (2H, bs, NH2), 1.71-1.65 (1H, m, NHCHC(H)HCH2), 1.57-1.51 
(1H, m, NHCHC(H)HCH2), 1.38 (9H, s, (CH3)3C), 1.34 (3H, d, J = 7.0, CH3CH); 
13C  NMR  (150  MHz,  DMSO-d6)  ʴ  174.0  (NHCOC),  170.1  (NHCOC),  155.4 
(NHCOO), 149.9-148.9 (dd, JC-F = 137.7, 12.5, CF), 148.3-147.3 (dd, JC-F = 136.5, 
12.5,  CF),  144.5  (ArC),  136.7  (ArC),  128.3  (2  x  ArCH),  126.7  (ArCH),  126.1 
(ArCH), 125.8 (2 x ArCH), 118.2 (d, JC-F = 16.7, CHCF), 116.8 (d, JC-F = 16.7, 
CHCF), 77.7 (C(CH3)3), 55.7 (CHNH2), 50.0 (NHCHCH2CH2), 47.9 (CHCH3), 40.1 
(CH2CHNH2), 36.7 (CHCH2CH2NH), 33.2 (CHCH2CH2NH), 28.3 (C(CH3)3), 22.6 
(CH3CH);  m/z  (ESI+)  505  (75%,  [M+H]
+),  527  (100%,  [M+Na]
+);  HRMS 
C26H35F2N4O4 ([M+H]
+) calcd. 505.2626, found. 505.2621. 
   113 
(S)-4-Amino-2-({S}-2-{3-[1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-
indazol-6-yl]ureido}-3-{3,4-difluorophenyl}propanamido)-N-[(R)-1-
phenylethyl]butanamide dihydrochloride salt (51a) 
 
To a sonicated (5 min), then stirred, solution of 25 (50.0 mg, 133 μmol) in dry THF 
(5 mL), under dry conditions and cooled to 0 °C, was added together triphosgene 
(14.0 mg, 46.6 μmol) and DMAP (32.0 mg, 266 μmol). After 5 min the reaction 
mixture  was  allowed  to  reach  ambient  temperature  and  stirred  for  30  min  under 
argon. The reaction mixture was cooled again to 0 °C for 5 min and a solution of 56a 
(32.0 mg, 66.5 μmol) in dry THF (3 mL) was added. The reaction mixture was left to 
reach ambient temperature and stirred for 2 h under argon then concentrated in vacuo 
and the residue purified by flash column chromatography (2-5% MeOH/CH2Cl2) to 
give the Boc-protected intermediate, Rf 0.31 (10% MeOH/CH2Cl2). The off-white 
solid was suspended in a solution of HCl (4N) in dioxane (2 mL) and stirred for 2.5 h 
before  concentrating  in  vacuo  and  purifying  by  preparative  RP-HPLC  (retention 
time: 10.82 min). The isolated product was taken up in a 0.1 M HCl (aq) solution (2 
mL) and lyophilised to give the title compound (3.70 mg, 6%
‡‡); as a white solid; mp 
158-163 °C (decomp.); Rf 0.06 (10% MeOH/CH2Cl2); IR νmax (neat) 3274 (N-H), 
3059 (N-H), 2973 (C-H), 1663 (C=O), 1647 (C=O), 1515 (C=O), 1436 (C-H), 1198 
(C-N),  1177  (C-N),  1128  (C-F),  834-699  (ArC-H)  cm
-1; 
1H  NMR  (DMSO-d6, 
600MHz) ʴ 9.98 (1H, bs, N
+HCH2CNN), 9.08 (1H, s, NHCONHCH), 8.59 (1H, d, J 
= 8.3, NHCHCH2CH2), 8.49 (1H, d, J = 8.3, NHCH(CH3)Ph), 7.97 (1H, d, J = 1.1, 
CCHCNH), 7.75-7.70 (1H, d, J = 8.7, CHCHCNH & 3H, bs, N
+H3), 7.53 (2H, d, J = 
8.3, 2 x CHCCl), 7.42 (1H, t, J = 8.3, CHCHCCl), 7.32-7.10 (7H, m, ArH), 7.01 (1H, 
dd,  J  =  8.7,  1.1,  CHCHCNH),  6.97  (1H,  m,  ArH),  6.52  (1H,  d,  J  =  7.9, 
CHNHCONH), 5.62 & 5.57 (2H, ABq, J = 14.5, CH2NN), 4.95 (1H, dq, J = 7.5, 7.2, 
                                                 
‡‡ Low yield was suspected to be a result of poor quality THF (dry) 114 
CHCH3),  4.61  (2H,  d,  J = 5.3,  CH2CNN),  4.57  (1H,  apparent  dt,  J  =  4.9,  7.9, 
CHNHCONH), 4.41 (1H, apparent dt, J = 7.5, 7.2, CHCH2CH2), 3.38 (2H distorted 
by  H2O  peak,  m,  2  x  C(H)HN
+H(CH2)CH2C),  3.11-3.06  (2H,  m,  2  x 
C(H)HN
+H(CH2)CH2C),  2.99  (1H,  dd,  J  =  13.6,  4.1,  C(H)HCHNHCONH), 
2.83-2.77 (1H, m, C(H)HCHNHCONH & 2H, m, CH2CH2CHNH), 2.01-1.95 (1H, 
m,  C(H)HCHNHCOCH),  1.93-1.84  (1H,  m,  C(H)HCHNHCOCH  &  2H,  m,  2  x 
C(H)HCH2N
+H(CH2)CH2C),  1.81-1.74  (2H,  m,  2 x  C(H)HCH2N
+H(CH2)CH2C), 
1.37 (3H, d, J = 6.8, CH3); 
13C NMR (150 MHz, DMSO-d6) ʴ 171.3 (NHCOC), 
169.4 (NHCOC), 157.8  (d, J = 31.6, ArC), 154.6 (NHCONH), 149.1 (ArC), 147.5 
(ArC), 144.0 (ArC), 141.4 (ArC), 139.6 (ArC), 136.1 (2 x CCl), 135.6 (ArC), 131.4 
(ArC), 131.0 (CHCHCCl), 128.8 (2 x CHCCl), 128.3 (2 x ArCH), 126.8 (ArCH), 
126.2 (ArCH), 126.0 (2 x ArCH), 120.5 (CCHCHCNH), 118.2 (d, J = 16.7, ArCH), 
117.7 (ArC), 116.9 (d, J = 16.7, ArCH), 114.6 (CHCHCNH), 96.3 (CCHCNH), 53.6 
(CHNHCONH),  53.1  (2 x CH2N
+H(CH2)CH2C),  50.4  (CHCH2CH2),  48.0 
(CH2CNN),  47.95  (CHCH3),  47.3  (CH2NN),  37.6  (CH2CHNHCONH),  36.3 
(CH2CH2CHNH),  30.2  (CH2CHNHCOCH),  22.6  (2  x  CH2CH2N
+H(CH2)CH2C), 
22.3 (CH3); m/z (ESI+) 805 (100%, [
35,35M+H]
+), 807 (78%, [
35,37M+H]
+), 809 (12%, 
[
37,37M+H]
+);  HRMS  C41H45
35Cl2F2N8O3  ([M+H]
+)  calcd.  805.2960,  found. 
805.2922. 
(S)-4-amino-2-({S}-2-{3-[1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-
indazol-6-yl]ureido}-3-{3,4-difluorophenyl}propanamido)-N-[(S)-1-
phenylethyl]butanamide dihydrochloride salt (51b) 
 
To a sonicated (5 min), then stirred, solution of 25 (60.0 mg, 133 μmol) in dry THF 
(8 mL), under dry conditions and cooled to 0 °C, was added together triphosgene 
(16.0 mg, 54.0 μmol) and DMAP (37.0 mg, 306 μmol). After 5 min the reaction 
mixture  was  allowed  to  reach  ambient  temperature  and  stirred  for  30  min  under 115 
argon. The reaction mixture was cooled again to 0 °C for 5 min and a solution of 56b 
(39.0 mg, 77.0 μmol) in dry THF (3 mL) was added. The reaction mixture was left to 
reach  ambient  temperature  and  stirred  for  2  h  under  argon  then  concentrated  in 
vacuo. The residue was suspended in a solution of HCl (4N) in dioxane (2 mL) and 
stirred  for  2.5  h  before  concentrating  in  vacuo  and  purifying  by  preparative 
RP-HPLC (retention time: 8.56 min). The isolated product was taken up in a 0.1 M 
HCl (aq) solution (2 mL) and lyophilised to give the title compound (22.5 mg, 33%); 
as a white solid; mp 174-178 °C (decomp.); Rf 0.06 (10% MeOH/CH2Cl2); IR νmax 
(neat) 3275 (N-H), 3061 (N-H), 2972 (C-H), 1665 (C=O), 1633 (C=O), 1514 (C=O), 
1436 (C-H), 1198 (C-N), 1179 (C-N), 1129 (C-F), 834-699 (ArC-H) cm
-1;
 1H NMR 
(DMSO-d6, 600MHz) ʴ 10.11 (1H, bs, N
+HCH2CNN), 9.17 (1H, s, NHCONHCH), 
8.58-8.55  (overlapping  1H,  d,  J  =  7.9,  NHCHCH2CH2  &  1H,  d,  J  =  7.9, 
NHCH(CH3)Ph), 8.01 (1H, d, J = 0.9, CCHCNH), 7.78-7.76 (3H, bs, N
+H3 & 1H, d, 
J = 8.5, CHCHCNH), 7.55 (2H, d, J = 8.3, 2 x CHCCl), 7.44 (1H, m, CHCHCCl), 
7.36-7.21 (7H, m, ArH), 7.07-7.03 (1H, m, ArH & 1H, dd, J = 8.9, 1.5, CHCHCNH), 
6.63 (1H, d, J = 7.7, CHNHCONH), 5.63 (1H, s, CH2NN), 4.94 (1H, overlapping dq, 
J = 7.0, 7.3, CHCH3), 4.63-4.58 (2H m, CH2CNN & 1H, m, CHNHCONH), 4.43 
(1H, overlapping dt, J = 6.2, 7.9, CHCH2CH2), 3.39 (2H, obscured by H2O peak, 2 x 
C(H)HN
+H(CH2)CH2C), 3.10 (2H, m, 2 x C(H)HN
+H(CH2)CH2C), 3.04 (1H, dd, J = 
13.9, 4.7, C(H)HCHNHCONH), 2.88 (1H, dd, J = 13.9, 8.1, C(H)HCHNHCONH), 
2.77-2.67  (2H,  m,  CH2CH2CHNH),  1.98-1.88  (2H,  m,  2  x 
C(H)HCH2N
+H(CH2)CH2C  &  1H  C(H)HCHNHCOCH),  1.87-1.75  (2H,  m,  2  x 
C(H)HCH2N
+H(CH2)CH2C & 1H C(H)HCHNHCOCH), 1.37 (3H, d, J = 7.0, CH3); 
13C NMR (150 MHz, DMSO-d6) ʴ 171.3 (NHCOC), 169.4 (NHCOC), 158.0  (q, J = 
30.8, ArC), 154.7 (NHCONH), 149.9-149.2 (dd, J = 104.5, 13.2, CF), 148.2-147.5 
(dd, J = 103.4, 13.2, CF), 144.4 (ArC), 141.5 (ArC), 139.7 (ArC), 136.1 (2 x CCl), 
135.6  (ArC),  131.5  (ArC),  131.0  (CHCHCCl),  128.8  (2  x  CHCCl),  128.4  (2  x 
ArCH),  126.8  (ArCH),  126.2  (ArCH),  125.9  (2  x  ArCH),  120.5  (CCHCHCNH), 
118.3  (d,  J  =  17.6,  CHCF),  117.7  (ArC),  117.0  (d,  J  =  16.5,  CHCF),  114.6 
(CHCHCNH),  96.3  (CCHCNH),  53.6  (CHNHCONH),  53.1  (2  x 
CH2N
+H(CH2)CH2C),  50.3  (CHCH2CH2),  48.2  (CH2CNN),  48.05  (CHCH3),  47.3 
(CH2NN),  37.6  (CH2CHNHCONH),  36.2  (CH2CH2CHNH),  30.4 
(CH2CHNHCOCH),  22.7  (2 x  CH2CH2N
+H(CH2)CH2C),  22.6  (CH3);  m/z  (ESI+) 116 
805 (100%, [
35,35M+H]
+), 807 (64%, [
35,37M+H]
+), 809 (11%, [
37,37M+H]
+); HRMS 
C41H45
35Cl2F2N8O3 ([M+H]
+) calcd. 805.2960, found. 805.2968. 
Racemic mixture of (S)-1-(2,6-dichlorophenyl)ethyl methanesulfonate & (R)-1-
(2,6-dichlorophenyl)ethyl methanesulfonate (58) 
 
To a solution of 2,6-dichlorobenzaldehyde (2.00 g, 11.4 mmol) in THF (dry) (50 mL) 
at 0 °C under dry conditions was added a solution of methyl magnesium bromide 
(3 M) in Et2O (11.4 mL, 34.3 mmol) in two portions.  The reaction mixture was 
stirred for 1.5 h before quenching with cold sat. NH4Cl (aq) solution (100 mL) and 
extracting with Et2O (3 x 80 mL).  Organics were combined, dried (MgSO4) and 
concentrated in vacuo to leave a clear yellow oil, which was taken up in CH2Cl2 (30 
mL) and stirred at 0 °C.  To this solution was added triethylamine (3.25 mL, 22.2 
mmol) followed by methanesulfonyl chloride (1.17 mL, 14.4 mmol).  The reaction 
mixture was stirred for 1.5 h before quenching with H2O (30 mL) and extracting with 
CH2Cl2 (3 x 20 mL).  Organics were combined and washed with H2O (20 mL), HCl 
(1 M) (20 mL), sat. NaHCO3 (aq) solution (20 mL) and brine (20 mL), then dried 
(MgSO4) and concentrated in vacuo to leave clear, colourless oil.  Purified by flash 
column chromatography (5% Et2O/Pet) and dried under high vacuum to give target 
compound (2.72 g, 89%); as a white solid; mp 49-50 °C; Rf 0.06 (20% Et2O/Pet); IR 
νmax  (neat)  3025-2934  (C-H),  1580  (ArC=C),  1562  (ArC=C),  1435  (C-H),  1349 
(SO2), 1171 (SO2), 1084 (C-O), 906-763 (ArC-H), 518 (C-Cl) cm
-1; H NMR (600 
MHz, CDCl3) ʴ 7.35 (2H, d, J = 8.3, CHCCl), 7.22 (1H, t, J = 8.3, CHCHCCl), 6.49 
(1H, q, J = 6.8, CHCH3), 2.86 (3H, s, CH3S), 1.84 (3H, d, J = 6.8, CH3CH); 
13C 
NMR  ʴ 134.8 (2 x CCl), 133.8 (ArC), 130.4 (CHCHCCl), 129.7 (CHCCl), 75.9 
(CHCH3), 38.5 (CH3S), 19.6 (CH3CH); m/z (CI+) 268 (2%, 
35,35M
+), 173 (100%, 
[
35,35M-OMs]
+)  ,  175  (66%,  [
35,37M-OMs]
+)  ,  177  (11%,  [
37,37M-OMs]
+);  HRMS 
C9H10
35Cl2O3S (M
+) calcd. 267.9728, found. 267.9727. 117 
Racemic  mixture  (S)-1-[1-(2,6-dichlorophenyl)ethyl]-6-nitro-3-(pyrrolidin-1-
ylmethyl)-1H-indazole  &  (R)-1-[1-(2,6-dichlorophenyl)ethyl]-6-nitro-3-
(pyrrolidin-1-ylmethyl)-1H-indazole (59) 
 
To  a  stirred  solution  of  23  (183  mg,  0.743  mmol)  in  DMF  (20  mL),  under  dry 
conditions, was added 58 (200 mg, 0.743 mmol) and caesium carbonate (242 mg, 
0.743 mmol). The reaction mixture was stirred under argon at 100 °C for 20 h before 
allowing to reach ambient temperature then diluted with H2O (10 mL) and extracted 
with EtOAc (3 x 20 mL). The organics were combined and washed with H2O (10 
mL) then brine (2 x 10 mL), dried (MgSO4) and concentrated in vacuo to leave an 
oily brown residue. Purification by flash column chromatography (0-1.5% MeOH in 
CH2Cl2) gave target compound (171 mg, 55%); as a light brown solid; mp 92-96 °C; 
Rf 0.44 (10% MeOH in CH2Cl2); IR νmax (neat) 3063-2783 (C-H), 1579 (ArC=C), 
1561 (ArC=C), 1521 (NO2), 1438 (C-H), 1339 (NO2), 1210 (C-N), 1122 (C-N), 1067 
(C-N), 870-734 (ArC-H), 593 (C-Cl) cm
-1;
 1H NMR (400 MHz, CDCl3) ʴ 7.91 (1H, 
dd, J = 8.8, 0.8, CHCHCNO2), 7.85 (1H, ddd, J = 8.8, 2.0, 0.8, CHCHCNO2), 7.68 
(1H, dd, J = 1.8, 0.8, CCHCNO2), 7.26 (2H, d, J = 8.1, 2 x CHCCl), 7.13 (1H, m, 
CHCHCCl),  6.45  (1H,  q,  J  =  7.1,  CHCH3),  4.07  &  3.98  (2H,  ABq,  J  =  13.5, 
CH2CNN), 2.55 (4H, m, 2 x CH2N(CH2)CH2C), 2.15 (3H, d, J = 7.1, CH3), 1.73 (4H, 
m, 2 x CH2CH2N(CH2)CH2C); 
13C NMR (100 MHz, CDCl3) ʴ 146.1 (ArC), 142.5 
(ArC),  138.8  (ArC),  135.2  (ArC),  134.6  (2  x  CCl),  129.9  (2  x  CHCCl),  129.7 
(CHCHCCl),  127.4  (ArC),  121.9  (CHCHCNO2),  115.1  (CHCHCNO2),  105.9 
(CCHCNO2), 56.2 (CHCH3), 54.1 (2 x CH2N(CH2)CH2C), 52.0 (CH2CNN), 23.7 (2 
x  CH2CH2N(CH2)CH2C),  17.0  (CH3);  m/z  (ESI+)  419  (100%,  [
35,35M+H]
+),  421 
(95%,  [
35,37M+H]
+),  423  (19%,  [
37,37M+H]
+);  HRMS  C20H21
35Cl2N4O2  ([M+H]
+) 
calcd. 419.1042, found. 419.1046.  118 
Racemic  mixture  of  (S)-1-[1-(2,6-dichlorophenyl)ethyl]-3-(pyrrolidine-1-
ylmethyl)-1H-indazol-6-amine  &  (R)-1-[1-(2,6-dichlorophenyl)ethyl]-3-
(pyrrolidine-1-ylmethyl)-1H-indazol-6-amine (61) 
 
To a solution of 59 (138 mg, 0.33 mmol) in MeOH (30 mL) was added FeCl3.6H2O 
(21.0  mg,  0.077  mmol)  and  activated  charcoal  (168  mg),  followed  by 
N,N-dimethylhydrazine (0.50 mL, 6.58 mmol). The reaction mixture was heated to 
reflux for 2 h then allowed to cool to ambient temperature before filtering through 
celite, washing through with a cold mixture of CH2Cl2/MeOH (60 mL, 4:1). The 
filtrate was concentrated in vacuo to leave a brown solid residue. Purification by 
flash  column  chromatography  (0-5%  MeOH/CH2Cl2)  gave  the  desired  product 
(107 mg, 84%); as a light brown solid; mp 196-199 °C (decomp.); Rf 0.25 (10% 
MeOH in CH2Cl2); IR νmax (neat) 3310-3202 (N-H), 2953-2789 (C-H), 1619 (C=N), 
1560-1514 (ArC=C), 1434 (C-H), 1086 (C-N), 812-778 (ArC-H), 608 (C-Cl) cm
-1;
 
1H NMR (600 MHz, CDCl3) ʴ 7.62 (1H, d, J = 8.6, CHCHCNH2), 7.30 (2H, d, 
J = 8.1, 2 x CHCCl), 7.16 (1H, t, J = 8.1, CHCHCCl), 6.54 (1H, dd, J = 8.6, 1.8, 
CHCHCNH2), 6.29 (1H, q, J = 7.1, CHCH3), 5.98 (1H, d, J = 1.8, CCHCNH), 4.24 
(1H, d, J = 13.6, C(H)HCCC), 4.14 (1H, d, J = 13.6, C(H)HCCC), 3.73 (2H, s, NH2), 
2.90  (4H,  bs,  2  x  CH2NCH2C),  2.14  (3H,  d  J  =  7.1,  CH3),  1.87  (4H,  bs,  2  x 
CH2CH2N); 
13C NMR (150 MHz, CDCl3) ʴ 179.1 (ArC), 145.4 (ArC), 141.8 (ArC), 
136.0  (ArC),  134.6  (2  x  CCl),  129.7  (2  x  CHCCl),  129.0  (CHCHCCl),  121.4 
(CHCHCNH2),  118.3  (ArC),  112.6  (CHCHCNH2),  92.2  (CCHCNH2),  55.4 
(CHCH3), 53.0 (2 x CH2NCH2), 50.4 (CCH2N), 23.7 (2 x CH2CH2N), 17.0 (CH3); 
m/z  (ESI+)  389  (100%,  [
35,35M+H]
+),  391  (91%,  [
35,37M+H]
+),  393  (15%, 
[
37,37M+H]
+); HRMS C20H23
35Cl2N4 ([M+H]
+) calcd. 389.1300, found. 389.1302. 
 119 
Racemic  mixture  of  (S)-4-amino-N-benzyl-2-[(S)-2-(3-{1-[(R)-1-(2,6-
dichlorophenyl)ethyl]-3-[pyrrolidin-1-ylmethyl]-1H-indazol-6-yl}ureido)-3-(3,4-
difluorophenyl)propanamido]butanamide dihydrochloride salt & (S)-4-amino-
N-benzyl-2-[(S)-2-(3-{1-[(S)-1-(2,6-dichlorophenyl)ethyl]-3-[pyrrolidin-1-
ylmethyl]-1H-indazol-6-yl}ureido)-3-(3,4-
difluorophenyl)propanamido]butanamide dihydrochloride salt (52) 
 
To a sonicated (5 min), then stirred, solution of 61 (50.0 mg, 129 μmol) in dry THF 
(5 mL), under dry conditions and cooled to 0 °C, was added together triphosgene 
(13.0 mg, 45.0 μmol) and DMAP (31.0 mg, 257 μmol). After 5 min the reaction 
mixture  was  allowed  to  reach  ambient  temperature  and  stirred  for  30  min  under 
nitrogen. The reaction mixture was cooled again to 0 °C for 5 min and a solution 
of 33 (32.0 mg, 64.3 μmol) in dry THF (3 mL) was added. The reaction mixture was 
left to reach ambient temperature and stirred for 2 h under nitrogen then concentrated 
in vacuo. The residue was suspended in a solution of HCl (4 N) in dioxane (2 mL) 
and stirred for 2.5 h before concentrating in vacuo and purifying by preparative RP-
HPLC (retention time: 8.92 min). The isolated product was taken up in a 0.1 M HCl 
(aq) solution (2 mL) and lyophilised to give the title compound (22.5 mg, 33%); as a 
white solid; mp 172-175 °C (decomp.); Rf 0.06 (10% MeOH/CH2Cl2); IR νmax (neat) 
3258 (N-H), 3084 (N-H), 2920-2850 (C-H), 1649 (C=O), 1547 (C=O), 1512 (C=O), 
1434 (C-H), 1158 (C-N), 1116 (C-F), 1080 (C-N), 770 (ArC-H), 576 (C-Cl) cm
-1;
 1H 
NMR  (400  MHz,  DMSO-d6)  ʴ  10.88  (1H,  bs,  N
+HCH2CNN),  9.10  (1H,  s, 
NHCONHCH), 8.64-8.57 (1H, m, NHCH2Ph & 1H, m, CHNHCOCH), 8.05 (3H, bs, 
N
+H3), 7.87 (1H, d, J = 8.8, CHCHCNH), 7.47 (2H, m, 2 x CHCCl), 7.40-7.14 (9H, 
ArH), 7.10 (1H, ddd, J = 8.8, 4.3, 1.5, CHCHCNH), 7.05-7.00 (1H, m, ArH), 6.54 
(1H, t, J = 7.8-8.1, CHNHCONH), 6.35 (1H, quintet, J = 7.1-7.6, CHCH3), 4.78-4.64 
(2H, m, CH2CNN), 4.56 (1H, m, CHNHCONH), 4.42 (1H, apparent dt, J = 6.0, 7.9, 
CHNHCOCH), 4.32 (2H, m, CH2NHCO), 3.47 (2H, m, 2 x C(H)HN
+H(CH2)CH2C), 120 
3.21  (2H,  m,  2  x  C(H)HN
+H(CH2)CH2C),  3.03  (1H,  dt,  J  =  13.9,  4.0, 
C(H)HCHNHCONH),  2.84-2.78  (1H,  m,  C(H)HCHNHCONH  &  2H,  m, 
CH2CH2CHNH),  2.07-1.89  (3H,  dd,  J  =  7.1,  2.0,  CH3CH  &  2H,  m, 
CH2CHNHCOCH & 4H, m, 2 x CH2CH2N
+H(CH2)CH2C); 
13C NMR (150 MHz, 
DMSO-d6) ʴ 171.5 (NHCOCH), 171.3 (ArC), 170.5 (NHCOCH), 154.5 (NHCONH), 
154.4 (ArC), 148.2 (ArC), 147.5 (ArC), 140.5 (ArC), 139.4 (ArC), 139.1 (ArC), 
134.8  (ArC),  133.7  (2  x  CCl),  130.4  (CHCHCCl),  130.1  (2  x  CHCCl),  128.34 
(ArCH), 128.3 (ArCH), 127.2 (ArCH), 127.1 (ArCH), 126.9 (ArCH), 126.3 (ArCH), 
120.8 (CHCHCNH), 118.8 (ArC), 118.3 (d, J = 16.5, ArCH), 116.9 (d, J = 16.5, 
ArCH), 114.4 (CHCHCNH), 95.7 (CCHCNH), 55.3 (CHCH3), 53.5 (CHNHCONH), 
52.8  (2  x  CH2N
+H(CH2)CH2C),  50.5  (CHNHCOCH),  48.1  (CH2CNN),  42.1 
(CH2NHCO),  37.8  (CH2CHNHCONH),  36.1  (CH2CH2CHNH),  30.1 
(CH2CHNHCOCH), 22.8 (2 x CH2CH2N(CH2)CH2C), 17.1 (CH3CH); m/z (ESI+) 
805 (100%, [
35,35M+H]
+), 807 (88%, [
35,37M+H]
+), 809 (22%, [
37,37M+H]
+); HRMS 
C41H45
35Cl2F2N8O3 ([M+H]
+) calcd. 805.2960, found. 805.2903. 
3-{[(3R)-3-Fluoropyrrolidin-1-yl]methyl}-6-nitro-1H-indazole (63a) 
 
6-Nitroindole (500 mg, 3.08 mmol) was added to a stirred solution of sodium nitrite 
(2.13 g, 30.8 mmol) in H2O (25 mL) and DMF (2 mL) at 18 °C.  6 M HCl (4.6 mL, 
27.8 mmol) was added dropwise over 10 min and stirring continued for 3 h before 
diluting with EtOAc (30 mL) and extracting.  Aqueous layer extracted further with 
EtOAc (2 x 15 mL).  Organic extracts combined and washed with H2O (15 mL) and 
brine (15 mL), then dried (MgSO4) and concentrated in vacuo. Residual dark brown 
solid was dissolved in CH2Cl2/DMF/AcOH (54/5.4/0.6 mL), to which was added 
3-R-(-)-fluoropyrrolidine.HCl (968 mg, 7.71 mmol) and the reaction mixture was 
stirred at 18 °C for 20 min.  Sodium triacetoxyborohydride (1.63 g, 7.70 mmol) was 
added portionwise over 10 min and stirring continued for 3 h before diluting with 
EtOAc (100 mL) and quenching with sat. aqueous NaHCO3 (60 mL).  Aqueous layer 
separated and extracted further with EtOAc (2 x 20 mL).  Organic extracts combined 121 
and washed with sat. NaHCO3 (aq) (2 x 25 mL), H2O (2 x 25 mL) and brine (2 x 
25 mL)  then  dried  (MgSO4)  and  concentrated  in  vacuo  to  leave  dark  brown  oil.  
Purified  by  flash  column  chromatography  (0.75%  MeOH/CH2Cl2)  gave  target 
compound (505 mg, 62%); as a dark brown oil; Rf 0.19 (5% MeOH/CH2Cl2); [ʱ]D
28 
+5.7 (c 0.35, MeOH); IR νmax (thin film from CHCl3) 3290 (N-H), 3059-2921 (C-H), 
1664  (C=N),  1548  (NO2),  1345  (NO2),  1238  (C-N),  1114  (C-F),  1086  (C-N), 
762-697  (ArC-H)  cm
-1; 
1H  NMR  (600  MHz,  CDCl3)  ʴ  8.41  (1H,  d,  J  =  1.3, 
CCHCNO2),  8.04-8.00  (1H,  d,  J  =  8.9,  CHCHCNO2  &  1H,  dd,  J  =  8.9,  1.5, 
CHCHCNO2), 5.20 (1H, m, CHF), 4.15 & 4.12 (2H, ABq, J = 13.7, CH2CNN), 
3.02-2.94 (1H, m, NC(H)HCHF & 1H, m, NC(H)HCH2CHF), 2.90-2.82 (1H, ddd, 
J = 29.9, 11.5, 5.1, NC(H)HCHF), 2.59 (1H, dt, J = 5.8, 8.3, NC(H)HCH2CHF), 
2.25-2.04 (2H, m, NCH2CH2CHF); 
13C NMR (150 MHz, CDCl3) ʴ 147.1 (ArC), 
144.9 (ArC), 140.0 (ArC), 125.7 (ArC), 122.0 (CHCHCNO2), 115.7 (CHCHCNO2), 
106.8 (CCHCNO2), 94.2-93.1 (d, J = 176.1, CHF), 60.7 (d, J = 23.1, NCH2CHF), 
52.5  (NCH2CH2CHF),  51.9  (CH2CNN),  33.0  (d,  J  =  22.0,  NCH2CH2CHF);  m/z 
(ESI+)  265  (30%,  [M+H]
+),  217  (100%,  [M+H+MeCN-C4H7FN]
+;  HRMS 
C12H14FN4O2 ([M+H]
+) calcd. 265.1101, found 265.1091. 
3-{[(3S)-3-Fluoropyrrolidin-1-yl]methyl}-6-nitro-1H-indazole (63b) 
 
6-Nitroindole (500 mg, 3.08 mmol) was added to a stirred solution of sodium nitrite 
(2.13 g, 30.8 mmol) in H2O (25 mL) and DMF (2 mL) at 18 °C.  6 M HCl (4.6 mL, 
27.8 mmol) was added dropwise over 10 min and stirring continued for 3 h before 
diluting with EtOAc (30 mL) and extracting.  Aqueous layer extracted further with 
EtOAc (2 x 15 mL).  Organic extracts combined and washed with H2O (15 mL) and 
brine (15 mL), then dried (MgSO4) and concentrated in vacuo. Residual dark brown 
solid was dissolved in CH2Cl2/DMF/AcOH (54/5.4/0.6 mL), to which was added 
3-S-(+)-fluoropyrrolidine.HCl (968 mg, 7.71 mmol) and the reaction mixture was 
stirred at 18 °C for 20 min.  Sodium triacetoxyborohydride (1.63 g, 7.70 mmol) was 
added portionwise over 10 min and stirring continued for 3 h before diluting with 122 
EtOAc (100 mL) and quenching with sat. aqueous NaHCO3 (60 mL).  Aqueous layer 
separated and extracted further with EtOAc (2 x 20 mL).  Organic extracts combined 
and washed with sat. NaHCO3 (aq) (2 x 25 mL), H2O (2 x 25 mL) and brine (2 x 
25 mL)  then  dried  (MgSO4)  and  concentrated  in  vacuo  to  leave  dark  brown  oil.  
Purified  by  flash  column  chromatography  (0.75%  MeOH/CH2Cl2)  gave  target 
compound  (483  mg,  59%);  as  a  dark  brown  oil;  Rf  0.19  (5%  MeOH/CH2Cl2); 
[ʱ]D
24 -12.5 (c 0.64, MeOH); IR νmax (thin film from CHCl3) 3343 (N-H), 2947-2848 
(C-H), 1710 (C=N), 1522 (NO2), 1345 (NO2), 1296-1173 (C-N), 1111 (C-F), 1079 
(C-N), 794-696 (ArC-H) cm
-1; 
1H NMR (600 MHz, CDCl3) ʴ 8.42 (1H, d, J = 1.5, 
CCHCNO2),  8.05-8.01  (1H,  d,  J  =  8.9,  CHCHCNO2  &  1H,  dd,  J  =  8.9,  1.7, 
CHCHCNO2), 5.20 (1H, m, CHF), 4.15 & 4.12 (2H, ABq, J = 13.8, CH2CNN), 
3.01-2.93 (1H, m, NC(H)HCHF & 1H, m, NC(H)HCH2CHF), 2.89-2.82 (1H, ddd, 
J = 30.1, 11.7, 5.1, NC(H)HCHF), 2.59 (1H, dt, J = 5.8, 8.5, NC(H)HCH2CHF), 
2.25-2.04 (2H, m, NCH2CH2CHF); 
13C NMR (150 MHz, CDCl3) ʴ 147.1 (ArC), 
145.0 (ArC), 140.0 (ArC), 125.7 (ArC), 122.0 (CHCHCNO2), 115.7 (CHCHCNO2), 
106.7 (CCHCNO2), 94.2-93.1 (d, J = 176.1, CHF), 60.7 (d, J = 23.1, NCH2CHF), 
52.5  (NCH2CH2CHF),  51.9  (CH2CNN),  33.0  (d,  J  =  22.0,  NCH2CH2CHF);  m/z 
(ESI+)  265  (32%,  [M+H]
+),  217  (100%,  [M+H+MeCN-C4H7FN]
+);  HRMS 
C12H13FN4O2 ([M+H]
+) calcd. 265.1101, found 265.1111. 
1-(2,6-Dichlorobenzyl)-3-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-6-nitro-1H-
indazole (64a) 
 
To a stirred solution of 63a (505 mg, 1.91 mmol) in dry THF (30 mL) under argon 
was  added  2,6-dichlorobenzyl  bromide  (454 mg,  1.89  mmol)  followed  by 
portionwise addition over 10 min of caesium carbonate (616 mg, 1.89 mmol). The 
reaction mixture was stirred at 16 °C for 24 h then diluted with H2O (10 mL) and 
extracted with EtOAc (2 x 20 mL). Organic extracts were washed with H2O (2 x 10 123 
mL) then brine (10 mL), dried (MgSO4) and concentrated in vacuo. The residue was 
purified  by  flash  column  chromatography  (0-0.25%  MeOH/CH2Cl2)  gave  target 
compound (630 mg, 79%); as a pale  yellow solid; mp 134-136 °C; Rf 0.63 (5% 
MeOH/CH2Cl2); IR νmax (neat) 2957-2812 (C-H), 1578 (C=N), 1515 (NO2), 1427 (C-
H), 1347 (NO2), 1202 (C-N), 1139 (C-F), 1085 (C-N), 821-627 (ArC-H), 500 (C-Cl) 
cm
-1;
 1H NMR (600 MHz, CDCl3) ʴ 8.34 (1H, d, J = 1.9, CCHCNO2), 7.98 (1H, d, J 
= 8.7, CHCHCNO2), 7.96 (1H, dd, J = 8.7, 1.9, CHCHCNO2), 7.39 (1H, d, J = 7.9, 
CHCCl), 7.27 (1H, t, J = 8.3, CHCHCCl), 5.85 (2H, s, CH2NN), 5.20-5.09 (1H, m, 
CHF), 4.04 (2H, d, J = 1.1, NCH2CN), 2.93-2.84 (1H, m, NC(H)HCHF & 1H, m, 
NC(H)HCH2), 2.83-2.75 (1H, ddd, J = 29.7, 11.7, 4.9, NC(H)HCH2), 2.52 (1H, dt, 
J = 5.7, 8.7, NC(H)HCHF), 2.19-1.98 (2H, m, CH2CH2CHF); 
13C NMR (150 MHz; 
CDCl3) ʴ 146.7 (ArC), 143.5 (ArC), 139.5 (ArC), 137.0 (2 x CCl), 130.9 (ArC), 
130.6 (CHCHCCl), 129.0  (2 x CHCCl), 126.4  (ArC), 122.1  (CHCHCNO2), 115.2  
(CHCHCNO2), 106.3  (CCHCNO2), 94.2-93.1  (d, JC-F = 175.8, CHF), 60.5-60.4  (d, 
JC-F = 23.3, NCH2CHF), 52.3  (NCH2CH2CHF), 51.6  (NCH2CN), 48.8  (CH2NN), 
33.1-32.9  (d, JC-F = 22.1, CH2CH2CHF); m/z (CI+) 423 (100%, [
35,35M+H]
+), 425 
(62%,  [
35,37M+H]
+),  427  (10%,  [
37,37M+H]
+);  HRMS  C19H18
35Cl2FN4O2  ([M+H]
+) 
calcd. 423.0791, found. 423.0793. 
1-(2,6-Dichlorobenzyl)-3-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-6-nitro-1H-
indazole (64b) 
 
To a stirred solution of 63b (483 mg, 1.83 mmol) in dry THF (30 mL) under argon 
was  added  2,6-dichlorobenzyl  bromide  (454 mg,  1.89  mmol)  followed  by 
portionwise addition over 10 min of caesium carbonate (616 mg, 1.89 mmol). The 
reaction mixture was stirred at 16 °C for 24 h then diluted with H2O (10 mL) and 
extracted with EtOAc (2 x 20 mL). Organic extracts were washed with H2O (2 x 10 
mL) then brine (10 mL), dried (MgSO4) and concentrated in vacuo. The residue was 124 
purified  by  flash  column  chromatography  (0-0.25%  MeOH/CH2Cl2)  gave  target 
compound  (536 mg,  69%);  as  a  yellow  solid;  mp  134-136  °C;  Rf  0.63  (5% 
MeOH/CH2Cl2); IR νmax (neat) 2955-2811 (C-H), 1562 (C=N), 1515 (NO2), 1427 (C-
H), 1346 (NO2), 1202 (C-N), 1139 (C-F), 1085 (C-N), 802-627 (ArC-H), 500 (C-Cl) 
cm
-1; 
1H NMR (600 MHz, CDCl3) ʴ 8.34 (1H, dd, J = 1.7, 0.8, NCCHC), 7.99 (1H, 
dd, J = 8.7, 0.8, NCCHCHC), 7.97 (1H, dd, J = 8.7, 1.7, NCCHCHC), 7.39 (2H, d, J 
= 8.1, 2 x CHCCl), 7.27 (1H, dd, J = 8.3, 7.7, CHCHCCl), 5.85 (2H, s, CH2NN), 
5.20-5.09  (1H,  m,  CHF),  4.04  (2H,  d,  J  =  1.5,  NCH2CN),  2.93-2.84  (1H,  m, 
NC(H)HCHF & 1H, m, C(H)HCH2CHF), 2.83-2.75 (1H, ddd, J = 29.7, 11.7, 5.1, 
NC(H)HCHF),  2.52  (1H,  dt,  J  =  5.7,  8.7,  C(H)HCH2CHF),  2.19-1.99  (2H,  m, 
CH2CH2CHF); 
13C NMR  (150 MHz, CDCl3)  ʴ  146.7 (ArC), 143.5 (ArC), 139.5 
(ArC), 137.0 (2 x CCl), 130.9 (ArC), 130.6 (CHCHCCl), 129.0 (2 x CHCCl), 126.4 
(ArC), 122.1 (CHCHCNO2), 115.2 (CHCHCNO2), 106.3 (CCHCNO2), 94.2-93.1 (d, 
JC-F = 175.8, CHF), 60.5 (d, JC-F = 23.3, NCH2CHF), 52.3 (NCH2CH2CHF), 51.7 
(NCH2CN),  48.8  (CH2NN),  33.0  (d,  JC-F  =  22.1,  CH2CH2CHF);  m/z  (ESI+)  423 
(100%,  [
35,35M+H]
+),  425  (75%,  [
35,37M+H]
+),  427  (15%,  [
37,37M+H]
+);  HRMS 
C19H18
35Cl2FN4O2 ([M+H]
+) calcd. 423.0791, found 423.0810. 
 (R)-1-(2,6-Dichlorobenzyl)-3-[(3-fluoropyrrolidin-1-yl)methyl]-1H-indazol-6-
amine (65a) 
 
To a solution of 64a (610 mg, 1.44 mmol) in MeOH (40 mL) was added FeCl3.6H2O 
(78.0  mg,  0.290  mmol)  and  activated  charcoal  (784  mg),  followed  by  N,N-
dimethylhydrazine (2.19 mL, 28.8 mmol). The reaction mixture was heated to reflux 
for 2 h then allowed to cool to ambient temperature before filtering through celite, 
washing through with a cold mixture of CH2Cl2/MeOH (90 mL, 4:1). The filtrate was 
concentrated in vacuo to leave a brown solid residue, which was purified by flash 
column chromatography (0-1% MeOH/CH2Cl2) to give the desired product (408 mg, 125 
72%); as a pale yellow solid; mp 158-160 °C; Rf 0.09 (5% MeOH/CH2Cl2); IR νmax 
(neat) 3438-3209 (N-H), 2956-2786 (C-H), 1625 (C=N), 1564-1496 (ArC=C), 1435 
(C-H), 1292-1088 (C-N), 803-688 (ArC-H), 594 (C-Cl) cm
-1; 
1H NMR (600 MHz, 
CDCl3) ʴ 7.57 (1H, d, J = 8.7, CHCHCNH2), 7.34 (2H, d, J = 8.3, 2 x CHCCl), 7.21 
(1H, t, J = 7.9, CHCHCCl), 6.52 (1H, dd, J = 8.7, 1.9, CHCHCNH2), 6.45 (1H, d, J = 
1.9,  CCHCNH2),  5.64  (2H,  s,  CH2NN),  5.18-5.07  (1H,  m,  CHF),  3.95  (2H,  s, 
NCH2CN),  3.80  (2H,  bs,  NH2),  2.91-2.79  (2H,  m,  NCH2CHF  &  1H,  m, 
NC(H)HCH2), 2.54  (1H, m,  NC(H)HCH2), 2.17-1.95  (2H, m,  CH2CH2CHF); 
13C 
NMR (150 MHz, CDCl3) ʴ 145.7 (ArC), 142.4 (ArC), 142.3 (ArC), 137.0 (2 x CCl), 
131.9 (ArC), 129.9 (CHCHCCl), 128.8 (2 x CHCCl), 121.9 (CHCHCNH2), 117.6 
(ArC), 112.1 (CHCHCNH2), 93.3-94.4 (d, JC-F = 175.2, CHF), 92.5 (CCHCNH2), 
60.3  (d,  JC-F  =  23.3,  NCH2CHF),  52.0  (NCH2CH2CHF),  51.4  (NCH2CN),  48.4 
(CH2NN), 33.0 (d, JC-F = 22.1, CH2CH2CHF); m/z (ESI+) 415 (20%, [
35,35M+Na]
+), 
304 (100%, [
35,35M-C4H7FN]
+) , 306 (70%, [
35,37M-C4H7FN]
+) , 308 (13%, [
37,37M-
C4H7FN]
+); HRMS C19H19
35Cl2FN4Na ([M+Na]
+) calcd. 415.0869, found 415.0851. 
(S)-1-(2,6-Dichlorobenzyl)-3-[(3-fluoropyrrolidin-1-yl)methyl]-1H-indazol-6-
amine (65b) 
 
To a solution of 64b (520 mg, 1.23 mmol) in MeOH (40 mL) was added FeCl3.6H2O 
(68.0  mg,  0.250  mmol)  and  activated  charcoal  (669  mg),  followed  by  N,N-
dimethylhydrazine (1.87 mL, 24.6 mmol). The reaction mixture was heated to reflux 
for 2 h then allowed to cool to ambient temperature before filtering through celite, 
washing through with a cold mixture of CH2Cl2/MeOH (90 mL, 4:1). The filtrate was 
concentrated in vacuo to leave a brown solid residue, which was purified by flash 
column chromatography (0-1% MeOH/CH2Cl2) to give the desired product (375 mg, 
78%); as a pale yellow solid; mp 158-160 °C; Rf 0.09 (5% MeOH/CH2Cl2); IR νmax 
(neat) 3438-3209 (N-H), 2956-2786 (C-H), 1625 (C=N), 1564-1496 (ArC=C), 1435 126 
(C-H), 1292-1087 (C-N), 803-689 (ArC-H), 594 (C-Cl) cm
-1; 
1H NMR (600 MHz, 
CDCl3) ʴ 7.57 (1H, d, J = 8.7, CHCHCNH2), 7.34 (2H, d, J = 7.9, 2 x CHCCl), 7.21 
(1H, t, J = 8.1, CHCHCCl), 6.52 (1H, dd, J = 8.5, 1.7, CHCHCNH2), 6.45 (1H, d, J = 
1.5,  CCHCNH2),  5.64  (2H,  s,  CH2NN),  5.18-5.07  (1H,  m,  CHF),  3.95  (2H,  s, 
NCH2CN),  3.81  (2H,  bs,  NH2),  2.92-2.80  (2H,  m,  NCH2CHF  &  1H,  m, 
NC(H)HCH2), 2.56 (1H, m,  NC(H)HCH2), 2.16-1.95  (2H, m,  CH2CH2CHF); 
13C 
NMR (150 MHz, CDCl3) ʴ 145.7 (ArC), 142.4 (ArC), 142.3 (ArC), 137.0 (2 x CCl), 
131.9 (ArC), 129.9 (CHCHCCl), 128.8 (2 x CHCCl), 121.9 (CHCHCNH2), 117.6 
(ArC), 112.1 (CHCHCNH2), 94.5-93.3 (d, JC-F = 175.2, CHF), 92.5 (CCHCNH2), 
60.3  (d,  JC-F  =  22.7,  NCH2CHF),  52.0  (NCH2CH2CHF),  51.4  (NCH2CN),  48.4 
(CH2NN), 33.0 (d, JC-F = 21.5, CH2CH2CHF); m/z (ESI+) 415 (25%, [
35,35M+Na]
+), 
304 (100%, [
35,35M-C4H7FN]
+) , 306 (87%, [
35,37M-C4H7FN]
+) , 308 (8%, [
37,37M-
C4H7FN]
+); HRMS C19H19
35Cl2FN4Na ([M+Na]
+) calcd. 415.0869, found 415.0865. 
(S)-4-Amino-N-benzyl-2-{[S]-2-[3-(1-{2,6-dichlorobenzyl}-3-{[(R)-3-
fluoropyrrolidin-1-yl]methyl}-1H-indazol-6-yl)ureido]-3-[3,4-
difluorophenyl]propanamido}butanamide dihydrochloride salt (62a) 
 
To a sonicated (5 min), then stirred solution of 65a (50.0 mg, 0.127 mmol) in dry 
THF (5 mL), under dry conditions and cooled to 0 °C, was added triphosgene (13.0 
mg, 44.5 μmol) and DMAP (31.0 mg, 254 μmol). After 5 min the reaction mixture 
was allowed to reach ambient temperature and stirred for 30 min under argon. The 
reaction mixture was cooled again to 0 °C for 5 min and a solution of 33 (31.0 mg, 
63.6 μmol) in dry THF (1 mL) was added. The reaction mixture was left to reach 
ambient temperature and stirred for 2 h under argon then concentrated in vacuo and 
the residue purified by flash column chromatography (0-2% MeOH/CH2Cl2) to give 
the Boc-protected intermediate (42.0 mg), Rf 0.31 (10% MeOH/CH2Cl2). The off-
white solid was suspended in a solution of HCl (4 N) in dioxane and stirred for 2.5 h 127 
before  concentrating  in  vacuo  and  purifying  by  preparative  RP-HPLC  (retention 
time: 8.68 min). The isolated product was taken up in a 0.1 M HCl (aq) solution (2 
mL) and lyophilised to give the title compound (6.70 mg, 17%); as a white solid; mp 
169-172 °C; Rf 0.06 (10% MeOH/CH2Cl2); IR νmax (neat) 3273 (N-H), 3060 (N-H), 
2926 (C-H), 1633 (C=O), 1585 (C=N), 1536 (C=O), 1512 (C=O), 1434 (C-H), 1209 
(C-N), 1162 (C-F), 1027 (C-N), 770-696 (ArC-H), 608 (C-Cl) cm
-1;
 1H NMR (600 
MHz,  DMSO-d6)  ʴ  10.94-10.75  (1H,  m,  CH2N
+H(C4H7F)),  9.20  (1H,  s, 
NHCONHCH),  8.63  (1H,  d,  J  =  7.9,  NHCHCH2CH2),  8.58  (1H,  t,  J  =  5.9, 
NHCH2Ph),  8.00 (1H, s, CCHCNH), 7.84 (3H, bs,  N
+H3), 7.75  (1H, d, J =  8.7, 
CCHCHCNH), 7.54 (2H, d, J = 8.1, 2 x CHCCl), 7.44 (1H, m, CHCHCCl), 7.32-
7.22 (7H, m, ArH), 7.06 (1H, m, ArH) 7.03 (1H, dd, J = 8.9, 1.5, CCHCHCNH), 
6.69 (1H, d, J = 7.7, NHCONHC), 5.62 (2H, s, CH2NN), 5.39 (1H, m, CHF), 4.67 
(2H, bs, CH2N
+H(C4H7F)), 4.58 (1H, dt, J = 4.9, 8.1, CHNHCONH), 4.42 (1H, dt, J 
= 6.2, 7.7, CHCH2CH2), 4.33 (2H, m, NHCH2Ph), 3.80-3.25 (4H distorted by H2O 
peak,  m,  2  x  CH2N
+H(CH2)CH2C),  3.06  (1H,  dd,  J  =  13.9,  4.5, 
C(H)HCHNHCONH),  2.89-2.77  (1H,  m,  C(H)HCHNHCONH  &  2H,  m, 
CH2CH2CHNH),  2.40-2.24  (1H  distorted  by  solvent  peak,  m,    CHFC(H)HCH2), 
2.18-2.05 (1H, m, CHFC(H)HCH2), 2.05-1.86 (2H, m, CH2CH2CHNH); 
13C NMR 
(600 MHz, DMSO-d6) ʴ 171.5 (NHCOC), 170.4 (NHCOC), 158.5-157.9  (q, J = 
31.9, ArC), 154.8 (NHCONH), 149.9-149.1 (dd, J = 105.6, 12.1, CF), 148.3-147.5  
(dd, J = 105.6, 12.1, CF), 141.4 (ArC), 139.7 (ArC), 139.1 (ArC), 136.1 (2 x CCl), 
135.3 (ArC), 131.4 (ArC), 131.0 (CHCHCCl), 128.8 (2 x CHCCl), 128.3 (ArC), 
127.1 (ArC), 126.9 (ArC), 126.2 (ArC), 120.5 (CCHCHCNH), 118.3 (d, J = 17.6, 
ArC),  117.8  (ArC),  117.0  (d,  J = 16.5,  ArC),  114.6  (CCHCHCNH),  96.3 
(CCHCNH), 92.3-91.2 (d, JC-F = 175.2, CHF), 58.9 (NH
+CH2CHF), 53.8 (CHCH2C), 
51.5  (N
+HCH2CH2CHF),  50.5  (CHCH2CH2),  48.5  (CH2N
+H(C4H7F)),  47.3 
(CH2NN);  42.1  (CH2Ph),  37.5  (CHCH2C),  36.3  (CH2N
+H3),  30.6  (CHFCH2CH2), 
30.1  (CHCH2CH2N
+H3);  m/z  (ESI+)  809  (100%,  [
35,35M+H]
+),  811  (55%, 
[
35,37M+H]
+),  813  (5%,  [
37,37M+H]
+);  HRMS  C40H42
35Cl2F3N8O3  ([M+H]
+)  calcd. 
809.2709, found. 809.2719. 
 128 
(S)-4-Amino-N-benzyl-2-{[S]-2-[3-(1-{2,6-dichlorobenzyl}-3-{[(S)-3-
fluoropyrrolidin-1-yl]methyl}-1H-indazol-6-yl)ureido]-3-[3,4-
difluorophenyl]propanamido}butanamide dihydrochloride salt (62b)   
 
To a sonicated (5 min), then stirred, solution of 65b (60.0 mg, 0.153 mmol) in dry 
THF  (8  mL),  under  dry  conditions  and  cooled  to  0  °C,  was  added  triphosgene 
(16.0 mg, 54.0 μmol) and DMAP (37.0 mg, 306 μmol) under argon. After 5 min the 
reaction mixture was allowed to reach ambient temperature and stirred for 30 min. 
The reaction mixture was cooled again to 0 °C for 5 min and a solution of 33 (38.0 
mg, 77.0 μmol) in dry THF (4 mL) was added. The reaction mixture was left to reach 
ambient temperature and stirred for 2 h under argon then concentrated in vacuo and 
the residue purified by flash column chromatography (0-3% MeOH/CH2Cl2) to give 
the Boc-protected intermediate (45.0 mg), Rf 0.31 (10% MeOH/CH2Cl2). The off-
white solid was suspended in a solution of HCl (4 N) in dioxane and stirred for 2.5 h 
before  concentrating  in  vacuo  and  purifying  by  preparative  RP-HPLC  (retention 
time: 8.84 min). The isolated product was taken up in a 0.1 M HCl (aq) solution (2 
mL) and lyophilised to give the title compound (20.0 mg, 46%) as a white solid; mp 
154-156 °C; Rf 0.06 (10% MeOH/CH2Cl2); IR νmax (neat) 3267 (N-H), 3061 (N-H), 
2943 (C-H), 1633 (C=O), 1585 (C=N), 1537 (C=O), 1512 (C=O), 1434 (C-H), 1209 
(C-N), 1161 (C-F), 1025 (C-N), 769-695 (ArC-H), 607 (C-Cl) cm
-1;
 1H NMR (600 
MHz,  DMSO-d6)  ʴ  10.86-10.60  (1H,  m,  CH2N
+H(C4H7F)),  9.15  (1H,  s, 
NHCONHCH),  8.63  (1H,  d,  J = 7.9,  NHCHCH2CH2),  8.58  (1H,  t,  J  =  6.0,  
NHCH2Ph),  8.00 (1H, s,  CCHCNH), 7.78 (3H, bs, N
+H3),  7.75  (1H, d, J = 8.7, 
CCHCHCNH), 7.55 (2H, d, J = 8.3, 2 x CHCCl), 7.44 (1H, t, J = 8.7, CHCHCCl), 
7.32-7.22  (7H,  m,  ArH),  7.05  (1H,  m,  ArH),  7.03  (1H,  dd,  J  =  9.0,  1.5, 
CCHCHCNH), 6.62 (1H, d, J = 7.9, NHCONHC), 5.62 (2H, s, CH2NN), 5.39 (1H, 
dd, J = 53.8, 25.6, CHF), 4.70 (2H, d, J = 25.2, CH2N
+H(C4H7F)), 4.60 (1H, dt, J = 
4.9, 8.3, CHCH2C), 4.42 (1H, apparent dt, J = 6.4, 7.9, CHCH2CH2), 4.35 (2H, ddd, 129 
J  =  21.1,  15.4,  6.0,  NHCH2Ph),  3.80-3.25  (4H  distorted  by  H2O  peak,  m,  2  x 
CCH2N
+HCH2), 3.06 (1H, dd, J = 13.9, 4.5, CHC(H)HC), 2.85 (1H, dd, J = 13.9, 
8.3, CHC(H)HC), 2.83-2.74 (2H, m, CH2N
+H3), 2.37-2.23 (1H distorted by solvent 
peak, m,  CHFC(H)HCH2), 2.13-2.07 (1H, m, CHFC(H)HCH2), 2.05-1.86 (2H, m, 
CHCH2CH2N
+H3); 
13C  NMR  (150  MHz,  DMSO-d6)  ʴ  171.5  (NHCOC),  170.4 
(NHCOC), 158.4-157.7  (dd, J = 63.8, 31.6, ArC), 154.7 (NHCONH), 149.9-149.1 
(dd, J = 104.9, 11.9, CF), 148.3-147.5  (dd, J = 104.3, 12.5, CF), 141.4 (ArC), 139.7 
(ArC), 139.1 (ArC), 136.1 (2 x CCl), 135.2 (ArC), 131.4 (ArC), 131.0 (CHCHCCl), 
128.8 (2 x CHCCl), 128.3 (ArC), 127.2 (ArC), 126.9 (ArC), 126.2 (ArC), 120.5 
(CCHCHCNH), 118.3 (d, J = 16.7, ArC), 117.8 (ArC), 117.0 (d, J = 16.7, ArC), 
114.6 (CCHCHCNH), 96.3 (CCHCNH), 92.3-91.2 (d, JC-F = 175.2, CHF), 58.9 (d, 
JC-F  =  22.7  NH
+CH2CHF),  53.7  (CHCH2C),  51.5  (N
+HCH2CH2CHF),  50.5 
(CHCH2CH2),  48.5  (CH2N
+H(C4H7F)),  47.3  (CH2NN);  42.1  (CH2Ph),  37.5 
(CHCH2C),  36.3  (CH2N
+H3),  30.6  (d,  JC-F  =  21.5,  CHFCH2CH2),  30.1 
(CHCH2CH2N
+H3); m/z (ESI+) 809 (100%, [
35,35M+H]
+), 811 (40%, [
35,37M+H]
+), 
813 (6%, [
37,37M+H]
+); HRMS C40H42
35Cl2F3N8O3 ([M+H]
+) calcd. 809.2709, found. 
809.2718. 
Racemic  mixture  of  (S)-1-[(6-nitro-1H-indazol-3-yl)methyl]pyrrolidin-3-ol  & 
(R)-1-[(6-nitro-1H-indazol-3-yl)methyl]pyrrolidin-3-ol (67) 
 
i) 6-Nitroindole (500 mg, 3.08 mmol) was added to a stirred solution of sodium 
nitrite (2.13 g, 30.8 mmol) in H2O (25 mL) and DMF (2 mL) at 18 °C.  6 M HCl (4.6 
mL, 27.8 mmol) was added dropwise over 10 min and stirring continued for 3 h 
before diluting with EtOAc (30 mL) and extracting.  Aqueous layer extracted further 
with EtOAc (2 x 15 mL).  Organic extracts combined, washed with H2O (15 mL) and 
brine  (15  mL),  then  dried  (MgSO4)  and  concentrated  in  vacuo  to  leave  the 
indazole-3-carbaldehyde intermediate as a dark brown solid.  130 
ii) HCl (g), generated by the dropwise addition of conc. H2SO4 (65 mL, 1.20 mol) to 
NaCl  (s) (58.0 g, 1.07  mol), was  bubbled through a stirred solution  of 1-Boc-3-
pyrrolidinol (1.00 g, 5.34 mmol) in Et2O (50 mL) for 3 h. Stirring was then continued 
for 20 h before concentrating in vacuo and drying further under high vacuum to leave 
the hydrochloride salt of 3-pyrrolidinol as a pale pink solid.  
iii) The indazole-3-carbaldehyde intermediate was dissolved in CH2Cl2/DMF/AcOH 
(45/4.5/0.5 mL), to which was added the 3-pyrrolidinol (660 mg, 5.36 mmol) and the 
reaction mixture was stirred at 18 °C for 20 min.  Sodium triacetoxyborohydride 
(1.63 mg, 7.70 mmol) was added portionwise over 10 min and stirring continued for 
3 h before diluting with EtOAc (100 mL) and quenching with sat. aqueous NaHCO3 
(60 mL).  Aqueous layer separated and extracted further with EtOAc (2 x 30 mL).  
Organic extracts combined and washed with sat. NaHCO3 (aq) (2 x 25 mL), H2O 
(2 x 25 mL) and brine (2 x 25 mL) then dried (MgSO4) and concentrated in vacuo to 
leave  brown  residue.    Purification  by  flash  column  chromatography  (0-10% 
MeOH/CH2Cl2)  gave  target  compound  (406  mg,  50%);  as  a  brown  solid; 
mp 166-168 °C;  Rf  0.13  (10%  MeOH/CH2Cl2); IR  νmax  (neat)  3122  (O-H),  3068 
(N-H),  2959-2835  (C-H),  1513  (NO2),  1341  (NO2),  1125-1059  (C-N),  874-730 
(ArC-H)  cm
-1;
  1H NMR  (600 MHz,  CDCl3) ʴ  12.09 (1H, bs, NH), 8.40 (1H, d, 
J = 1.9, CCHC), 7.94 (1H, dd, J = 1.9, 9.0, CHCHCNO2), 7.87 (1H, d, J = 9.0, 
CHCHCNO2), 4.40 (1H, m, CHOH); 4.10 (2H, s, CCH2N); 3.07 (1H, td, J = 8.7, 4.1, 
NCHHCH2), 2.93 (1H, d, J = 10.2, NCHHCHOH), 2.63 (1H, dd, J = 10.2-10.5, 
5.3-5.7, NCHHCHOH), 2.41 (1H, q, J = 8.3-8.7, NCHHCH2), 2.29-2.23 (1H, m, 
NCH2CHH), 1.84-1.79 (1H, m, NCH2CHH); 
13C NMR (150 MHz, CDCl3) ʴ 147.0 
(ArC),  144.1  (ArC),  140.0  (ArC),  125.4  (ArC),  121.2  (CHCHCNO2),  115.5 
(CHCHCNO2),  107.5  (CCHC),  71.5  (CHOH),  63.4  (NCH2CHOH),  53.1 
(NCH2CH2), 51.5 (CH2CNN), 35.2 (NCH2CH2); m/z (CI+) 263 (100%, [M+H]
+); 
HRMS C12H15N4O3 ([M+H]
+) calcd. 263.1144, found. 263.1143. 
 
 131 
Racemic  mixture  of  (S)-1-{[1-(2,6-dichlorobenzyl)-6-nitro-1H-indazol-3-
yl]methyl}pyrrolidin-3-ol  &  (R)-1-{[1-(2,6-dichlorobenzyl)-6-nitro-1H-indazol-
3-yl]methyl}pyrrolidin-3-ol (68) 
 
To a stirred solution of 67 (319 mg, 1.22 mmol) in dry THF (30 mL) under argon 
was  added  2,6-dichlorobenzyl  bromide  (293 mg,  1.22  mmol)  followed  by 
portionwise addition over 10 min of caesium carbonate (396 mg, 1.22 mmol). The 
reaction mixture was stirred at 16 °C for 20 h then diluted with H2O (10 mL) and 
extracted with EtOAc (2 x 20 mL). Organic extracts were washed with H2O (2 x 10 
mL) then brine (10 mL), dried (MgSO4) and concentrated in vacuo. The residue was 
purified  by  flash  column  chromatography  (0-1.5%  MeOH/CH2Cl2)  gave  target 
compound (292 mg, 57%); as a light brown solid; mp 161-163 °C; Rf 0.45 (10% 
MeOH/CH2Cl2); IR νmax (neat) 3083 (O-H), 2963-2839 (C-H), 1579 (ArC=C), 1524 
(NO2),  1437  (C-H),  1345  (NO2),  1298-1089  (C-N),  874-732  (ArC-H),  666 
(C-Cl) cm
-1; 
1H NMR (600 MHz, CDCl3) ʴ 8.34 (1H, d, J = 1.9, NCCHC), 7.97 (1H, 
dd, J = 8.7, 1.9, NCCHCHC), 7.94 (1H, d, J = 8.7, NCCHCHC), 7.40 (2H, d, J = 7.9, 
2 x CHCCl), 7.28 (1H, t, J = 7.9, CHCHCCl), 5.85 (2H, s, CH2NN), 4.32 (1H, m, 
CHOH), 4.02 (2H, s, NCH2CN), 2.90 (1H, td, J = 8.7, 5.3,  CHHCH2CHOH), 2.69 
(1H, d, J = 10.2, NCHHCHOH), 2.62 (1H, dd, J = 10.2, 4.9, NCHHCHOH), 2.40 
(1H, dt, J = 6.0-6.4, 8.7-9.4, CHHCH2CHOH), 2.20-2.14 (1H, m, CH2CHHCHOH), 
1.93 (1H, bs, CHOH), 1.76-1.71 (1H, m, CH2CHHCHOH); 
13C NMR (150 MHz, 
CDCl3) ʴ 146.7 (ArC), 143.6 (ArC), 139.5 (ArC), 137.0 (2 x CCl), 130.8 (ArC), 
130.6 (CHCHCCl), 129.0 (2 x CHCCl), 126.5 (ArC), 121.9 (NCCHCHC), 115.2 
(NCCHCHC),  106.3  (NCCHC),  71.7  (CHOH),  62.9  (NCH2CHOH),  52.4 
(CH2CH2CHOH), 51.5 (NCH2CN), 48.8 (NCH2CCCl), 35.2 (CH2CH2CHOH); m/z 
(CI+) 421 (100%, [
35,35M+H]
+), 423 (55%, [
35,37M+H]
+); HRMS C19H19
35Cl2N4O3 
([M+H]
+) calcd. 421.0834, found. 421.0831. 132 
Racemic  mixture  of  (S)-1-{[6-amino-1-(2,6-dichlorobenzyl)-1H-indazol-3-
yl]methyl}pyrrolidin-3-ol & (R)-1-{[6-amino-1-(2,6-dichlorobenzyl)-1H-indazol-
3-yl]methyl}pyrrolidin-3-ol (69) 
 
To a solution of 68 (206 mg, 0.489 mmol) in MeOH (30 mL) was added FeCl3.6H2O 
(31.0  mg,  0.114  mmol)  and  activated  charcoal  (248  mg),  followed  by  N,N-
dimethylhydrazine (0.74 mL, 9.78 mmol). The reaction mixture was heated to reflux 
for 5 h then allowed to cool to ambient temperature before filtering through celite, 
washing through with a cold mixture of CH2Cl2/MeOH (90 mL, 4:1). The filtrate was 
concentrated in vacuo to leave a brown oily residue, which was purified by flash 
column chromatography (0-6% MeOH/CH2Cl2) to give the desired product (120 mg, 
63%); as a light brown/pink solid; mp 148-152 °C; Rf 0.25 (20% MeOH/CH2Cl2); IR 
νmax (neat) 3432 (O-H), 3344-3230 (N-H), 2958-2848 (C-H), 1626 (C=N), 1564-
1495 (ArC=C), 1434 (C-H), 1292-1090 (C-N), 767-691 (ArC-H), 631 (C-Cl) cm
-1;
  
1H NMR (600 MHz, CDCl3) ʴ 7.51 (1H, d, J = 8.7, CHCHCNO2), 7.33 (2H, d, J = 
8.3,  2  x  CHCCl),  7.20  (1H,  t,  J  =  8.3,  CHCHCCl),  6.51  (1H,  dd,  J = 8.7,  1.9, 
CHCHCNO2), 6.45 (1H, d, J = 1.9, CCHC), 5.62 (2H, s, NNCH2C), 4.26 (1H, m, 
CHOH), 3.95 (2H, s, CH2CNN), 3.42 (1H, s, CHOH), 2.97 (1H, dt, J = 5.7, 8.7,  
CHHCH2CHOH), 2.78 (1H, d, J = 10.5, NCHHCHOH), 2.62 (1H, dd, J = 10.4, 5.3, 
NCHHCHOH),  2.40  (1H,  dt,  J  =  6.4,  9.0,  CHHCH2CHOH),  2.13-2.08  (1H,  m, 
CH2CHHCHOH), 1.74-1.69 (1H, m, CH2CHHCHOH); 
13C NMR (150 MHz, CDCl3) 
ʴ  145.9  (ArC),  142.4  (ArC),  141.7  (ArC),  136.9  (2  x  CCl),  131.8  (ArC),  130.0 
(CHCHCCl),  128.8  (2  x  CHCCl),  121.6  (CHCHCNO2),  117.5  (ArC),  112.3 
(CHCHCNO2),  92.5  (CCHC),  71.5  (CHOH),  62.5  (NCH2CHOH),  52.0 
(CH2CH2CHOH), 50.9 (CH2CNN), 48.3 (CH2NN), 35.1 (CH2CH2CHOH); m/z (CI+) 
391 (100%, [
35,35M+H]
+), 393 (64%, [
35,37M+H]
+), 395 (9%, [
37,37M+H]
+); HRMS 
C19H21
35Cl2N4O ([M+H]
+) calcd. 391.1092, found. 391.1091. 133 
Racemic mixture of (S)-4-amino-N-benzyl-2-{[S]-2-[3-(1-{2,6-dichlorobenzyl}-3-
{[(S)-3-hydroxypyrrolidin-1-yl]methyl}-1H-indazol-6-yl)ureido]-3-[3,4-
difluorophenyl]propanamido}butanamide dihydrochloride salt & (S)-4-amino-
N-benzyl-2-{[S]-2-[3-(1-{2,6-dichlorobenzyl}-3-{[(R)-3-hydroxypyrrolidin-1-
yl]methyl}-1H-indazol-6-yl)ureido]-3-[3,4-
difluorophenyl]propanamido}butanamide dihydrochloride salt (66) 
 
To a sonicated (5 min), then stirred solution of 69 (60.0 mg, 0.153 mmol) in dry THF 
(8 mL), under dry conditions and cooled to 0 °C, was added triphosgene (16.0 mg, 
54.0 μmol) and DMAP (37.0 mg, 306 μmol) under argon. After 5 min the reaction 
mixture  was  allowed  to  reach  ambient  temperature  and  stirred  for  30  min.  The 
reaction mixture was cooled again to 0 °C for 5 min and a solution of 33 (38.0 mg, 
77.0 μmol) in dry THF (4 mL) was added. The reaction mixture was left to reach 
ambient temperature and stirred for 2 h under argon then concentrated in vacuo and 
the residue purified by flash column chromatography (0-3% MeOH/CH2Cl2) to give 
the Boc-protected intermediate (27.0 mg). The off-white solid was suspended in a 
solution of HCl (4 N) in dioxane and stirred for 2.5 h before concentrating in vacuo 
and  purifying  by  preparative  RP-HPLC  (retention  time:  7.81  min).  The  isolated 
product was taken up in a 0.1 M HCl (aq) solution (2 mL) and lyophilised to give the 
title compound (12.0 mg, 19%); as a white solid; mp 182-186 °C (decomp.); Rf 0.06 
(10% MeOH/CH2Cl2); IR νmax (neat) 3273 (O-H), 3080 (N-H), 2958-2848 (C-H), 
1634 (C=O), 1584 (C=N), 1539-1493 (ArC=C), 1434 (C-H), 1280-1086 (C-N), 769-
696 (ArC-H), 608 (C-Cl) cm
-1;
  1H NMR (600 MHz, DMSO-d6) ʴ 10.72 (1H, m, 
N
+HCH2CNN),  9.35  &  9.32  (1H,  2 x  s,  NHCONHCH),  8.68-8.66  (1H,  m, 
NHCHCH2CH2 & 1H, m, NHCH2Ph), 8.03 (3H, m, N
+H3), 7.99 & 7.97 (1H, 2 x s, 
CCHCNH), 7.83 & 7.80 (1H, 2 x d, J = 8.9 & 8.7, CCHCHCNH), 7.54 (2H, m, 2 x 
CHCCl), 7.43 (1H, m, CHCHCCl), 7.37-7.17 (7H, m, ArH), 7.09 (1H, m, ArH), 7.02 
& 7.01 (1H, 2 x d, J = 8.9 & 8.7, CCHCHCNH), 6.75 & 6.72 (1H, 2 x d, J = 7.7 & 134 
7.7, NHCONHC), 5.61 (2H, m, CH2NN), 4.65-4.54 (2H, m, CH2CNN & 1H, m, 
CHNHCONH), 4.43 (1H, dt, J = 6.0, 7.9, CHCH2CH2), 4.36-4.29 (2H, m, NHCH2Ph 
& 1H, m CHOH), 3.48 & 3.20 (0.5H & 0.5H, m, Pyr-C(5)H2), 3.47 & 3.01 (0.5H & 
0.5H, m, Pyr-C(2)H2), 3.41 & 3.26 (0.5H & 0.5H, m, Pyr-C(5’)H2), 3.19 (0.5H & 
0.5H,  m,  Pyr-C(2’)H2),  3.07  (1H,  m,  C(H)HCHNHCONH),  2.86-2.78  (1H,  m, 
C(H)HCHNHCONH  &  2H,  m  CH2CH2CHNH),  2.08-1.91  (2H,  m, 
CH2CHNHCONH), 2.02 & 1.74 (0.5H & 0.5H, m, Pyr-C(4)H2), 1.94 & 1.84 (0.5H 
& 0.5H, m, Pyr-C(4’)H2); 
13C NMR (150 MHz, DMSO-d6) ʴ 171.5 (NHCOC), 170.5 
(NHCOC), 154.82 & 154.81 (NHCONH), 149.9-149.1 (dd, J = 104.5, 12.1, CF), 
148.2-147.5  (dd, J = 104.5, 12.1, CF), 141.5 & 141.4 (ArC), 139.7 (ArC), 139.1 
(ArC),  136.1  (2  x  CCl),  135.5  &  135.3  (ArC),  131.5  &  131.4  (ArC),  131.0 
(CHCHCCl),  128.83  (CHCCl),  128.80  (CHCCl),  128.3  (2  x  ArCH),  127.1  (2  x 
ArCH),  126.9  (ArCH),  126.3  (ArCH),  120.8  &  120.7  (CCHCHCNH),  118.4  (d, 
J = 17.6,  ArC),  117.9  (ArC),  117.6  (ArC),  117.0  (d,  J  =  16.5,  ArC),  114.5 
(CCHCHCNH), 96.1 (CCHCNH), 68.3 (Pyr-C(3)HOH), 68.1 (Pyr-C(3’)HOH), 60.3 
(Pyr-C(2’)H2),  59.8  (Pyr-C(2)H2),  53.9  (CHNHCONH),  51.8  (Pyr-C(5’)H2),  51.5 
(Pyr-C(5)H2), 50.6 (CHCH2CH2), 49.5 & 48.3 (CH2CNN), 47.33 & 47.26 (CH2NN), 
42.1 (CH2Ph), 37.5 (CH2CHNHCONH), 36.2 (CH2CH2CH), 33.1 (Pyr-C(4)H2), 32.5 
(Pyr-C(4’)H2), 30.1 (CH2CHNHCOCH); m/z (ESI+) 807 (100%, [
35,35M+H]
+), 809 
(71%, [
35,37M+H]
+), 811 (15%, [
37,37M+H]
+), 829 (20%, [M+Na]
+). 
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Biology 
Biological  testing  of  compounds  was  done  in  collaboration  with  Prof  Rachel 
Chambers’ research group at the Centre for Inflammation and Tissue Repair (UCL, 
Division of Medicine). Calcium mobilisation assay work was assisted by Dr Natalia 
Smoktunowicz and CCL2 ELISA work was also carried out by Natalia. In vivo work 
was carried out by Dr Ricardo José.  
Materials and methods 
Reagents:  
Thrombin, extracted from human plasma, was purchased from Calbiochem (Merck 
Biosciences,  UK).  PAR-1  agonist  peptide  and  reverse  peptide  were  supplied  by 
Bachem.  The  original  RWJ-58259  sample  used  as  standard  was  a  gift  from  Dr 
Claudia  Derian  (Johnson  &  Johnson  Pharmaceutical  Research  &  Development, 
USA).  
Cell culture:  
Primary human lung fibroblasts (pHLFs), grown from explant cultures of normal 
adult  lung  tissue,  were  a  gift  from  Dr  Robin  J  McAnulty  (University  College 
London). Cells were maintained in DMEM at 37 °C (10% CO2) supplemented with 
glutamine (4 mM), penicillin, streptomycin, and 10% (v/v) FBS (all from Invitrogen) 
and were below passage 10 when used for experiments. 
Measurement of intracellular Ca
2+ levels:  
pHLFs  were  seeded  in  clear-bottom,  black,  96-well  microplates  at  a  density  of 
10,000 cells/well for 48 h and then quiesced for 24 h. Intracellular Ca
2+ levels were 
assessed using the Fluo-4 NW kit (Invitrogen, UK) according to the manufacturer’s 
instructions.  The  dye  was  dissolved  in  assay  buffer  (20  mM  HEPES  in  HBSS) 
supplemented with 2.5 mM probenecid. Wells were aspirated and solutions of test 
compounds  (3mM  in  DMSO),  diluted  in  the  dye  buffer  solution  to  give  a  final 
concentration of 3 μM,  were added to the relevant wells (100 μL per well). For 
positive controls, the equivalent volume of DMSO only was diluted in the dye buffer 136 
solution and added to the relevant wells. The cells were then incubated again at 37 
°C (10% CO2) for 30 min and at ambient conditions, in the dark, for 30 min. Cells 
were then stimulated by addition of a solution of thrombin in assay buffer (50 μL, 10 
nM/3  nM/0.3  nM/0  nM)  and  changes  in  intracellular  Ca
2+  concentration  were 
monitored  in  real-time  using  a  fluorescent  imaging  plate  reader  (FLIPR®  Tetra 
System, Molecular Devices, Inc). Measurements were taken every 1 sec for 1 min, 
then every 6 sec for a further 2 min. Experiments were performed in three replicates 
on  the  same  plate  and  the  data  plotted  as  change  in  relative  fluorescence  units 
(RFU).
174 
Human CCL2 ELISA:  
Cells  were  seeded  at  10  x  10
4  cells/well,  grown  overnight  to  subconfluence  and 
quiesced  in  serum-free  medium  for  24  h  before  stimulation  or  siRNA  treatment. 
Wells of a 96-well ELISA plate were coated with 50 μL of 2 μg/mL MAB679 (R&D 
Systems Europe Ltd., Abingdon, UK) in bicarbonate coating buffer, left for 5 h at 
room temperature and then washed. 100 μL of PBS with 1% bovine serum albumin 
was added to each well and plates were left overnight at 4 ﾰC. 50 μL of either CCL2 
standard or sample was added to each well and left for 2 h at room temperature. After 
washing, 50 μL of 100 ng/mL BAF279 (R&D Systems) was added to each well and 
left for 2 h at room temperature. The plate was washed and 50 μL of a 2 μg/mL 
dilution of streptavidin-horseradish peroxidase (Dako UK Ltd, Ely, UK) was added 
for 30 min. After washing, 50 μL of 3,3’,5,5’-tetramethylbenzidine substrate (BD 
Biosciences,  San  Diego,  CA)  was  added  to  each  well.  After  30  min,  colour 
development was quenched with 0.19 M H2SO4, and absorbance was measured on a 
plate reader at 450 nm. Alternatively, the human CCL2 ELISA Duoset kit DY279 
(R&D Systems) was used according to the manufacturer’s instructions.
174 
LPS-induced pulmonary inflammation model:  
Experiments  were  conducted  with  local  ethical  approval  in  accordance  with  the 
Home Office, UK. Female Balb/c mice (6-8 wk old; Charles River, Margate, UK) 
were anesthetized (5% isofluorane) and challenged with LPS in sterile saline (125 
μg/kg, 50 μL intranasally;  Escherichia coli 0127:B8; Sigma Aldrich, Gillingham, 
UK)  or  sterile  saline  only.  Treated  mice  were  injected  intraperitoneally  with 137 
compound 20 (5 mg/kg), 30 min after LPS administration. After 24 h, animals were 
euthanized (urethane, intraperitoneally, 20 g/kg), and BAL performed (3 x 0.5 mL of 
PBS). Total and differential cell counts were quantified after cytospin. Alternatively, 
BAL fluid was isolated and whole lungs were removed and homogenized.
176  
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Appendix 
MetaSite output 
Statistical analysis of means from medium only versus medium with 0.1% DMSO 
FLIPR traces for compounds 62a & 62b   149 
MetaSite Output: 
 150 
 
 151 
Student’s T-test: 
To determine if difference between mean values is significant (requires p < 0.05)  
   
[Thrombin] 
   
0 nM  0.3 nM  3 nM  10 nM 
            Medium  Experimental replicate 1  70  108  767  868 
 
Experimental replicate 2  83  144  756  886 
 
Experimental replicate 3  46  115  713  921 
 
Experimental replicate 4  79  140  660  837 
 
Mean value  69.5  126.75  724  878 
            Med+DMSO  Experimental replicate 1  78  86  755  864 
 
Experimental replicate 2  54  142  730  908 
 
Experimental replicate 3  67  115  718  891 
 
Experimental replicate 4  54  166  733  965 
 
Mean value  63.25  127.25  734  907 
           
           
 
t test score  0.559351  0.980311  0.708511  0.334408 
 
Therefore, difference is not significant and values can be said to be collect from same 
population, i.e. there is no significant difference caused by the presence of 0.1% 
DMSO. 
   152 
FLIPR traces for compounds 62a & 62b: 
 
Rows A-C: Compound 62a (Col 1-11, conc. 300 μM-3 nM; Col 12, conc. 300 μM) 
Row D: Medium only 
Row E: Compound 20 (Col 1-11, conc. 10 μM-0.1 nM; Col 12, conc. 10 μM) 
Rows F-H: Compound 62b (Col 1-11, conc. 300 μM-3 nM; Col 12, conc. 300 μM) 
Columns 1-11: 10 nM thrombin 
Column 12: 0 nM thrombin 
All
A
B
C
D
E
F
G
H
1 2 3 4 5 6 7 8 9 10 11 12